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Amphipathic peptides with an a-helical structure disrupt membranes rich in negatively 
charged phospholipids and have antibiotic properties. They are toxic to eukaryotic cells 
if internalised by  a  suitable targeting  mechanism.  We  have targeted  one  such peptide 
D(KLAKLAK)2 to haemopoetic cells by conjugating it to monoclonal antibodies which 
recognise lineage-specific cell-surface molecules. An anti-CD33: peptide conjugate was 
cytotoxic  to  one  of three  CD33-positive  myeloid  leukaemia  lines,  whereas  an  anti- 
CD 19: peptide conjugate efficiently killed three out of three B lymphoid lines with IC50 
in the low nanomolar range. Cell lines which did not express the relevant antigen were 
resistant to the conjugates at the concentrations used. Peptide conjugated to anti-CD 19 
and  anti-CD33  antibodies  had  cytotoxic  activity  towards  cells  isolated  from  the 
peripheral  blood  of patients  with  chronic  lymphocytic  leukaemia  (CLL)  and  acute 
myeloid  leukaemia  (AML)  respectively.  CLL  cells  isolated  from  heavily  pre-treated 
patients or from poor risk category individuals, as determined by elevated expression of 
the ZAP-70 protein tyrosine kinase, were as sensitive to the conjugate as were untreated 
or good risk category patients.  Cell death was shown to be by an apoptotic mechanism 
and independent of the level of expression of anti-apoptotic proteins Bcl-2, Mcl-1  and 
XIAP. In addition the conjugate acted synergistically with chlorambucil. The data here 
suggest that anti-CD 19 D(KLAKLAK)2 displays a highly selective and potent cytotoxic 
activity  against  CLL  cells  and  may  be  of therapeutic  value  in  the  treatment  of this 
incurable leukaemia.  We also panned a phage display library in an attempt to isolate a 
peptide that would bind to CD33  and thereby create a peptide with both targeting and 
cytotoxic activity towards malignant myeloid cells.Declaration
The work contained in this thesis is the result of original research carried out by myself 
under the  supervision of Dr.  R.G.  Wickremasinghe.  All  sources  of information have 
been specifically acknowledged by means of reference.  None of the work contained in 
this thesis has been used in any previous application for a degree.
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17Chapter 1. Introduction
l.l.Introduction to targeted therapy
The  goal  of targeted  therapy  in  malignant  disease  is  to  develop  protocols  which  kill 
cancer  cells  while  leaving  normal  healthy  tissue  untouched.  The  advantage  of this 
specificity  is  to  decrease  side  effects,  and  by  doing  so,  to  allow  higher  and  more 
effective doses of drug to be administered. It also allows treatment of groups of patients 
who would  otherwise  be  considered poor risk  in terms  of age  and  coexistent disease. 
This is especially relevant in view of the increasing age of the patient population.
All chemotherapeutic agents in use today are in principle, targeted to a certain extent, in 
that  they  affect  the  malignant  cells  more  profoundly  than  healthy  cells.  Most 
conventional  agents  target  DNA,  exploiting the  fact that the  tumour cells  differ  from 
normal  cells  in  their  mitotic  rate.  Alkylating  agents  such  as  cyclophosphamide  and 
chlorambucil  alkylate  DNA,  while  antimetabolites  such  as  methotrexate,  a  folic  acid 
antagonist and purine /pyrimidine antagonists such as cytarabine interfere with nucleic 
acid  precursor  synthesis.  The  plant  alkaloids  such  as  vincristine  cause  microtubule 
depolymerisation,  thus  disrupting  chromosome  segregation  during  mitosis.  These 
agents have side effects related to the drug effects  on the rapidly dividing cells  of the 
normal bone marrow, gastrointestinal tract and hair follicles. Side effects that occur as a 
result  of these  toxicities  means  that  chemotherapeutic  agents  are  often  given  at  sub 
optimal doses, resulting in eventual  failure of therapy,  which may be  accompanied by 
the evolution of drug resistance and onset of metastatic disease.
181.1.1  Targeting specific genetic lesions in leukaemia
With  increasing  knowledge  and  understanding  of  the  molecular  basis  of  many 
haematological  malignancies,  novel  therapies  have  emerged  that  target  more  specific 
pathways. In some diseases, the elucidation of specific genetic changes and their altered 
gene  products  has  been  exploited.  For  example,  in  acute  promyelocytic  leukaemia 
(APL), all trans retinoic acid (ATRA), an active derivative of vitamin A, binds directly 
to  the  pml-rara  fusion  protein,  overcoming  the  differentiation  block  which  is 
characteristic of this disease  1.  In chronic myelogenous leukaemia (CML), a reciprocal 
translocation occurs  in the  haemopoietic  stem  cell  leading  to  the  creation  of a  BCR- 
ABL gene on the resultant Philadelphia chromosome (t (9; 22)). This encodes a protein 
with  dysregulated  tyrosine  kinase  activity.  Imatinib  mesylate  (or  STI-571) 
competitively inhibits the interaction of adenosine triphosphate (ATP) with this bcr-abl 
tyrosine  kinase  thus  decreasing  its  ability  to  phosphorylate  and  activate  downstream 
target proteins 2.
There  are  many  other  leukaemias  where  relatively  disease  specific  mechanisms  are 
being  targeted  and  new  classes  of  drugs  are  in  development.  Some  of  these  are 
summarised in Table 1.1
19Drug class Target pathway Ref
Inhibitors of 
famesyl 
transferase 
(FTase)
Famesylation is an important post-translational 
modification step for RAS proteins involved in signal 
transduction and growth regulation. Ras mutations are a 
common finding in haematological and other 
malignancies
3
Inhibitors of DNA 
methyltransferase 
Azacytidine, 
Decitabine
DNA hypermethylation is associated with suppression of 
regulatory genes involved in cell proliferation and 
differentiation is a common phenomenon in 
myelodysplastic syndrome (MDS), acute myeloid 
leukaemia (AML) and CML.
4
FLT 3 inhibitors FLT3 is a transmembrane tyrosine kinase growth factor 
receptor selectively expressed on haematopoietic cells 
Activating FLT3 mutations occur in up to 41% of AML
5
Proteasome
inhibitors
PS-341
The ubiquitin-proteasome pathway is the principal 
intracellular pathway responsible for the regulated 
degradation of proteins, including many that participate 
in cell cycle regulation and tumour growth.
Inactivation of the transcription factor NF-kB is thought 
to be important in the anti neoplastic activity of this class 
of drug especially in multiple myeloma (MM).
6
Bcl-2 antisense 
oligonucleotide
Bcl-2 overexpression occurs in many B cell non- 
Hodgkin’s lymphoma (NHL) and chronic lymphocytic 
leukaemia (CLL) and is also associated with treatment 
resistance in AML, CLL and NHL.
7
Thalidomide
derivatives
Main action is to target angiogenesis in MM, MDS
T
Table 1.1 New drugs which target specific pathways in haematological 
malignancies
201.1.2  Immunotherapy
Immunotherapy  represents  one  of the  most  important  arms  of  the  targeted  therapy 
approach.  Tumour  cells  often  express  specific  receptors  or  other  molecules,  on  their 
surface  membranes,  which  distinguish  them  from  their  surrounding  normal  tissues. 
These  are  called  tumour-associated  antigens  (TAAs).  TAAs  include  tumour  specific 
antigens,  which  are  the  result  of mutations  or  gene  rearrangements,  viral  antigens  in 
cancers associated with viruses,  and tissue  specific  differentiation antigens, which are 
also  expressed by normal  cells  from  which the  malignant clone  arose.  TAAs  may be 
truly specific as in idiotype  surface immunoglobulin in B cell malignancies or may be 
overexpressed in the malignant population compared to healthy cells.
Many tumour-associated antigens may be recognised by the immune system and play a 
critical  role  in  the  host  -   tumour  interaction.  Immunotherapy  exploits  this  by  either 
stimulating  the patient’s  immune  system  to  augment  this  response  using  cytokines  or 
vaccination  strategies  (active  immunotherapy),  or  by  manipulating  or  mimicking 
certain  aspects  of the  normal  immune  response  to  target the  malignant  cells  (passive 
immunotherapy).
As a general rule,  foreign viral antigens and mutation-related tumour specific antigens 
are  more  immunogenic  than  self-antigens.  Some  key  TAAs  expressed  by 
haematological malignancies are summarised in Tablel.2.
21Antigen type Haematological malignancy
Tumour specific antigens
Fusion gene products bcr-abl
AML/ETO 
PML-RARcc 
Idiotype epitopes  Id Immunoglobulin
T-cell receptor idiotypes
CML
AML
APL
B-cell malignancies 
T-cell malignancies
Viral associated antigens
Epstein Barr virus
HTLV-1
Burkitt’s lymphoma 
Hodgkin’s lymphoma 
Adult T-cell leukaemia
Over expressed normal antigens
Proteinase 3
WT-1
MUC-1
AML, CML 
AML, CML, ALL 
MM
Mutated oncogenic proteins
p53
RAS
Numerous malignancies
Tissue specific differentiation antigens
CD33
CD19
AML
CLL, NHL, B-cell acute 
lymphocytic leukaemia (ALL)
Tablel. 2 Tumour associated antigens expressed by haematological malignancies
221.1.2.1  Immune response to TAAs: immunosurveillance and escape mechanisms
Bumet  and  Thomas  first  coined  the  term  ‘immunosurveillance’  in  19679.  This 
described the concept that the immune system can recognise and destroy tumour cells. 
Initially,  the  finding  that  several  immunocompromised  mouse  strains  showed  no 
significant increase  in  incidence  of common tumours,  with the  exception  of the  viral 
associated tumours, dampened enthusiasm  for this hypothesis10.  However more recent 
epidemiological  evidence  from  immunosupressed  post-transplant  populations  shows 
increased incidence of a broad range of tumours with no apparent viral aetiology 11. The 
finding  in  many  malignancies  that  the  presence  of tumour  infiltrating  lymphocytes 
(TIL)  correlates  with  improved  survival  further  supports  the  theory  of 
immunosurveillance  12.  Microarray  studies  have  further  deomonstrated  that  the
moelucular features of TILs in lymphoma biopsy specimens have a profound effect on 
survival13
Many tumour specific antigens can be shown to evoke an anti - tumour T cell response 
in  vitro  and  in  vivo  14.  Major  histocompatability  (MHC)  molecules  on  antigen 
presenting  cells  (APC),  present  TAAs  to  lymphocytes  that  participate  in  the  innate 
immune  response  (NKT,  NKyp  T  cells)  which  are  then  stimulated  to  produce 
interferon-y. This has several effects, which include recruitment of other immune cells, 
a direct antiproliferative effect and the activation of the cyocidal action of macrophages 
and NK  cells.  Tumour cell  debris  ingested  by  dendritic  cells  is  trafficked  to  draining 
lymph  nodes  where  tumour  specific  CD4+  T  helper  cells  and  CD8+  T  cells  are 
produced.  CD8+  T  cells  ultimately  differentiate  into  cytotoxic  T  lymphocytes  (CTL) 
and lyse tumour cells 15.
Despite all the mechanisms described above, it is exceptional for such a response to
23spontaneously eliminate an established malignancy.  There are  several reasons for this. 
The  first  is  that  most  tumours  do  not  make  distinctive  antigenic  peptides  or  do  not 
express  the  co-stimulatory  molecules  necessary  to  initiate  an  adaptive  immune 
response. Second, many tumour cells can use their genetic instability to their advantage 
by  developing  escape  mechanisms  by  which they  can  avoid  or  suppress  the  adaptive 
immune  response.  This  may  involve  down regulating the  expression  of MHC  class  1  
molecules16  or  the  tumour  antigens  themselves,  or  secreting  immunosuppressive 
cytokines such as transforming growth factor p17 (TGF-p) and IL-1018. Thirdly, tumour 
cells  may  induce  T-cell  apoptotic  clonal  deletion  by  upregulating  Fas  ligand,  which 
initiates cell killing mechanisms by engaging Fas molecules on the T cells19.
1.1.2.2  Active immunotherapy
The  aim  of  active  immunotherapy  is  to  stimulate  the  patient’s  immune  system  to 
augment the anti-tumour response; this  can be achieved by using therapeutic  cytokine 
or vaccination strategies,
a.  Cytokines
Cytokines are small hormone-like proteins (of ~20 kDa) that act by binding to specific 
receptors, leading to activation of signalling pathways which result in changes in gene 
expression in the nucleus.  Cytokines are  secreted by a variety of cells,  and can act on 
the cells that produce them (autocrine action), on other cells in the immediate vicinity 
(paracrine  action), or on cells at a distance  (endocrine  action).  Cytokines have  role  in 
controlling the  growth,  development,  and  functional  differentiation  of the  cells  of the 
immune  system.  A  variety  of cytokines  are  used  alone  or  in  combination  with  other 
therapies in the treatment of haematological malignancies.
24Interferon -a (IFN-a)
IFN-a is secreted mainly by monocytes and lymphoid cells. This cytokine is used alone 
or in combination with chemotherapy and/or STI 571  in patients with Ph-positive CML 
who are not candidates for allogeneic stem cell transplantation (SCT). As a single agent 
it induces durable cytogenetic responses and prolongs the duration of the chronic phase 
and  of  survival  compared  with  conventional  chemotherapy  .  In  the  maintenance 
treatment of MM,  IFN-a  has been  shown to prolong the plateau phase  of the  disease
A 1
following high dose chemotherapy or autologous transplantation  . It is also used in the 
treatment of hairy cell leukaemia22.  The exact mechanism of action of IFN-a in these 
diseases is not known.  It may have a direct anti-proliferate effect or an indirect one on 
the immune system through non-specific enhancement of anti-leukaemic cell -mediated 
responses  .  In  some  diseases  it  is  thought  to  stimulate  the  synthesis  of  tumour 
associated cell surface antigens.
Granulocyte macrophage colony stimulating factor (GM-CSF)
GM-CSF  is  secreted  by  activated  T-cells  and  macrophages.  Its  main  functions  are  to 
stimulate growth and differentiation of leukocytes. It is chemotactic for neutrophils and 
enhances  microbicidal  activity,  oxidative  metabolism,  and  phagocytotic  activity  of 
neutrophils and macrophages.
The  main  uses  for  GM-CSF  in  the  treatment  of haematological  malignancies  are  to 
enhance  the  reconstitution  of the  haematopoietic  system  post  chemotherapy  or  bone 
marrow  transplant  and  as  an  adjuvant  in  vaccination  therapies  to  induce  the 
differentiation and activation of dendritic cells (see whole cell vaccines p29).
25Interleukin-2 (IL-2)
IL-2  is  secreted  by  CD4-  positive  T-cells,  NK  cells  and  lymphokine-activated  killer 
cells  (LAK).  IL-2  is  a  central  regulator  of  the  immune  response;  it  induces  the 
proliferation  of T-cells  and  NK  cells  and  in  combination  with  IL-4  also  promotes 
proliferation  of activated  B-cells.  It  stimulates  the  synthesis  of  IFN-y  in  peripheral 
leukocytes and induces the secretion of IL-land TNF.
In the treatment of haematological malignancies IL-2 has been shown, in some cases to 
induce some tumour response in B cell NHL, but with no increase in overall survival24. 
Its  use  has  been  limited  by  non-specific  toxic  side  effects.  IL-2  is,  however,  an 
important  component  of  adoptive  immunotherapy  strategies,  where  it  is  used  to 
stimulate the production and ex vivo proliferation of LAK cells and TILs (see p30). 
Chimeric fusion toxins obtained by the fusion of cDNAs of IL-2 and the coding regions 
of  toxic  protein  molecules  such  as  Diphtheria  toxin  have  been  developed  for  the
c
treatment of T- cell malignancies that express the IL-2 receptor  .
Cytokine gene transfer is another strategy being developed with the aim  of increasing 
the immunogenicity of tumours by incorporating a functional IL-2 gene  .
b.  Vaccination
In  1796 Edward Jenner used vaccination with cowpox to induce immunity to smallpox, 
eventually leading to eradication of the disease  180 years later11.
William Coley introduced the idea of vaccination for cancer therapy in the  1890s28. The 
objective of cancer vaccination is to elicit an active  immune response against antigens 
expressed by tumour cells leading to specific rejection of disseminated malignant cells 
and  ideally  providing  long-lived  immunological  memory  capable  of  protecting  the 
vaccinated patient against relapse.
26Active immune responses against tumour cells can be induced in normal animals 
and  can  render  them  immune  to  subsequent  challenge  with  the  tumour.  However 
successful  vaccination  against  actively  growing  tumours  is  much  more  difficult  to 
achieve. This may suggest that vaccination would have the most clinical benefit either 
used  in  the  setting  of  disease  remission  or  minimal  residual  disease  or  even  as  a 
prophylactic treatment in individuals deemed to be at high risk of developing a specific 
malignancy.
Tumour specific idiotype vaccines for B-cell malignancies
B-lymphocytes  express  an  immunoglobulin  (or  idiotype  Id)  that  is  the  product  of a 
unique combination of gene rearrangements. All of the malignant cells that arise from a 
single  B  cell  will  express  the  same  idiotype.  Using  Id  as  a  vaccination  target  would 
require  generation of a different vaccine  for each patient.  By  generating  a hybridoma 
from tumour cells obtained at lymph node biopsy fused to a myeloma cell line, a group 
at Stanford University were the first to purify large quantities of idiotype protein.  This 
was then chemically coupled to keyhole limpet haemocyanin (KLH), a foreign protein, 
to  make  it more  immunogenic.  This  approach was  used  in  a trial  of 32  patients  with 
low-grade  follicular  lymphoma  in  first  remission  post  chemotherapy.  Approximately 
half  the  patients  mounted  an  immunological  response  to  the  vaccine,  mainly  by 
generating  anti-id  antibodies.  This  response  strongly  correlated  with  freedom  from 
disease  progression  and  overall  survival29.  Dendritic  cells,  isolated  from  peripheral 
blood  or  generated  in  vitro  from  monocytes,  and  then  pulsed  with  Id  proteins,  have 
been  used  as  an  alternative  route  for  Id  vaccination30.  Other  variations  include  co­
administration of GM-CSF and/or IL-2 as an adjuvant31. Anti-idiotype vaccine
27strategies of this type are currently being tested in two large Phase III randomised trials 
in first complete remission (CR) patients32.
DNA Id vaccination involves cloning the genes encoding idiotype variable regions in a 
mammalian  vector  and  delivering  it,  often  in  the  form  of  a  fusion  protein  with  a 
fragment of tetanus toxin, directly into muscle33. The mechanisms by which antigen is 
presented  to  the  immune  system  after  DNA  vaccination  is  complex.  It  involves  a 
process  called  ‘cross-priming’,  in  which  antigen  translated  in  the  muscle  cells  is 
released and taken up by bone marrow derived antigen presenting cells, as well as the 
direct transfection of dendritic cells.  DNA vaccines are therefore capable of inducing 
both  humoral  and  cellular  responses,  as  opposed  to  mainly  humoral  responses  in 
conventional Id vaccination strategies34,35.
Bcr-abl peptide vaccination for CML
Although the bcr-abl fusion protein is an intracellular peptide, Clark et al demonstrated 
that  smaller  peptides  which  span  the  bcr-abl junction,  and  are  derived  from  the  full 
length  peptide,  are  expressed  on  the  surface  of CML  cells  in  association  with  HLA 
class  I  molecules  36.  Furthermore  they  demonstrated  an  in-vitro  cytotoxic  T-cell 
response to these peptide fragments that was capable of killing autologous CML cells. 
Another  groups  used  bcr-abl  peptide  fragments  to  vaccinate  12  patients  with 
Philadelphia  positive  CML,  3  patients  demonstrated  specific  proliferative  immune 
responses but none showed any evidence of cytotoxic T lymphocyte activity37.
28Whole cell vaccines
This is an approach that has been used when no specific TAA has been identified. It 
involves  using  genetically  altered  autologous  tumour  cells  transduced  to  secrete 
cytokines such as GM-CSF or IL-12 or express co-stimulatory molecules such as CD40 
ligand or B7, to make the tumour cells  more  immunogenic38,39.  Tumour vaccines that 
secrete  GM-CSF,  which induces  differentiation and  activation of dendritic  cells,  have 
been shown to induce an increased immune response in mouse models of AML40. 
Another novel  experimental  approach to  tumour vaccination  is  the  use  of heat-shock 
proteins isolated from tumour cells. The underlying principle of this therapy is that one 
of the physiological activities of heat-shock proteins is to act as intracellular chaperones 
of antigenic  peptides.  There  is  evidence  for  receptors  on  the  surface  of professional 
antigen-presenting  cells  that  take  up  certain  heat-shock  proteins  together  with  any 
bound  peptides.  Uptake  of  heat-shock  proteins  via  these  receptors  delivers  the 
accompanying  peptide  into  the  antigen-processing  pathways  leading  to  peptide 
presentation by MHC class I molecules41.
1.1.2.3  Passive immunotherapy
Passive  immunotherapy  involves  the  administration  of  pre-formed  immune  system 
components,  or  monoclonal  antibodies,  to  target  diseased  cells  without  directly 
activating the patient’s immune system.
a.  Adoptive immunotherapy
In  this  strategy  tumour  specific  lymphocytes  are  removed  from  the  patient  and 
expanded in vitro, in the presence of cytokines, before being returned.
29Lymphokine activated killer (LAK) cells
Initial  experiments  in  adoptive  immunotherapy  involved  removing  lymphocytes  from 
the blood of a patient and  growing them  in the presence  of IL-2.  The  cells were then 
returned  to  the  patient.  These  lymphocytes  were  called  lymphokine-activated  killer 
(LAK) cells and are now thought to be derived mainly from NK cells. In an early trial, 
out of 25 patients with advanced chemotherapy resistant cancers,  10 patients showed a 
50% or greater reduction in tumour size42.
Tumour infiltrating lymphocytes (TIL)
The results of adoptive  immunotherapy with blood derived LAK cells  led to a search 
for  more  specific  cytotoxic  cells.  CD4  +  and  CD8+  lymphocytes  which  infiltrate 
tumours can be isolated from the tumour tissue and expanded in the presence of IL-2, at 
lower  concentrations  than  those  required  for  LAK  cells43.  These  cells  have  tumour- 
targeting properties and have shown a much stronger anti-tumour effect than LAK cells 
on a per cell basis in animal models. The mechanism of anti-tumour activity of TILs is 
not  known,  though  there  is  some  evidence  that  these  cells  secrete  cytotoxins  and 
cytokines  capable  of killing  tumour  cells  and  recruiting  other  immune  cells.  Due  to 
their  tumour  homing  properties  TILs  are  suitable  targets  for  T-cell  mediated  gene 
therapy  and  some  groups  have  engineered  TILs  with  genes  encoding  cytokines  or
44 4*5 cytotoxins  ’  .
At  the  present  time  the  clinical  use  of TILs  is  limited  because  of the  difficulty  in 
finding sufficient numbers of TILs at diagnosis and the long ex vivo expansion process.
30Donor lymphocyte infusion (DLI)
DLI has proved to be very effective, particularly in patients with CML, restoring a state 
of  haematological  remission  after  leukaemic  relapse  following  an  allograft  in 
approximately 70% of patients46,47. Furthermore most of these remissions are sustained 
indicating the eradication of the clonogenic leukaemia cells. DLI has also been used to 
reverse relapse in patients with acute leukaemia, NHL and MM. However the response 
rates of patients with other haematological malignancies is significantly lower than for 
patients  with  CML48.  DLI  also  has  a  role  in  the  treatment  of  EBV  induced  post 
transplant lymphoproliferative disorders49.
DLI cells  may target MHC  differences, minor histocompatibility antigens,  or tumour- 
specific  antigens.  Myelosupression and graft versus host disease  (GVHD)  are the two 
main side effects of DLI. One approach to limit the morbidity associated with GVHD is 
to  infuse  thymidine  kinase  gene-transduced DLI,  followed by treatment of the patient 
with gancyclovir if this side effect occurs50.
Genetically modified T-cells
Advances  in  gene  therapy  have  allowed  the  manipulation  of T-cells  in  an  effort  to 
improve  the  immunological  response  to  adaptive  therapy.  T-cells  can  be  transduced 
with genes that encode antigen receptors thus enabling the recognition of antigens that 
are  poorly  immunogenic.  T-cell  proliferation  and  function  can  be  increased  by 
manipulating  cells  to  express  modified  co-stimulatory  receptors,  or  be  genetically 
protected  from  immunosuppressive  factors  such  as  TGF-p.  T  cells  can  also  be 
transduced with regulatable suicide genes, thereby improving the safety of adoptive cell 
therapy 51.
31b.  Antibody therapy
Monoclonal  antibodies  can  be  used  either  alone  or  conjugated  to  cytotoxic  drugs  or 
radioisotopes.
i.Unconjugated monoclonal antibodies 
Rituximab
The unconjugated monoclonal antibody that has been the most extensively studied and 
used  clinically  is  the  chimeric  anti-CD20  monoclonal  antibody  Rituximab.  This 
antibody  consists  of  murine  variable  regions  grafted  onto  a  human  IgGl  constant 
region.  In  vitro  results  have  shown  that  Rituximab  acts  by  complement  dependent 
cytotoxicity  (CDC),  antibody-dependent  cell  mediated  cytotoxicity  (ADCC)  and 
induction  of  apoptosis,  but  it  is  not  clear  by  which  mechanism  Rituximab  works 
clinically  .
The  first pivotal  trial  of Rituximab  in patients  with relapsed indolent NHL,  showed a 
48%  overall  response  rate53.  More  recent  studies  have  shown  a  significant  benefit  of 
Rituximab  used  as  maintenance  therapy  following  standard  chemotherapy  regimes  in 
newly  diagnosed  follicular  lymphoma54.  Two  trials  of  Rituximab  as  single  agent 
therapy in aggressive NHL have shown overall response rates of around 30%55’56. 
Rituximab  has  used  most  successfully  in  combination  with  other  chemotherapeutic 
regimes, most notably  in combination with CHOP.  A  large  Phase  III  randomised trial 
by  Coiffier  et  al  evaluated  397  patients  aged  60-80  years,  with  newly  diagnosed 
aggressive  NHL  who  were  randomised  to  CHOP  alone  versus  CHOP  +  Rituximab 
(CHOP-R).  In this trial, the CR rate, event-free and overall survival rates were superior 
for the  combination arm  57.  The  superiority of CHOP-R over CHOP  alone  for  1st line
32treatment  of patients  with  newly  diagnosed  advanced  follicular  lymphoma  has  also
f  o
been recently demonstrated  .
Rituximab  has  also  been  shown  to  have  therapeutic  activity  in  CLL59  and 
Waldenstroms  macroglobulinaemia60  and  has  been  reported  to  be  effective  in  certain 
non-malignant  autoimmune  disorders  such  as  idiopathic  thrombocytopenic  purpura, 
auto-immune  haemolytic  anaemia,  cold  agglutinin  disease,  rheumatoid  arthritis61  and 
acquired  haemophilia  .
Alemtuzumab
Alemtuzumab  (CAMPATH-1H  anti-CD52)  is  a  humanised  monoclonal  antibody that 
targets CD52,  an antigen present on 95% of all normal  human B  and T lymphocytes, 
monocytes  and macrophages,  as well as  in most B-cell  and T-cell  lymphomas.  It acts 
by  a  combination  of CDC  and  ADCC  and  has  also  been  shown  in  vitro  to  directly 
induce apoptosis.
The main clinical uses of Campath  1  -H are in the treatment of CLL and as a method of 
T-cell  depletion  to  prevent  GVHD  in  the  allogenieic  transplant  setting.  In  a  pivotal 
study,  93  patients with advanced CLL who had  failed other therapies  gave  an overall 
response  rate  of  33%63.  Other  studies  have  also  shown  significant  results  in  the 
treatment  of  T-PLL64and  first  line  treatment  of  CLL65.  Ongoing  studies  are 
investigating the efficacy of Campath -1H  in combination with other therapies such as 
fludarabine and Rituximab.
33Other  unconjugated  monoclonal  antibodies  for  B-cell  malignancies
Apolizumab/  HuldlO,  a  humanised  monoclonal  antibody,  is  directed  against  a 
polymorphic determinant of HLA-DR expressed on normal  and malignant B-cells and 
is  capable  of inducing  ADCC,  CDC  and  direct  apoptosis  of lymphoma cell  lines.  A 
phase I dose escalation study in 20 B-cell lymphoma patients demonstrated that 4 of 8 
follicular lymphoma patients achieved durable responses. A Phase II randomised study 
is  currently  being  performed  in  patients  with  relapsed  or  refractory follicular,  small 
lymphocytic or marginal zone/MALT B-cell lymphoma. 66
Epratuzumab  is a humanised monoclonal antibody directed against the  CD22  antigen, 
present on 75% of B-lymphocytes.  Overall response rates of 43% and 34% have been 
shown  in  phase  I/II  trials  in  follicular  lymphoma  and  diffuse  large  cell  lymphoma 
respectively66.
IDEC-152  is  a  primatised  monoclonal  antibody  that  targets  CD23  on  B-cell 
malignancies, it has been shown to induce ADCC, CDC and apoptosis in CLL cells in
fn
vitro and also has synergistic actions with both fludarabine and rituximab  .
HuM-195
HuM195  (anti-CD33)  is  a  humanised  monoclonal  antibody  directed  against  the  cell 
surface antigen, CD33, which is detectable in over 90% of patients with acute myeloid 
leukaemia. It has been shown to induce cell death by activation of complement as well 
as by ADCC, but there is no evidence that binding of the antibody to the CD33 antigen 
initiates  intracellular  signalling  leading  to  direct  activation  of apoptosis.  As  a  single 
agent  in  patients  with  relapsed  or  refractory  AML,  HuM195  showed  only  modest 
results, with just two complete and one partial remission out of 49 evaluable patients68.
34HuM195  however showed better efficacy in minimal residual  leukaemia in a study of 
patients with APL in CR with minimal disease documented by RT-PCR for PMLRARa 
positivity.  In  this  trial,  11  of  22  patients  converted  to  a  RT-PCR  negative  state 
following maintenance therapy with Hum 195 69.
ii.  Conjugated monoclonal antibodies 
Gemtuzamab ozogamicin
This consists of a humanised anti-CD-33  antibody conjugated to  a potent anti-tumour 
antibiotic, calicheamicin.  As with unconjugated Hum 195  it is used in the treatment of 
AML.
The  combined  results  of  3  multicenter  phase  II  clinical  trials  of  Gemtuzamab 
ozogamicin  in  142  patients  with relapsed  AML  showed  a remission rate  of 30%.  An 
analysis of the leukaemic blasts from the above study showed a positive correlation of 
P-glycoprotein  drug  efflux  pump  surface  expression  and  treatment  failure70.  Side 
effects  of  this  immunoconjugate  noted  during  this  trial  included  a  transient  post 
transfusion  syndrome  with  fever,  chills  and  hypotension  and  notably  an  increase  in 
transaminases in 17% of patients with one report of fatal hepatic veno-occlusive disease 
(VOD),  a  clinical  syndrome  consisting  of weight  gain,  ascites,  painful  hepatomegaly 
and jaundice. There have also been additional reports of VOD in approximately  16% of 
patients  treated  with  Gemtuzamab  ozogamicin  after  myeloablative  therapy  and 
haemopoetic  cell  transplantation.  It  is  thought  that  this  toxicity  arises  from  uptake  of 
the conjugate by CD33-positive cells in hepatic sinusoids71.
The  role  for  Gemtuzamab  ozogamicn  in  the  treatment  of  AML  is  currently  being 
investigated as part of the UK MRC  15 AML trial72.
35Immunotoxins
Immunotoxins  are  composed  of internalising  monoclonal  antibodies  or  other  ligands 
linked to extremely potent plant or bacterial toxins  or modified toxin subunits,  which 
kill cells by inactivating protein synthesis.
Initial studies in the  1980s were performed with monoclonal antibodies linked to toxins 
which  had  been  chemically  or  genetically  altered  to  reduce  normal  tissue  binding. 
Trials  of patients  with  NHL,  CLL,  and  peripheral  T-cell  lymphoma  resulted  in  few 
durable remissions  .  In the  1990s,  genetic  engineering was  used to  fuse the  catalytic 
domains  of  toxins  to  single-chain  Fv  (scFv)  antibody  fragments  and  cytokines  to 
produce fusion toxins74. Some immunotoxins currently in clinical trials are summarised 
in Table 1. 3.
With a few exceptions, immunotoxin therapies have not yet shown impressive results. 
They  are  associated  with  higher  levels  of  systemic  toxicities  than  other  therapies 
including  infusion  related  events  and  vascular  leak  syndrome  as  well  as 
immunogenicity of both the antibody and the toxin.
36Trade name Indication Ligand /toxin Ref.
Dinileukin Difitox 
(Ontak)
FDA approved
Cutaneous T-cell
lymphoma
CLL
IL2-DT fusion protein 75,76
Anti-B4 blocked 
ricin
NHL Murine anti CD 19 - 
blocked ricin
77
HD-37-dgA Refractory B cell 
lymphoma
Anti-CD22 -  dgA
78
RFB4-dgA Refractory B cell 
lymphoma
Anti-CD 19- dgA 78
RFT5-dgA Hodgkin’s
lymphoma
Anti-CD25- dgA
79
Anti-Tac (Fv)-
PE38
(LMB2)
CD25+
haematological
malignancies
Anti-CD25 Fv-truncated 
PE fusion protein
80
RFB4-dsFv-PE3 8 
(BL22)
Hairy cell 
leukaemia
Disulphide stabilised anti- 
CD22 Fv-truncated PE 
fusion protein
~ 8 T 1  ...  '
DT388GMCSF AML GM-CSF-DT fusion 
protein
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Tablet.3  Immunotoxins currently in clinical trials
DT: diphtheria toxin
dgA: deglycosylated ricin A chain
PE: pseudomonas exotoxin
37iii.  Radioimmunotherapy
In  this  mode  of therapy,  monoclonal  antibodies  with  selectivity  for  target  cells  are 
linked  to  radionucleotides  with  high  linear  energy  transfer  (LET)  such  as  beta 
(131 Iodine,90Yttrium) or alpha (213Bismuth,21 Astatine) emitters that deliver radiation to 
the  targeted  cell  and  the  neighbouring  cells  (cross  fire  effect).  Beta  particles  have  a 
penetration  range  of millimetres  and  are  used  for  therapy  of bulky  disease,  whereas 
alpha particles have a penetration range of only a few cell diameters and are suitable for 
treatment  of  micrometastases  and  circulating  tumour  cells.  The  cytotoxicity  of 
radioimmunotherapy  results  from  a  combination  of direct  radiation  activity  causing 
DNA  strand  breaks  and  the  effects  of the  antibody  itself such  as  CDC,  ADCC  and 
direct induction of apoptosis. Radioimmunotherapy regimes often require a pretherapy 
step  in  which  cold  mouse  antibody  is  administered,  either  as  a  predose  or 
concomitantly,  which  improves  the  biodistribution  of the  labelled  antibodies  to  the
O 1
tumour cells  .
Radioimmunotherapy has been most successful in the treatment of NHL. The first trial 
for B-cell  lymphomas  used a  13 iodine  labelled  anti-HLA DR 10  p  subunit (Lyml).  In 
this  trial  objective  remissions  were  seen  in  50%  of patients  treated  with  advanced 
relapsed B-cell malignancies84.
The  most  commonly  used  antibody  used  in  the  radioimmunotherapy  of  B-cell 
malignancies  is  anti-CD20:  murine  anti-CD20  conjugated  to  90Yttrium  (Zevalin)  has 
been approved for use  in NHL.  A  randomised controlled trial  demonstrated responses 
to this  treatment are  significantly better than to  unlabeled  anti-CD20  Rituximab,  with 
overall  responses  of 80%  vs.  56%  for the  unlabeled  antibody.  However  these  higher 
response rates have not yet translated into improved overall survival85.
38Tositumomab, an  13 iodine labelled murine anti-CD20 antibody (Bexxar) has also had 
encouraging  results,  with  response  overall  response  rates  of 47-68%  in  patients  with
relapsed or refractory follicular lymphoma86,87 and a recently reported overall response
*  88 rate of 95% when used as initial therapy in newly diagnosed patient  .
Other therapies which are currently in phase I/II clinical trials  include 90Yttrium-Anti- 
CD22  for  B-cell  malignancies,  90Yttrium-humanised  anti-Tac/CD25  for  T-cell 
leukaemia and 2l3Bismuth-humanised anti-CD33 for AML.
The  main  side  effects  of these  treatments  are  the  development  of human  anti-mouse 
antibodies  (HAMA)  and  myelosupression.  Fears  of  increased  incidence  of  therapy 
related  MDS  or  AML  as  compared  to  conventional  therapy  have  so  far  been 
unfounded89.
iv.  Antibody directed enzyme therapy (ADEPT)
This  novel  targeting  strategy  involves  a  two  step  approach:  in  the  first  step  non- 
internalising monoclonal antibodies are used to localise enzymes to target cells bearing 
specific  tumour  antigens.  After  any  unbound  antibody-enzyme  conjugate  has  cleared 
from the circulation, prodrugs are administered, which are converted to active drug by 
the targeted enzyme. This strategy allows high concentrations of drug to localise to the 
tumour  site,  where  it  can  be  taken  up  passively  both  by  antigen  positive  cells  and 
antigen negative bystander cells. Many enzymes and prodrugs are available for use with 
ADEPT  technology,  including  P-lactamase  which  cleaves  P-lactam  rings  to  release 
active  drugs  such  as  doxorubucin  and  cytosine  deaminase,  which  converts  5- 
flurocytosine to the active drug 5-flurouracil.
To  date  there  have  been  no  clinical  trials  of ADEPT  technology  for  haematological 
malignancies  but  phase  I  trials  in  colorectal  cancer  have  shown  only  modest  anti-
39tumour responses and significant immune responses against the targeted enzyme have 
been observed90.
401.2.  Vectors for targeted therapy
1.2.1 Monoclonal antibodies (mAbs)
IgG molecules are the most common antibodies employed in cancer therapy. Antibodies 
are Y shaped (Fig  1.1), having two arms attached to a single stem.  The arms of the Y 
are  the  variable  regions,  the  tips  of the  arms  containing  specific  complementarity  - 
determining  regions,  with  the  stem  being  the  constant  region.  The  constant  region 
triggers effector cell function i.e. ADCC and CDC by linking the complex to other cells 
of the immune system.
In  1953  Pressman and Komgold demonstrated that antibodies could specifically target 
tumour cells 91.  The advent of hybridoma technology 20 years later, when Kohler and 
Milstein  discovered  that  the  antibody producing cells  from  a  mouse  spleen  could  be 
immortalised  by  fusion  with  myeloma  cells,  allowed  the  production  of  unlimited
Q9
supplies of monoclonal antibody directed against a specific antigen  . In  1979 the first 
patient was treated with a monoclonal antibody directed against a lymphoma-associated
93 antigen  .
1.2.1.1 Structural modifications of monoclonal antibodies
a.  Antibody fragments
In an effort to increase the ability of relatively large monoclonal antibodies to penetrate 
solid and often poorly vascularised tumours, antibody fragments have been used in the 
place  of the  whole  antibody  molecule  (Fig. 1.1).  Fragments  consisting  of the  specific 
binding  regions  with  much  of the  constant  region  deleted:  Fab  or  F  (ab’)2  can  be 
prepared by digestion of whole antibody using papain or pepsin proteases respectively.
41Recombinant  antibody technology  has  allowed  the  production  of even  smaller  single
chain Fvs antibody fragments (sCFvs), consisting of only the variable light chain (VL) 
and variable heavy chain (VH) domains covalently connected by a polypeptide linker
There  are  however,  disadvantages  to  using  smaller  antibody  fragments,  they  have 
significantly  reduced  serum  half-life  when  compared  to the  whole  antibody,  binding 
avidity that comes from the presence of two binding sites on the molecule is lost,  and 
lack of the Fc portion of the antibody  means that  much of the host  effector response 
(CDC, ADCC) is diminished.
Fig 1.1  Relative sizes of an antibody molecule and antigen binding fragments
94. These antibody fragments have the potential to penetrate deeper into tumour masses.
Fc regie
IgG  150kD
F (ab’)2  95kD 
Fab  47kD
9
sFv  25kD
42b.  Humanisation of monoclonal antibodies
The  first  generation  of monoclonal  antibodies  were  murine  antibodies  derived  from 
mouse  B  cell  hybridomas92.  However  it  soon  became  clear,  that  they  had  limited 
clinical potential as the murine mAbs were recognised by the immune system as foreign 
material,  resulting  in  the  production  of human  anti-mouse  antibodies  (HAMA).  The 
HAMA  response  alters  the  pharmakokinetics  of  mAb  therapy,  leading  to  rapid 
clearance of the agent and limiting the ability to retreat patients95. Furthermore, murine 
mAbs are inefficient at triggering host effector cell responses.
An  initial  strategy  to  humanise  monoclonal  antibodies  was  to  produce  human 
hybridomas using human B cell lines.  However these cell lines were unstable yielding 
only  small  amounts  of  antibody.  Subsequently,  genetic  manipulation  was  used  to 
produce more human-like monoclonal products by splicing the antigen binding parts of 
the  murine  antibody  into  a  human  antibody  backbone96.  The  extent  to  which  the 
antibody  molecule  is  humanised  can  vary;  a  chimeric  mAb  such  as  Rituximab  is 
approximately  half human  and  half murine,  whereas  a  humanised  antibody  such  as 
CMA-676  (anti-CD33  part  of gentuzamab  ozogomicin)  is  95%  human  with  only  the 
complementarity  determining  regions  being  derived  from  the  mouse.  (Fig 1.2).  Fully 
human antibodies can be obtained using phage display libraries or transgenic mice, both 
of which make use of repertoires of human V-regions97.
II
Murine Ab Chimeric Ab Humanised Ab
Fig. 1. 2 Murine, chimeric and humanised monoclonal antibodies
43
i1.2.1.2  Mechanism of action of monoclonal antibodies
Monoclonal antibodies can kill tumour cells in one of 4 general ways:
a.  By  inducing  fatal  immunological  injury  via  host  effector  mechanisms:  CDC  and 
ADCC.
b. By binding to cell-surface receptors resulting in signal transduction events leading to 
apoptosis.
c.  By  blocking  binding  of growth  factors  and/or  survival  factors  to  the  cell-surface 
receptor.
c.  By targeting cytotoxic therapy to the cell (conjugated antibodies).
a.  Antibody  dependent  cell  mediated  cytotoxicity  and  complement  dependent 
cytotoxicity.
ADCC  is  triggered  by the  interaction  between the  Fc  region  of an  antibody  that  has 
bound,  through  its  antigen-binding region to  a tumour cell,  and  the  Fey  receptors  on 
immune  effector  cells  (Figl.3).  Effector  cells  include  phagocytic  cells  such  as 
macrophages and neutrophils which engulf and destroy antibody coated cells, and other 
cells  such  as  NK  cells  which  are  triggered  to  release  stored  cytoplasmic  cytotoxic 
granules  containing  perforin  and  granzyme  when  their  Fc  receptors  are  engaged, 
leading to cell lysis.
The  first  step  of CDC  is  the  recruitment  of the  complement  component  Clq  by  IgG 
bound to  the  tumour cell  surface  (Figl.3).  This  activates  the  proteolytic  complement 
cascade, which leads to the formation of a membrane attack complex that kills the cell 
by  disrupting  its  cell  membrane.  Tumour  cell-bound  C lq  can  also  bind  directly  to 
complement receptors on effector cells, which can trigger cell-mediated tumour lysis or 
phagocytosis.
44Effector cell
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Fig 1.3 Antibody Effector Function97
45b.  Signaling events
Several  antibodies  have  shown  evidence  of  direct  signaling  effects  consequent  to 
binding  to  their  ligands;  these  include  chimeric  anti-CD20  (Rituximab),  humanised 
anti-CD52 (Campath 1-H) and humanised anti-HLA-DR (Apolizumab/ HuldlO). 
Crosslinking  of target  antigens  by  mAb  seems  to  be  important  in  the  induction  of 
signaling events98. Furthermore, increased signaling activity is noted in vitro when the 
mAbs themselves are  crosslinked by a second layer of antibody.  In vivo this function 
may be performed by Fc receptor expressing cells.
Rituximab crosslinking has been shown to mediate cell death in CD20-positive B-cell 
lines  independent  of  ADCC/CDC,  by  disrupting  normal  B-cell  signaling  and  the 
induction of cell cycle arrest and apoptosis " . Binding of CD20 was shown to increase 
intracellular calcium  levels  secondary to  the  phosphorylation  and  activation  of CD20 
associated  serine  and  tyrosine  kinases.  More  recent  work  has  demonstrated  that 
Rituximab  induced  cross-linking  of  CD20  causes  a  conformational  change  in  the 
protein  that  promotes  its  stable  association  with  lipid  raft  platforms.  Within  the  raft 
CD20  co-localises  with  the  Src  family  protein  tyrosine  kinase,  thus  facilitating 
transmembrane signaling .It was also noted that the accumulation of CD20 in lipid rafts 
increases  the  sensitivity  of the  glycosylphosphatidylinositol  (GPI)  anchored  CD55  C 
defence protein to phospholipase C and D, which may alter the complement defence of 
cells that bind to Rituximab in vivo.  100 101
Crosslinking  of  Campath- 1H  has  similarly  been  shown  to  trigger  tyrosine 
phosphorylation events in human T and CLL cells in vitro, however CD52 ligation did 
not lead to any detectable changes in intracellular calcium  levels102,103.  CD 19 has  also 
been  shown  to  be  physically  and  functionally  associated  with  the  src  family  protein
46tyrosine  kinases  and  that  antibody  binding  to  CD 19  initiates  multiple  intracellular 
signal transduction cascades including increases in intracellular calcium ions 104.
c.  Growth factor blockade
Monoclonal  antibodies  can  be  used  directly  to affect the  survival  of tumour  cells  by 
depriving  them of essential  extracellular proliferation  and/or  survival  signals  such  as 
those  mediated  by  growth  factors  through  their  cell-surface  receptors.  Examples  of 
these are growth factor receptors such as epidermal growth factor receptor (EGF) which 
is overexpressed in a variety of tumours105, HER2 overexpressed in 30% of metastatic 
breast  cancers106  and  vascular  endothelial  growth  factor  receptor  (VEGF)  which  is 
essential  for  angiogenesis  and  may  be  important  in  the  pathogenesis  of  multiple
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myeloma as well as numerous solid tumours  .
Increased surface growth factor receptor is often associated with increased production 
of the  growth  factor  by  the  tumour  cells,  indicating  autocrine  growth  control  in  the 
progression of these tumours. Binding of the growth factors to their receptors triggers a 
cascade  of  cellular  biochemical  events  including  receptor  autophosphorylation  and 
activation.  Receptor  autophosphorylation  activates  in  turn  the  RAS  GTP-binding 
protein,  thus  initiating  a  cascade  of protein  phosphorylation  events  culminating  in 
activation of ERK1/2  and  consequent triggering  of the  cell  cycle108.  Blocking  growth 
factor-receptor  interaction  with  monoclonal  antibodies  can  therefore  effectively 
decrease tumour cellular proliferation or neovascularisation of solid tumours.
47d.Conjugated monoclonal antibodies
Most  conjugated  antibodies  need  to  be  internalised  to  deliver  their  toxic  conjugate. 
Exceptions to this are ADEPT enzymes, which need to be present on the cell surface to 
convert  non-active  prodrugs  into  active  cytotoxic  molecules,  and  radiolabelled 
antibodies, which are for the most part non-internalising.
Internalisation  of  receptor  bound  antibody  occurs  through  clathrin-mediated 
endocytosis.  Internalised molecules are delivered to early endosomes where receptor -  
ligand  uncoupling  occurs  in  the  mildly  acidic  environment  of the  lysosomes.  Some 
receptors are then recycled back to the plasma membrane through cycling endosomes, 
whereas  ligands  and  downregulated  receptors  are  transported  to  late  endosomes  and 
lysosomes for degradation109.
Many factors need to be taken into account when selecting the most suitable antigen for 
targeted drug delivery to malignant cells; these  include  level  of antigen expression on 
malignant  and  healthy  tissues,  the  degree  of  shredding  of  the  antigen  into  the 
circulation and the effect of the antigen binding to the ligand such as receptor mediated 
internalisation into the endosome and other signaling events.
1.2.1.3  Choice  of  target  antigen  for  targeting  of  cytotoxic  molecules  to 
haematological malignancies
a.  Targeting lymphoid malignancies 
Idiotype protein
The idiotype protein would seem to be the ideal antigen to target for delivering therapy 
to  B-cell  malignancies,  since  it  is  completely  specific  to  the  malignant  clone  and  is 
rapidly internalised on binding to the  antigen.  Early  studies targeted the  idiotype with
48individual monoclonal antibodies designed for a particular patient’s  lymphoma.  Many 
of these  patients  had  direct  anti-tumour  responses  that  lasted  several  years  and  were 
associated with very little toxicity110. However as well as the practical issues of having 
to make patient specific antibodies, idiotype also has the disadvantage of being shed in 
large  amounts  into the  circulation where  it  competes  with the target cells  for binding 
and  forms  complexes  that  are  rapidly  cleared.  Another  problem  with  idiotype 
immunoglobulin is that it undergoes rapid somatic mutations generating tumour clones 
that fail to bind the antibody1 1 1 .
Pan B-cell antigens
Targeting  pan-B-cell  antigens  with  cytotoxic  molecules  leads  to  the  temporary 
elimination of normal as well as malignant B-cells.  However as long as the antigen is 
not  also  expressed  on  the  pluripotent  stem  cell,  repopulation  of the  bone  marrow 
haemopoetic cells can occur post-treatment. Although there is also a theoretical risk of 
increased susceptibility to infections during the period of repopulation, it has not been a 
major problem associated with the use of conjugated antibodies vs. pan B-cell markers, 
presumably because plasma cells  do not express  many of the  antigens  concerned and 
serum immunoglobulin levels are therefore not adversely affected.
CD 19  and  CD22  are  the  most  commonly  used  pan  B-cell  antigens  used  for  drug 
delivery  to  lymphoid  malignancies.  They  are  both  members  of the  immunoglobulin 
supergene  family.  CD 19  is  the  earliest  of  the  B-lineage  restricted  antigens  to  be 
expressed and is detectable on the surface of pre-B cells at approximately the same time 
as  Ig.  heavy chain rearrangement occurs  whereas  CD22  is  only detectable  on the  cell 
surface at more mature stages of B-cell differentiation. The expression of both antigens 
is lost during terminal differentiation to plasma cells.  CD 19 is expressed on almost all
49B-cell  malignancies  whereas  CD22  is  expressed  on  75-80%  of B-cell  NHLs  and  is
more variably expressed cell to cell than CD19112. Neither receptor is shed from
the cell surface and both are internalised on binding to the ligands. CD22 is thought to
be internalised particularly rapidly113. Anti-CD19 antibodies conjugated to toxins such
as  blocked  ricin  77  and  tyrosine  kinase  inhibitors114,115  have  been  used  in  therapeutic
trials  for  the  treatment  of B-cell  malignancies.  BL22,  a  recombinant  immunotoxin
consisting  of the  Fv  domain  of anti-CD22  fused  to  a  fragment  of the  pseudomonas
81 exotoxin has shown impressive activity in purine analog resistant hairy cell leukaemia 
and a phase 2 trial in CLL is currently underway.
The IL-2 receptor and lymphocyte activation markers
The  IL-2  receptor  comprises  three  subunits,  the  alpha  (also  known  as  Tac,  p55  or 
CD25),  beta and  gamma chains.  The  IL-2  receptor is  overexpressed on the malignant 
cells in adult T-cell  lymphoma, peripheral  T-cell  leukaemia/lymphomas, cutaneous T- 
cell lymphomas, B-cell NHL, Hodgkin’s disease, hairy cell leukaemia, CLL and AML 
as well as on activated T-cells.
Immunotoxins have been targeted to the  IL-2 receptor using anti-CD25  antibodies79,80 
or IL-2 fusion toxins116,117.
CD30  is  another  lymphocyte  activation  marker  which  is  also  expressed  on  Reed 
Sternberg  cells  in  Hodgkin’s  disease  and  anaplastic  large  cell  lymphoma.  As  with 
CD25, it internalises on binding to the ligand and in phase I/II clinical trials anti-CD30 
immunotoxins have shown some efficacy in heavily pretreated refractory patients with 
Hodgkin’s disease118,119.
50b.  Targeting myeloid malignancies
CD33
CD33  is  a  member  of the  immunoglobulin  supergene  family  that  shares  sequence
similarity with CD22. Expression is restricted to cells of the myelomonocytic lineage, it
is  not expressed  on pluripotent stem  cells  but  is  first  detected  on a  sub-population of
mixed  colony  forming  cells,  expression  then  continues  along  the  myelomonocytic
pathway  until  it  is  downregulated  on  granulocytes  but  retained  by  monocytes  and
macrophages120. CD33 is the principal antigen used for targeting myeloid malignancies.
121 CD33  is expressed on blast cells in AML and to a lesser extent in MDS  and CML  .
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Anti-CD33  antibodies  have  been  conjugated  to  toxins  ’  ’  and  more  recently  the
70
anti-tumour antibiotic calicheamicin for the targeted therapy of AML  .
1.2.2  Non antibody-derived targeting vectors
Non-antibody  ligands  can  be  used  to  target  toxic  vectors  (Table 1.4).  Non-antibody 
ligands are often readily available, inexpensive and easy to manufacture as compared to 
monoclonal antibodies or antibody fragments. The disadvantage is that their binding is 
often less selective than with monoclonal antibodies.
Non-antibody vectors can be the natural  ligands that bind specific known receptors on 
target cells such the folate or transferrin receptor, which are overexpressed in a variety 
of malignancies.  Alternatively, phage display technology can be used to identify short 
peptides  sequences  that  bind  to  specific  molecules,  cells,  tissues  or  organs.  Some 
examples of non-antibody vectors used to target toxic ligands can be found in Table 1.4. 
* Indicates sequence identified by phage display.
51Vector Target Target tissue Ref.
Folate Folate receptor Cancer cells that overexpress 
the folate receptor
"  T24
Transferrin Transferrin receptor Cancer cells that overexpress 
the transferrin receptor
125
.
GM-CSF GM-CSF receptor Leukaemic blasts
*RGD Cellular adhesion molecules 
such as avp3 integrin
Vascular endothelial cells in 
solid tumours
126
*NGR Aminopeptidase N (CD 13) Vascular endothelial cells in 
solid tumours
126
♦SMSIARL Prostate vasculature Prostate vasculature
127
♦THALWHT Human airway epithelial 
cells
Human airway epithelial cells
128
Table 1.4  Non-antibody vectors used to target toxic ligands .
1.2.3  Phage display technology
Phage display comprises a selection technique in which a peptide or protein (including 
antibody or enzymes) is expressed as a fusion with the coat protein of a bacteriophage, 
resulting in the display of the fused protein on the exterior surface of the phage virion. 
Phage  display  libraries  of peptides  and proteins  can  be  screened,  both  in vivo  and  in 
vitro,  to  rapidly  identify  those  compounds  that  bind  with  high  affinity  and  high 
specificity  to  targets  of interest.  Each  library  contains  millions  of different  peptide 
sequences. The in vitro method of screening these libraries to select phage that bind to a 
specific  target with  high  affinity  is  termed  biopanning  (Figl.4).  In  it’s  simplest  form 
biopanning  is  carried  out  by  incubating  a  library  of phage  displayed peptides  with  a 
plate (or bead) coated with the target, washing away the unbound phage, and eluting the
52specifically-  bound  phage.  The  eluted  phage  is  then  amplified  and  taken  through 
additional  cycles  of biopanning  and  amplification  to  successively  enrich  the  pool  of 
phage  in favour of the tightest binding  sequences.  After 3-4 rounds,  individual clones 
are characterised by DNA sequencing
Phage  display  technology  has  been  used  in  this  way  to  identify  scFv  against  many 
purified  haematological  cell  surface  antigens  including  blood  group  antigens  and 
malignant  cell  surface  molecules  such  as  CD 19  expressed  in  B-cell  malignancies, 
CD38 in multiple myeloma and CD30, which is overexpressed on Reed Sternberg cells 
in  Hodgkin’s  disease129,130.  These  scFvs  can  be  linked  to  radionucleotides  or 
fluorophores  for  imaging  purposes  (having  better  tumour  penetration  than  larger 
immunoglobulin)  or  to  toxins.  The  therapeutic  usefulness  of  these  immunotoxins 
however can be limited by their rapid renal clearance and short half-life.
Phage display may also be performed to select peptides that bind to immunoglobulin on
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the surface of myeloma  or CLL cells  or to identify peptides that bind whole cells 
such as fibroblasts133 or more recently whole CLL cells134.
A method of in vivo phage selection has also been reported: by injecting phage display 
libraries  into  the  tail  vein  of mice,  sacrificing  the  mice  after  several  minutes,  then 
isolating  and  amplifying  phage  which  bound  to  specific  organs  or  tissues,  specific 
homing peptides have been identified135.
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Fig 1.4 Schematic representation of biopanning a phage display library 136
541.3.  Toxic ligands used in targeted therapy
1.3.1 Conventional chemotherapeutic agents
Conventional chemotherapeutic agents linked to monoclonal antibodies have not been 
very  successful  in  treating  malignancies.  A  number  of  agents  incorporating 
doxorubicin,  methotrexate,  vinca  alkaloids  or  cytosine  arabinoside  have  been  used 
against a wide variety of tumour types, but none are currently in clinical development. 
The  lack of success  is mainly due to  insufficient cytotoxicity of the agents, because a
137 therapeutic  concentration  of  the  drug  in  target  cells  has  not  been  achieved  . 
Liposomal formulations of various conventional chemotherapeutic drugs conjugated to 
antibodies  (immunoliposomes),  allow  the  delivery  of increased  concentrations  of the 
drugs  with  improved  pharmakokinetics  to  target  cells  and  have  been  investigated  in
n o  i in
vitro in lymphoma cell lines and in mouse models.  ’
1.3.2 Protein toxins
These are  extremely potent toxins, which once  internalised into  a cell,  disrupt protein 
synthesis  by  action  on  the  ribosome.  They  are  significantly  more  toxic  than 
conventional chemotherapeutic agents.  Whereas conventional chemotherapeutic agents 
act  stoichiometrically,  protein  toxins  act  catalytically.  Thus  a  single  catalytic  toxin 
molecule in the cytoplasm of a cell can cause cell death.
Because the toxins themselves show widespread binding to many normal tissues, which 
might  override  the  specific  binding  of  the  ligand,  their  binding  domains  are  often 
removed  or  mutated  to  prevent  them  from  binding  to  normal  cells140.  They  are  then 
fused  or  chemically  conjugated  to  a  ligand  specific  for  tumour  cells  Alternatively,
55inserting the DNA encoding the  fusion toxin into  an expression plasmid can produce 
recombinant toxins.
Ribosome targeting toxins include plant and bacterial toxins:
1.3.2.1  Plant toxins
Plant toxins exist in nature as holotoxins (class II ribosome inactivating proteins) such 
as  ricin,  which  contains  a  binding  domain  connected  to  an  enzymatic  domain  via  a 
disulphide  bond,  or  hemitoxins  (class  I  ribosome  inactivating  proteins)  such  as 
pokeweed  antiviral protein (PAP),  saporin and  gelonin,  which  contain  enzymatic,  but 
no binding domains.  It is thought that only the  enzymatic  domain translocates to the 
cytosol and hence the binding domains of holotoxins are removed by reduction of the 
disulphide  bond  prior  to  translocation.  After  internalisation  into  endosomes,  plant 
toxins are believed to traffic through the golgi and then translocate into the cytosol via 
the  endoplasmic  reticulum.  Once  in  the  cytosol  they  inhibit  intracellular  protein 
synthesis by preventing the association of elongation factor  1   and 2 (EF-1, 2) with the 
60s ribosomal subunit141.
Originally the  enzymatic domains  of the plant toxins  were conjugated to their ligands 
via  disulphide  bonds,  however  even  without  its  binding  domain  ricin,  was  taken  up 
non-specifically  by  macrophages  and  hepatic  parenchymal  cells.  The  hepatic  uptake 
was  due  to  glycosylated  side  residues  on  the  ricin  enzymatic  domain  (ricin  A  chain) 
binding to mannose receptors on the liver cells. Chemical deglycosylation, blocking the 
ricin A chain or using a recombinant ricin A chain  improved the therapeutic  index  of 
these immunotoxins142
561.3.2.2 Bacterial toxins
The two bacterial toxins used in immunotoxin therapy are Pseudomonas exotoxin (PE) 
made  by  Pseudomonas  aeruginosa  and  Diphtheria  toxin  (DT),  made  by 
Corynebacterium diptherium.  These toxins  are  single  chain proteins that contain both 
binding and catalytic  domains.  They prevent protein  synthesis  by  catalysing the  ADP 
ribosylation of EF-2, resulting in its inactivation.
Both DT and PE  undergo proteolysis  and  disulphide  bond  reduction to  separate their 
binding and catalytic domains.  PE undergoes  further processing,  resulting in a 37kDa 
carboxy terminal toxin fragment ending in the residues REDL.  This binds to a REDL 
receptor  and  is  transported  via  the  golgi  to  the  endoplasmic  reticulum  and  then  the 
cytosol. In contrast, the catalytic A chain of DT is translocated into the cytosol directly 
from the endosome141.
BL22, an immunotoxin consisting of truncated PE linked to CD22, has been shown to 
cause apoptotic cell death in CLL cells.143
1.3.2.3 Limitations of protein toxins
The  extreme  potency,  non-specific  binding  and  immunogenicity  of the  protein toxins 
have been a major limitation in their clinical use.  Although immune responses against 
antibodies  can  be  reduced  by  antibody  engineering,  the  toxins  themselves  are 
immunogenic  and  cannot be  humanised.  New  strategies  such  as  linking  polyethylene 
glycol to ricin molecules have  significantly reduced the  immunogenicity of the toxin, 
with no effect on its ability to  inhibit protein synthesis144.  Another way to circumvent 
the  immunogenicity  of non  human  proteins  is  to  use  human  proteins  as  toxins,  for 
example the human ribonuclease angiogenin has been genetically fused to fragments of
57an  anti-transferrin  receptor  antibody  and  found to  be selectively  cytotoxic  for
transferrin receptor bearing cells145.
Vascular  leak  syndrome  has  been  the  major  dose  limiting  toxicity  in  immunotoxin
78 therapy,  especially  in  patients  who  have  received  prior  radiotherapy  .  It  involves
damage  to  vascular  endothelial  cells,  resulting  in fluid  and  protein  extravasation,
leading  to  weight  gain  and  peripheral  oedema  and  in  its  more  severe  form,  renal 
dysfunction and pulmonary oedema146.  Baluna et al  have  identified  a  structural  motif 
LDV,  which  is  common to  several  molecules  that  exhibit vascular toxicity  including 
ribosome inactivating proteins, IL-2 and disintegrins.  They also demonstrated that this 
motif is not essential for the protein synthesis inhibiting function of these toxins147.
1.3.3  Non protein toxins
Maytansinoids  148  and  calicheamicins149  are  the most  extensively  studied  small
molecule  toxins.  These  molecules,  which  are  100-1000  times  more  potent  than 
conventional  chemotherapeutic  agents  can  be  delivered  to  target  cells  as  inactive 
prodrugs by conjugating them to monoclonal  antibodies. Activation of the prodrug on 
release of the drug from the antibody and occurs in the tumour cells following receptor 
binding and antibody internalisation.
Maytansine  kills  cells  by  interfering  with  microtubule  formation.  Derivatives  of 
maytansine  have  cured  mice  that  bear human  tumour  xenografts  150  and two  phase  I 
trials for antibody-maytansinoid conjugates are currently in progress.
Calicheamicin y1   is a member of the very potent enediyne family of natural antitumour 
antibiotics, originally isolated from Micromonospora echinospora dsp calichenis.
The  anti-tumour  activity  of  Calicheamicin  is  approximately  4000  x  greater  against 
mouse  tumours  than is  adriamycin  151.  It binds  to  the  minor  groove  of DNA  causing
58double  strand  breaks  and  ultimately  apoptotic  cell  death.  As  the  toxic  ligand  of 
Gemtuzumab ozogamicin, it has yielded promising results for the treatment of AML.
591.4.  Apoptosis and mitochondria
Apoptosis  is  an  evolutionarily  conserved  mechanism  of programmed  cell  death,  in 
which  cells  undergo  carefully  orchestrated  self-destruction  and  phagocytosis  without 
eliciting  an  inflammatory  response152.  In  contrast,  necrotic  cell  death,  ensuing  from 
damage to the cell membranes, results in the release of proteins and nucleic acids into 
the intracellular space.
Apoptotic  cells  display  characteristic  morphological  features,  which  include  DNA 
fragmentation,  chromatin  condensation,  membrane  blebbing,  cell  shrinkage,  and
152 disassembly into membrane-enclosed fragments  .
All  of the  above  changes  occur  as  a  result  of the  action  of a  group  of intracellular 
cysteine  proteases  called  caspases.  These  become  activated  in  response  to  a  wide 
variety  of  cell  death  stimuli.  Caspases  are  organised  in  cascades,  with  upstream 
(initiator) caspases responsible for activating downstream (effector) caspases.
1.4.1  Apoptotic pathways
There are two major pathways by which effector caspases become activated (Fig 1.5):
1.  The extrinsic pathway:  this involves  ligation of cell  surface  death receptors of the 
TNF  family,  which  activates  a  series  of events  leading  to  the  recruitment  of death 
effector protein Fadd/Mort and activation of caspase 8153.
2.  The  intrinsic  pathway:  this  occurs  in  response  to  disturbances  of intracellular 
homeostasis  or  damage  to  specific  organelles  secondary  to  stress  conditions  such  as 
ultraviolet  (UV)  irradiation,  cytotoxic  drugs  or  growth  factor  deprivation.  In  this 
pathway, caspase 9 is activated, via a poorly understood mechanism involving changes 
in  mitochondrial  membrane  permeabilisation  (MMP),  cytochrome  c  release  into  the
60cytosol and the dATP/ATP dependent assembly of the apoptosome, a complex made up 
of cytochrome c, apoptotic protease activating factor 1   (Apaf-1) and pro-caspase 9154. 
Both  pathways  culminate  in  the  activation  of  downstream  effector  caspases.  The 
cleavage  targets  of these  effectors  are  a  restricted  set of cellular  substrates.  Up to  60 
different  caspase  substrates  have  been  identified155,  some  of which  are  listed  in table
1.5.  The  net  result  of the  action  of the  effector  caspases  on  their  substrates  is  the 
morphologically distinct apoptotic cell.
Extrinsic pathway  Intrinsic pathway
Damage to cellular compartments 
Ligand  V   I  Signalling pathways
TNF Receptor
FADD/MORT 
Pro-caspase 8
Caspase 8 □
Bcl-2
T
Cytochrome c  •
ATP
Apaf-1 
Caspase 9
Pro-caspase 3 
Caspase 3
T
Apoptosis
Fig.l. 5 Pathways of apoptotic cell death.
61Substrate Caspase Consequences
Cytoskeletal scaffold proteins
Lamin:  scaffold  protein  of  nuclear 
envelope
6 Chromatin condensation and 
pyknosis
Gelsonin: actin depolymerising enzyme 3 Actin depolymerisation and 
membrane blebbing
a-fodrin  and  focal  adhesion  kinase: 
make up focal adhesion complex which 
links  plasma  membrane  to  the 
extracellular matrix
3,6,7 Cell body shrinkage and 
detachment from basement 
membrane and neighbouring 
cells.
Inhibitor  of  p21-activated  kinase 
(iPAK-2)
3 Activation  of  PAK2,a  GTPase 
involved  in  actin  dynamics,leads 
to formation of apoptotic bodies
Repair and housekeeping enzymes
Poly (ADP) ribose polymerase (PARP) 3,7 Blockade of DNA repair
DNA metabolism
Inhibitor  of  caspase-activated  Dnase 
Protein kinase C (ICAD)
3,7 Activation  of  ICAD  nuclease, 
leading to DNA fragmentation
Tablel. 5 Classes of caspase substrates 155
621.4.2 Recognition of apoptotic cells by phagocytes
One of the important distinctions between apoptotic and necrotic cell death is the lack 
of an  inflammatory  response  during  apoptosis.  This  is  in  part  due  to  the  fact  that 
apoptotic  cells  are  engulfed  with  their  outer  membrane  intact  thereby  preventing  the 
release  of intracellular components,  but also  because the  macrophages  themselves  do 
not elicit an inflammatory cytokine response as they do when phagocytosing necrotic or 
infective tissue. There are a number of macrophage receptors such as CD 14, vitronectin 
and other integrins that play a role in recognising markers displayed by apoptotic cells. 
The best characterised of the signals in the apoptotic cell  is a change in the pattern of 
phospholipid  distribution  in  the  cell  membrane  with  exposure  of phosphatidylserine 
residues on the outer surface of the membrane. This is recognised by a newly identified 
macrophage  receptor,  the  PtdSer  receptor,  which  not  only  initiates  phagocytosis,  but 
also  seems  to  be  coupled  to  anti-inflammatory  clearance  mechanisms,  stimulating 
macrophage TGF-P secretion and inhibiting TNF-a release156.
1.4.3 Role of mitochondria in apoptotic (and non-apoptotic) cell death
1.4.3.1  Triggers of mitochondrial disruption
Mitochondria,  the  organelles  responsible  for  cellular  oxidative  phosphorylation  and 
ATP production, also play a central role in apoptotic (and non-apoptotic) cell death. A 
wide variety of triggers can cause mitochondrial disruption. Many cellular insults such 
as  radiation,  drug-induced  DNA  damage,  osmotic  stress  or  cytokine  withdrawal  can 
trigger the mitochondrial apoptotic pathway154.
DNA damage triggers the mitochondrial apoptotic pathway via a mechanism
63involving  activation  of  ataxia  telangiectasia  mutated  (ATM)  with  consequent 
stabilisation  of the  tumour  suppressor  protein  p53157.  ATM  is  a  protein  kinase  that 
belongs  to  a  group  of  PI3-K  related  kinases  that  also  includes  DNA-PK  (DNA 
dependent protein kinase) and ATR (ataxia telangiectasia and Rad3 related).  ATM and 
DNA-PK  can  bind  directly  to  free  DNA  ends,  which  then  triggers  kinase 
phosphorylation cascades to transmit damage signals to checkpoint and repair proteins. 
p53 is a tumour suppressor protein that is normally maintained at low levels within the 
cell  through  its  interaction  with  Mdm2,  a  ubiquitin  ligase  that  escorts  p53  from  the 
nucleus and targets it for protein degradation by the 26S proteosome in the cytoplasm, 
thus ensuring that the p53  signal is carefully controlled.  Phosphorylation of either p53 
or  Mdm2  by  ATM  family  of proteins  after  DNA  damage  prevents  the  two  proteins 
from  interacting,  thus  stabilising  and  activating  p53.  A  key  consequence  of  p53 
induction is the increased transcription of the pro-apoptotic genes Puma and Noxa. p53 
also enhances reactive oxygen species (ROS) production by transcriptionally activating 
genes  such as PIG3  (p53  induced gene  3).  p53  has  been shown to directly upregulate 
Apaf-1, thus making cells more sensitive to apoptosis after cytochrome c release from 
the  mitochondria.  p53  can  also  downregulate  anti-apoptotic  proteins  such  as  Bcl-2. 
Thus,  cells  become  more  sensitive  to  apoptosis  by  upregulating  pro-  and 
downregulating anti-apoptotic proteins157.
641.4.3.2  Consequences of mitochondrial disruption
Disruption of the mitochondria leading to changes  in MMP  and cytochrome  c release 
commit a cell to die, either by a rapid apoptotic mechanism involving Apaf-1  mediated 
caspase activation or by a slower necrotic process due to collapse of electron transport 
due to depletion of cytochrome c from the mitochondria154
1.4.3.3. Cytochrome c and other mitochondrial pro-apoptotic factors
Mitochondria  contain  a  potent  cocktail  of  pro-apoptotic  proteins  that  are  released 
during  cellular stress.  One  of these pro-apoptotic  proteins  is  cytochrome  c,  which is 
localised  in  the  intermembrane  space  of  the  mitochondria.  In  addition  to  its 
involvement  in mitochondrial  electron transport,  oxidative  phosphorylation,  and  ATP 
production,  cytochrome  c  is  one  of the  components  required  for  the  activation  of 
caspase  9 in the cytosol.  Once released into the cytosol, cytochrome c associates  with 
Apaf 1   and then pro-caspase 9 (and possibly other proteins) in a dATP/ATP dependent 
process, to form the apoptosome. In the apoptosome juxtaposition of up to twelve pro- 
caspase  9  molecules  leads  to  their  activation,  either  by  conformational  change  or by 
autocatalysis  to  form  an  active  dimeric  protease.  Active  caspase  9  subsequently 
activates caspase 3 resulting in apoptosis158.
Other  mitochondrial  pro-apoptotic  factors  include  apoptosis  inducing  factor  (AIF), 
Smac/DIABLO  (second  mitochondria-derived  activator  of caspase,  also  called  direct 
IAP binding protein with low pi) and pro-caspases 2, 3 and 9.
AIF is a death effector, which is synthesised as a precursor in the cytosol and imported 
into the intermembrane space of the mitochondria where it is presumed to be involved 
in redox reactions.  Upon apoptosis  induction, AIF  translocates from  the mitochondria 
to  the  nucleus  before  the  release  of cytochrome  c.  AIF  induces  caspase-independent
65chromatin  condensation  and  large-scale  DNA  fragmentation  when  added  to  purified 
nuclei in-vitro.  However, caspases are still required for cells to die by apoptosis.  The 
early  stages  of  chromatin  condensation  involve  AIF,  whereas  later  stages  rely  on 
caspase activation by cytochrome c 159.
Smac/DIABLO  is  also  released  from  the  mitochondria  into  the  cytosol  during 
mitochondrial  apoptosis.  It  eliminates  the  inhibitory  effects  of  IAPs  (inhibitors  of 
apoptosis) on caspases160.
1.4.3.4  Mitochondrial structure
Mitochondria are bound by two membranes: the inner and outer membranes, which are 
separated  by  the  intermembranous  space.  The  inner  membrane  is  highly  convoluted; 
forming a series of infoldings called cristae .The space bound by the cristea is called the 
matrix.  Oxidative  phosphorylation  takes  place  in  the  inner  mitochondrial  membrane 
whereas the reactions of the citric acid cycle and fatty acid oxidation take place in the 
matrix.
The  outer  membrane  contains  protein  structures  called  porins  or  voltage  dependent 
anion  channels  (VDAC),  which  in  normal  conditions  are  permeable  to  solutes  up  to 
about 5000 Da. The inner membrane is almost is almost impermeable in physiological 
conditions (although transient increases in permeability may occur to selected ions and 
metabolites  of  less  than  1500  Da  as  a  consequence  of  various  ion  channels  and 
uniporters), thereby allowing the respiratory chain to create an electrochemical gradient 
(AT'm).  The  AT'm results  from  electron  transport  chain  mediated  pumping  of protons 
across  the  inner  mitochondrial  membrane  thus  driving  ATP  synthase  which 
phosphorylates  ADP  to  ATP.  ATP  generated  on  the  matrix  side  of  the  inner
66mitochondrial  membrane  is  then  exported  in  exchange  for  ADP  by  the  adenine 
nucleotide transported (Ant).
The  permeability  transition  (PT)  pore  is  a  poorly  characterised  conductance  channel, 
which is proposed to include both inner and outer membrane proteins (Ant and VDAC), 
operating in concert, at inner and outer mitochondrial membrane contact sites161.
1.4.3.5 Models for cytochrome c release into the cytosol
Several  models  have been proposed  to  explain  the  release  of cytochrome  c  from  the 
mitochondrial  intermembrane  space  into  the  cytosol  162 163.  One  model  involves 
mitochondrial  swelling  and  rupture  of the  outer  membrane  leading  to  cytochrome  c 
release.  Mitochondrial  swelling  in  this  model  may  occur  as  a  consequence  of the 
interaction of PTP  openers  such as Bax  interacting with Ant leading to to  opening of 
the  PTP  in the  inner membrane164  or to  mitochondrial  hyperpolarisation  secondary to 
closure  of  the  VDAC165.  Against  this  model  is  the  observation  that  cytochrome  c 
release and apoptotic cell death can occur in the absence of mitochondrial swelling. 
Other models propose that cytochrome c release  occurs  through channels  in the outer 
mitochondrial membrane.  Some pro-apoptotic members of the Bcl-2 family which bear 
structural resemblance to channel -  forming bacterial toxins can form  ion channels  in 
synthetic  lipid  bilayers166,167  and  have  been  demonstrated  to  induce  release  of 
cytochrome  c from  isolated mitochondria in the  absence  of mitochondrial  swelling168. 
Another  theory  proposes  that  Bax  interacts  with  VDAC  leading  to  conformational 
change in the channal thus allowing the passage of cytochrome c into the cytosol169.
671.4.4  Bcl-2 family of proteins
The mitochondria-mediated pathway of apoptosis  is  regulated by the  Bcl-2  family of 
anti-apoptotic  and proapoptotic  proteins  which  all  share  at  least one  Bcl-2  homology 
(BH) domain.
The Bcl-2 family of apoptosis regulating proteins fall into three sub-families (Fig 1.6)
Bcl-2 sub family  anti-apoptotic
BH4 BH3  BH1 BH2 TM
Examples 
Bcl-2, Bcl-Xl, Bcl-W, Mcl-1
Bax sub family  pro-apoptotic
BH3 BH1 BH2 TM Bax, Bak
BH3 only family  pro-apoptotic
BH3 TM
Bad, Bim, Bid, Puma, Noxa 
(note: Bid lacks a TM domain)
Fig. 1.6. The Bcl-2 protein family
The Bcl-2 homology (BH) domains  1  -4 and the transmembrane (TM) domain are 
shown aligned for comparison.
681.4.4.1  Pro-survival Bcl-2 subfamily
Bcl-2 is a 26-kDa membrane-associated protein with a hydrophobic carboxyl terminal 
transmembrane  domain  that  anchors  it  to  the  cytoplasmic  face  of the  endoplasmic 
reticulum, outer mitochondrial membrane, and the nuclear envelope.
Bcl-2 can protect cells from death induced by growth factor deprivation, y-irradiation, 
or cytotoxic drugs but not from cell death induced by cytotoxic T lymphocytes.
In the mitochondria, Bcl-2 exerts its antiapoptotic effects by interacting with BH3 -only 
pro-apoptotic family members.  A hydrophobic  groove made up of the BH1, BH2  and 
BH3  regions  of Bcl-2  binds  the  BH3  a-helix  region  of the  death  agonists  thereby 
forming inactive heterodimers170.
The  BH4  region  of Bcl-2  is  thought  to  be  responsible  for  a  stabilising  effect  on the 
VDAC channel preventing permeabilisation of the outer membrane165. It is also thought 
to be involved in cell cycle regulation and interaction with regulatory proteins outside 
the Bcl-2 family.
BH1  and BH2  domains, which are present in both pro-apoptotic  (Bax, Bak) and anti- 
apoptotic  (Bcl-2,  Bel  -xl)  members  of  the  family,  have  a  3  dimensional  structure 
resembling  the  pore  forming  domains  of  some  types  of  bacterial  toxins  such  as
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Diphtheria  toxin  ,  and  can  form  ion  channels  when  added  to  synthetic 
membranes166,167.  Bcl-2  can  also  homodimerize  and  form  small  ion  channels  in  the 
outer mitochondrial membrane, which may stabilise the membrane and prevent loss of 
and cytochrome c release172.
Bcl-X,  like  Bcl-2  has  a  hydrophobic  carboxy  terminal  domain  and  shows  a  similar 
subcellular  distribution.  Bcl-X  is  strongly  expressed  in  lymphoid  tissues  and  in  the 
nervous system.
691.4.4.2 Pro-apoptotic BH3-only subfamily
BH3-only proteins act as damage  sensors, detecting intracellular damage  and exerting 
their pro-apoptotic effect by interacting with the pro-apoptotic Bax subfamily proteins. 
BH3-only proteins are normally held in check by diverse mechanisms and are released 
or synthesised de novo in response to specific apoptotic  signals170, resulting in a rapid 
increase in their availability. For example Bim and Bmf are sequestered by binding to 
the  microtubules  or actin cytoskeleton respectively via interaction with a dynein light 
chain and are released in response to microtubule stress. Bad, after phosphorylation by 
kinases such as Akt and protein kinase A,  is bound by  14-3-3  scaffold proteins but is 
released following withdrawal of growth factors and the subsequent downregulation of 
Akt  activity.  Other  members  of the  BH3-only  family  such  as  Noxa  and  Puma  are 
controlled  primarily  at  the  transcriptional  level.  Expression  of  these  proteins  is 
upregulated by p53170. Bid is inactive until proteolytically cleaved by caspase 8 forming 
tBid.  This  excerts  its  actions  by  causing  conformational  change  and  translocation  of 
Bax  to  the  outer  mitochondrial  membrane  where  it  oligomerises  leading  to  pore 
formation  and  cytochrome  c  release173.  tBid  is  also  thought to  act  at the  cardiolipin- 
containing contact sites where the inner and outer mitochondrial membranes interact174.
1.4.4.3 Pro-apoptotic Bax subfamily
Bax  (Bcl-2  associated protein  X),  a 21kDa protein,  exists  as  a cytosolic  monomer in 
healthy  cells.  Like  Bcl-2,  Bax  protein  contains  a  hydrophobic  carboxy  terminus. 
However in Bax this tail occludes the BH1-3 hydrophobic groove. In the presence of a 
stress  signal  the  carboxy tail  is thought to  flip out allowing  integration  into the  outer 
mitochondrial  membrane  and  consequent  oligomerisation.170  BH3-only  proteins  are 
thought to  act catalytically  in  displacing the  c-terminal  tail.  Therefore  the  increase  in
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key event in initiating the mitochondrial pathway of cell killing.
Bax can interact with the mitochondria by three separate mechanisms:
Firstly, at the outer mitochondrial membrane Bax is known to accelerate the opening of 
VDAC with subsequent release of cytochrome c161,175.Secondly, Bax interacts with Ant 
at  the  inner  mitochondrial  membrane,  thus  enhancing  permeability164.  Thirdly,  when 
expressed at high levels Bax can oligomerize, leading directly to pore formation at the 
mitochondrial membrane166.
Bak  (Bcl-2  homologous  antagonist  killer)  is  an  oligomeric  integral  mitochondrial 
membrane protein, which is also thought to change  conformation in during apoptosis. 
Bak is expressed in a wide variety of tissues.
The  antiapoptotic  function  of  the  pro-survival  family  members  (Bcl-2,  Bcl-xl)  is 
thought to  be  mediated by their ability to  bind  and  neutralise the  BH3-only proteins, 
thus  blocking  their  ability  to  catalyse  the  translocation  of  Bax  and/or  Bak,  to  the 
mitochondria.  Thus,  the  susceptibility  of  cells  to  apoptotic  stimuli  is  critically 
dependent  on  the  relative  expression  of  Bcl-2  family  members  versus  the  Bax 
subfamily members. Earlier reports that members of these sub-families may bind each 
other directly are probably based on an artefact induced by detergent lysis of cells.
1.4.5  Mechanisms of resistance to apoptosis of haematological malignancies
In most malignancies the balance between proliferation and programmed cell death is 
disturbed, and defects in the apoptotic pathways allow cells with genetic abnormalities 
to survive. Most chemotherapeutic strategies, including radiation, ultimately kill cancer 
cells by causing irreparable  cellular damage that triggers apoptosis.  Consequently, the 
efficacy of cancer treatments  depends  not only on the  cellular damage they  cause  but
71also on the cell’s ability to respond to the damage by engaging the apoptotic machinery. 
Accordingly,  mutations  affecting  the  apoptotic  pathway  may  result  in  resistance  to 
drugs and radiation.  The two most studied genes  in relation to resistance to  apoptosis 
are p53 and Bcl-2.
p53 Deletion and/or mutation of p53  alleles  results  in the  generation of tumours with 
impaired  expression  of functional  p53  protein  and  are  the  most  frequently  observed 
genetic lesions in human cancers176.With the exception of Burkitt’s lymphoma and L3
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ALL in which mutations are observed in 30% and 55% respectively  , p53 changes are 
relatively  rare  in  haematological  malignancies  and  tend  to  be  associated  with 
progression  or  transformation  of  disease  i.e.  blast  crisis  in  CML  or  Richter’s
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immunoblastic transformation in CLL  . As with other malignancies p53 mutations are
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associated with aggressive disease, drug resistance and poor survival  .
Bcl-2: Abnormalities in Bcl-2 expression represent the single most common molecular 
event  associated  with  lymphomas.  The  t  (14;  18)  translocation  that  places  the  Bcl-2 
gene  on  chromosome  18  under  the  aberrant  transcriptional  control  of  the 
immunoglobulin  heavy  chain  gene  located  on  chromosome  14,  is  present  in  90%  of 
follicular  NHL,  50%  of undifferentiated  B-cell  lymphomas  and  10%  of  large  cell 
diffuse  B-cell  lymphomas179.  Generally,  close  associations  have  been  found  between 
the  presence  of translocation  and  the  expression  of Bcl-2  protein.  However  in  many 
haematological  malignancies,  such  as  mantle  cell  lymphoma,  MM,  CLL  and  AML, 
high level expression of Bcl-2 occurs in the absence of translocations and are associated 
with poor response to therapy180.
721.4.6 Drugs designed to specifically target the mitochondrial apoptotic pathway
Targeting the mitochondrial apoptotic pathway may have advantages over conventional 
chemotherapeutic strategies that act mainly through causing DNA damage and rely on 
the p53  pathway to induce apoptosis.  By acting at the mitochondrial level these drugs 
can bypass the block  caused by p53  mutations  and may overcome the chemoresistant 
effects  of raised  Bcl-2  expression.  Bcl-2  is  an  attractive  therapeutic  target  due  to  its 
overexpression  in  a  wide  variety  of haematological  malignancies  and  its  association 
with oncogenesis as well as the development of chemoresistance.  Furthermore normal 
cells can tolerate reduced Bcl-2 levels, as mice that lack one Bcl-2 allele are completely 
healthy  170.  Bcl-2  knockout  mice  survive  embryonic  development  and  develop
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normally, only later exhibiting marked lymphoid apoptosis.
1.4.6.1  Bcl-2 anti-sense oligonucleotides (ASO)
One  strategy  to  inhibit  Bcl-2  involves  liposomal  oligonucleotides.  These  consist  of 
chemically modified single-strand DNA molecules that have a nucleotide sequence that 
is complementary to the Bcl-2 mRNA.  ASOs  inhibit gene expression by hybridisation 
with the mRNA, followed by cleavage of the mRNA by recruitment of RNAse-H.
Bcl-2  ASOs  have  been  shown  to  induce  apoptosis  in  HL60  cells  and  primary  AML 
blasts  and  to  sensitise  cells  to  the  treatment  with  Ara-C  182.  Increased  sensitivity  to 
chemotherapy has also been demonstrated in NHL and MM183 .
In  a  phase  I  study  in  relapsed  patients  with  Bcl-2-positive  lymphomas,  disease 
stabilisation was seen in 43% (9 of 21) and improvements were seen in  14% (3  of 21, 
including one complete responder)184. Bcl-2 ASOs are currently in phase III trials.
731.4.6.2  BH3 mimetics
Another  strategy  involves  drugs  that mimic  the  structure  of BH3  domains.  Synthetic 
peptides which represent the a-helical  BH3  domains of various Bcl-2  family proteins 
that have  been  modified  to  incorporate  cell  permeable  moieties  have  been  shown  to 
have  specific  effects  on  the  mitochondrial  apoptotic  pathway.  These  effects  include 
inducing  MMP,  interaction  with  ANT  and  stimulating  channel  formation  by 
recombinant Bax.185'188.
HA 14-1  is  a  small  organic  molecule  identified  by  screening  a  virtual  library  of 
compounds using the binding of Bak’s BH3  domain to the BH1-3 pocket of bcl-2 as a 
model. HA 14-1  has been demonstrated to bind to bcl-2 in vitro and to induce apoptosis 
in HL60 cells189. Another small cell permeable compound BH31-2’  has been reported 
to bind to the  hydrophobic pocket of Bc1-Xl  in  a  similar way to  BaxBH3  peptide190, 
and  has  been  demonstrated to  have  effects  at  both  the  inner  and  outer  mitochondrial
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membranes  .  A  further  BH3  mimetic  identified  by  nuclear  magnetic  resonance 
screening has been shown to lead to apoptosis  in lymphoma and small cell carcinoma 
cell lines and had been reported to induce solid tumour regression in mouse models191. 
Gossypol  is  a natural product  found  in  cotton  seed  and  used  as  a herbal  medicine  in 
China.  It interacts with the BH3  binding pocket on the surface of anti-apoptotic Bcl-2 
family  of  proteins.  Semi-synthetic  analogs  of  this  compound  are  currently  in 
development.192
Some antibiotic peptides with a a-helical structure have also been shown to have toxic 
effect on mitochondria; these will be discussed further in the next section (Section 5).
741.5  Antibiotic peptides
1.5.1  Naturally occurring antibiotic peptides
Antibiotic  peptides  form  a  key  component  of  the  innate  immune  system  of  most 
multicellular  organisms.  To  date  several  hundreds  of  structures  with  antimicrobial
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activity have been described in almost all groups of animal and plants  . The peptide 
antimicrobial responses have been most extensively studied in insects, where they have 
been  shown to  be  mediated by  structurally  homologous  signalling  molecules  such  as 
nuclear factor (NF)-kB transcription factors, which induce expression of multiple genes 
encoding antimicrobial peptides  in both blood cells  (haemocytes)  and the  insect body 
fat  (liver  equivalent)194.  Inducibility  of antimicrobial  proteins  and  peptides  is  also  a 
feature  of  the  innate  defence  both  systemically  and  at  epithelial  sites  in  plants, 
amphibians  and  mammals.  In  mammals  these  peptides  are  carried  in  the  cytosolic 
granules of leukocytes and platelets or are  secreted  from the  liver as part of the  acute
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These  peptides  are  generally  membrane  active  cationic  proteins  whose  affinity  for 
negatively charged bacterial membranes depends on both electrostatic interactions and 
their  tertiary  structure.  Many  share  common  structural  patterns,  one  of  the  best- 
described groups being the linear alpha helix forming peptides. They are also described 
as  amphipathic  as  they  contain  both  hydrophilic  and  hydrophobic  residues.  These 
peptides  are  very  potent,  with  IC50  in  the  submicromolar  range  and  act  through 
disrupting the bacterial membrane. They are made up of up to 40 amino acid residues 
and  are  basic  in  character.  They  have  the  common  feature  of adopting  an  unfolded 
conformation  in  aqueous  solution.  However,  on  contact  with  the  hydrophobic 
environment of the  membrane,  they stabilise  in an alpha helical  conformation.  In this 
form,  membrane  permeation  is  thought  to  occur  in  one  of  two  ways:(a)  a
75transmembrane pore formation via a “barrel-stave”  mechanism -  in which the peptide 
inserts into the membrane in a perpendicular orientation, or (b) a carpet like mechanism 
in which the peptide lies over and parallel to the membrane surface.196 (Fig 1.7).
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Fig. 1.7 Mechanisms of membrane permeation by amphipathic peptides196
76The selectivity of these peptides towards bacterial rather than eukaryotic membranes is 
based  on  differences  in  nett  charge  of  these  membranes.  The  cationic  peptides 
preferentially  bind  bacterial  membranes  which  are  rich  in  negatively  charged 
phospholipids  rather than  eukaryotic  cell  membranes  which  in which the  majority  of 
the  phospholipds  are  zwitterionic  in  character,  having  little  overall  charge.  These 
differences  in  charge  reflect  differences  in  phospholipid  composition  between 
eukaryotic  and  bacterial  membranes  (  ie  bacterial  membranes  generally  lack  sterols 
such as cholesterol and are rich in cardiolipin).
A number of studies have shown some tumour cells to be more susceptible to antibiotic 
peptides than their non-transformed counterparts.  The  reasons  for this  are  unclear but 
changes in membrane potential due to higher metabolism or higher exposure of acidic
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phospholipids in the outer leaflet of the membrane have been proposed  . Furthermore 
the cytotoxic activity of  these peptides is equivalent in both sensitive and multidrug -  
resistant cell lines ,97.
The  preference  to  disrupt  membranes  rich  in  negatively  charged  phospholipids  also 
provided the original impetus for the use of amphipathic peptides as tatgeted cytotoxic 
agents. Mitochondrial membranes have a similar phospholipid compostion to bacterial 
membranes  (being  rich  in  cardiolipin),  possibly  reflecting  the  common  ancestry  of 
bacteria and mitochondria.198. Therefore, although antibiotic peptides are generally not 
toxic to  eukaryotic  cells  ,  if they  are  internalised  into the  cell they have the potential 
ability to disrupt the mitochondrial membrane, possibly leading to the activation of the 
caspase  cascade  and  apoptotic  cell  death.  However  it  should  be  stressed  that  this 
mechanism has not been directly demonstrated in any study to date and that the presise 
mechansim underlying the toxicity of these agents when internalised by eukaryotic cells 
remainunclear.
771.5.2  Synthetic antibiotic peptides
Synthetic forms of antibiotic peptides have been developed by several groups ,  mainly
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for  use  against  antibiotic  resistant  bacteria  ’  ’  .  These  molecules  are  often
constructed  using  “non-natural”  amino  acid  residues  such  as  the  (3  or  D- 
conformations. These peptides  have the advantage of avoiding proteolytic degradation 
whilst maintaining their membrane disrupting properties , which are not dependent on 
chirality.
A  D-isomeric  form  of  a  synthetic  antibiotic  peptide  (KLAKLAK)2  which  was 
specifically  designed  to  have  low  mammalian  cell  toxicity202  has  been  used  as  a 
cytotoxic agent in a number of human disease models.
Fig  1.8 illustrates the structure of D(KLAKLAKh. It  is composed of 14  amino acids 
in an alpha helical formation with alternating cationic hydrophilic residues (in red) and 
non-polar hydrophobic residues (in green).
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Fig 1.8 Structure of D(KLAKLAK>2Z 03
781.5.3 Cytotoxicity of D (KLAKLAK)2
A  compound  peptide  consisting  of D(KLAKLAK)2  fused  to  a  protein  transduction 
domain  (RRQRRTSKLMKR),which  allows  receptor  independent  internalisation  into 
cells,  has  been  shown to  induce  tumour  cell  apoptosis  and to  reduce  tumour volume 
when directly injected into day 7 established MCA205 murine fibrosarcoma tumours in 
a mouse model.204.
Other  groups  have  targeted  D(KLAKLAK)2  to  specific  tissue  types,  using  short 
targeting  peptides  identified  by  phage  display  technology.  Arap  et  al  showed  that 
systemic  intravenous  injection  of a  chimeric  molecule  consisting  of D(KLAKLAK)2 
linked to a peptide, selected by phage display to specifically recognise the vasculature 
of the prostate, caused tissue destruction in the prostate of mice  , but not in any other
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organs  . Another peptide (RGD-4C),  identified by phage display to bind to integrins 
expressed on newly forming blood vessels  but not on establised vasculature  has been 
used  to  target  and  internalise  D(KLAKLAK )2  to  synovial  neovasculature  in  mouse 
model of inflammatory arthritis205. The identical chimeric peptide has also been shown 
to be effective in treating nude mice carrying human MDA-MD-435  breast carcinoma 
xenografts  by  inhibiting  tumour  angiogenesis.203.  In  both  these  studies,  the  targeted 
angiogenic cells showed the morphological features of apoptotic cell death, and caspase 
3 processing was also demonstrated.
791.6.  Aims
The aim of this project was to generate novel cytotoxic reagents that specifically target 
antigens expressed on leukaemia or lymphoma cells, leading to cell death.
The  initial  aim  of the  project  was  to  link  antibodies  against  CD 19  and  CD33  to  the 
small antibiotic peptide D (KLAKLAK) 2.  Targeting of D (KLAKLAK) 2 by linking it 
to antibodies will, in principle, allow selective killing of cells that express the relevant 
antigen whilst leaving cells that do not express these antigens intact.
There  are  potential  advantages  of using  peptides  rather than  antibodies  for targeting: 
They can be easily and economically synthesised. Purification is also easier as they are 
less likely to be  contaminated by DNA  and viruses.  They are  less  immunogenic than 
antibodies  and due to their small  size  may have better tumour penetration than larger 
antibody conjugates. However peptide sequences, which bind to CD19 and CD33, have 
not as yet been described. Therefore the second aim of the project was to identify such 
peptide  sequences  using  phage  display  technology  and  create  peptide  -   peptide 
conjugates which will have a selective cytotoxic effect on leukaemia/lymphoma cells.
80Chapter 2  Materials and methods 
2.1 Antibody conjugation protocol and characterisation of the conjugates
2.1.1 Monoclonal antibodies used in the conjugation reaction
Rat monoclonal anti-human CD45 (azide free, clone YTH 23.5) and mouse monoclonal 
anti-human CD33 (azide free, clone NHM 30.1.3.1) were both from Geoff Hale, 
Therapeutic Antibody Centre, Oxford, UK.
Mouse monoclonal anti-human CD 19 (azide free, clone B-C3) was from 
Immunodiagnostic systems Ltd -  Diaclone Research, Boldon, UK.
2.1.2 Conjugation protocol
The conjugation of D (KLAKLAK) 2  to monoclonal antibody using N-Succinimidyl-3-
(2-Pyridyldithio) Propionate ( SPDP, Pierce Chemical Company, Tattenhall, UK ) as a
206 cross-linker, was carried out using a method adapted from a published protocol.
Initial experiments designed to investigate the effect of changing reaction conditions on 
the conjugation efficiency used anti-CD45 as the monoclonal antibody, as it was readily 
available in the laboratory.
1   ml  of  carrier  solution  containing  lmg  of  antibody  was  buffer  exchanged  in  a 
centricon  50  device  (Amicon  Bioseparations  -  Millipore,  Edinburgh,  UK)  into 
phosphate buffered saline  (PBS) buffer (0.1M PBS,  0.9%NaCl,  5mM EDTA, pH  8.5) 
and  concentrated  to  approximately  500pl.  This  was  then  transferred  into  a  1.5ml 
microfuge tube.  16pl of 5mM SPDP in dimethylsulfoxide DMSO (a  1   in 12 molar ratio 
of antibody to  SPDP)  was  added  and  rotated  at room  temperature  for  5  minutes.  The 
reaction  mixture  was  subjected  to  gel  filtration  using  a  PD-10  Sephadex  column 
(Amersham  Pharmacia,  Little  Chalfont,  UK),  equilibrated  in phosphate  buffer  (0.1M
81PBS,  0.9%NaCl,  5mM  EDTA,  pH  6.6)  and  re-concentrated  in  a  centricon  50.  A  0.5 
mM solution of the amphipathic peptide L (CGG) D  (KLAKLAK^  (Alta Bioscience, 
Birmingham, UK) in PBS pH6.6  was prepared,  and reduced with 20mg of Cleland’s 
Reductacryl reagent ( Calbiochem, Nottingham,UK) by rotating for 15 minutes at room 
temperature.  Following centrifugation  at  10,000rpm  for  5  minutes to  separate  out the 
resin, 240pl of the peptide solution, a  1   in  18  molar ratio of antibody to peptide, was 
added to the  antibody -   SPDP  conjugate.  The  stoichiometry  of the  coupling  reaction 
between  the  peptide  and  the  antibody  -SPDP  conjugate  was  monitored  in  a  glass 
cuvette  in the  spectrophotometer  at  343nm  and  the  final  peptide:  antibody  ratio  was 
calculated from the plateau absorbance value using the molar extinction coefficient of 
pyridine-2-thione (8.08 xl03M '1.cm'1) as described207.The resulting conjugate was then 
subjected to gel filtration using a PD-10 column equilibrated with RPMI (Gibco,  Life 
Technologies,  Paisley,  U.K)  and concentrated  in  a  centricon  50.  Antibody conjugates 
were stored in 50pi aliquots.
2.1.3  Analysis of conjugates
2.1.3.1  Bio-Rad assay
The protein concentration of the final conjugate was quantified using Bio-Rad protein 
assay  kit  (Bio-Rad,  Hemel  Hempstead,  UK),  a  dye-binding  assay,  based  on  the 
differential  colour change  of a  dye  in response  to  various  concentrations  of proteins. 
The  colour  change  was  measured  using  a  spectrophotometer  at  595nm.  Murine  IgG 
(Sigma, Poole, UK) was used as a standard.
822.1.3.2 Gel electrophoresis under reducing conditions
NuPAGE Tris Glycine 4-12% precast gradient gel plates (NOVEX, Paisley, UK) were 
assembled according to manufacturer’s instructions. 20pl of each conjugate were mixed 
with 7.5pl of 1   x sodium dodecyl sulfate (SDS) sample buffer (NOVEX), 2.5pl of 1M 
dithiothreitol  (DTT)  reducing  agent.  Controls  consisted  of anti-CD45  antibody  and 
unconjugated  peptide  at  known  concentrations.  Samples  were  heat  denatured  for  10 
minutes at 70°C in a water bath, centrifuged briefly and loaded onto gels. Gels were run 
at  200  V  using  lx  N-morpholino  propanesulfonic  acid  (MOPS)  running  buffer  and 
NuPAGE  running  buffer  antioxidant  (NOVEX).  The  gels  were  simultaneously  fixed 
and stained by immersing in a solution of methanol, glacial acetic acid and Coomassie 
Brilliant  Blue  (Sigma)  for  1   hour  on  a  shaking  platform.  Gels  were  then  destained 
overnight by soaking in a methanol/acetic acid solution.
2.1.3.3 Western blot analysis of antibody conjugates
Antibody  conjugates  were  prepared  as  before  (section  2.1.2)  using  anti-CD33  and  a 
biotinylated  version  of  the  peptide,  biotin-L  (CGG)  D  (KLAKLAK)2  .  Gels  were 
prepared  as  in  section  2.1.3.2.  Two  Whatman  filter papers  and  one  nylon membrane 
(Hybond  C,  Amersham,  UK) per  gel  were  soaked  in blotting  buffer  (25  mM  Bicine, 
35mM Bis Tris,  ImM EDTA,  10-20% methanol,  pH7.2  and 200pl  of antioxidant per 
200ml of transfer buffer).  The  gel  was placed on top of one  filter,  followed by nylon 
membrane then another filter paper,  The  gel,  membrane  and  filter papers  sandwiched 
with blotting pads pre-soaked in transfer buffer were placed in a blot module (NOVEX) 
with transfer buffer.  Transfer of proteins was carried out at 25  V.  After blotting, the 
nylon  membrane  was  stained  with  Ponceau-S  stain  (Sigma)  to  ensure  equal  and 
satisfactory  transfer  of proteins.  The  membrane  was  then  placed  on  top  of a  plastic
83sheath, rolled up and placed in a 50ml Falcon tube with  10ml blocking buffer  (0.02M 
Tris, 0.14M NaCl, 5% new-born calf serum and 5% polyvinylpyrolidone  (PVP, Sigma) 
[pH7.6]) and rotated at room temperature for  1   hour.  0.5pl of streptavidin-horseradish 
peroxidase (HRP) (Pharmingen, Cowley, UK) was added to the blocking solution and 
the Falcon tube was rotated overnight in a rotisserie at room temperature. The blot was 
washed  in  0.02M  Tris,  0.14M  NaCl  and  0.02%  Tween  20  for  three  15  min  washes 
followed  by  two  5  min  washes.  The  enhanced  chemiluminescence  method 
(ECL,Amersham ) was used to detect immunoreactive protein bands as detailed in the 
protocol provided.
Another blot prepared in an identical way to the  first was probed by the  same method 
using anti-mouse immunoglobulin-HRP (Dako, Glostrup, Denmark).
2.2  Cell lines and patient samples
2.2.1  Cell lines
The  following  mycoplasma-free  leukaemia/lymphoma  cell  lines  were  used  in  this 
study:  Raji,  Daudi  and  721.221,  all  human  B  cell  lymphoblastic  cell  lines,  Jurkat,  a 
human acute T cell leukaemia cell line, THP1, a human acute monocytic leukaemia cell 
line,  HL60,  a  human  promyelocytic  cell  line,  K562,  an  erythromyeloblastic 
transformation  of  human  chronic  myelogenous  leukaemia  (CML)  and  U937,  a 
histiocytic lymphoma cell line.
All  cells  were  cultured  in  50ml  tissue  culture  flasks  (Nalge  Nunc  International 
Rochester USA) at 37°C in a humidified 5% CO2 incubator. Culture medium consisted 
of RPMI  1640 (Gibco, Life Technologies, Paisley, U.K) supplemented with  10% foetal 
calf  serum  (FCS),  100  units/mL  penicillin,  2mM  L-glutamine,  and  100  pg/mL
84streptomycin (all from Invitrogen Paisley, UK). Cell concentrations were maintained at 
between 0.2 and 0.6 xlO6 cells/ml by the addition of fresh medium.
CD33,  CD 19  and  CD2  expression by  each  cell  line  was  assessed by  flow cytometry. 
0.5  million cells were washed twice in Hanks Balanced Salts  Solution (HBSS;  Gibco, 
Life  Technologies)  and  incubated  with  lOpl  of  fluorescein  isothiocyanate  (FITC)- 
conjugated primary antibody in 50pl of PBS.  Antibodies used were CD19,  CD33  and 
CD2 (Becton Dickinson, San Jose, USA) and mouse isotype control.  After 20 minutes 
incubation at 4°C the cells were washed once in PBS, resuspended in 0.5ml of PBS and 
analysed by flow cytometry (FACScan, Becton Dickinson, Cowley, UK) equipped with 
Cell Quest software (Becton Dickinson).
Table 2.1  details the antigen expression pattern by human cell lines used
CELL
LINE
CD33 CD19 CD2
RAJI Negative Positive Negative
DAUDI Negative Positive Negative
721.221 Negative Positive Negative
HL-60 Positive Negative Negative
KG-1 Positive Negative Negative
U937 Positive Negative Negative
K562 Negative Negative Negative
JURKAT Negative Negative Positive
Table 2.1 Antigen expression by human cell lines
852.2.2  Patient’s cells
Mononuclear  cells  were  isolated  from  patient’s  peripheral  blood  samples  or  bone 
marrow with informed consent.  Clotting was prevented by the addition of preservative 
free heparin. Plasma was withdrawn after sedimentation at 700xg. Patient samples were 
then  diluted  three  to  four  fold  in  HBSS  and  30ml  carefully  layered  onto  20ml 
lymphoprep  (Axis-Shield,  Oslo,  Norway).  Tubes  were  centrifuged  at  600xg  for  30 
minutes.  The  top  layer  of the  medium  was  removed  and the  interface,  consisting  of 
mononuclear  cells,  was  transferred  to  another  universal  tube  and  washed  twice  in 
HBSS. Cell concentrations were estimated using a Coulter cell counter. Cells were then 
resuspended in supplemented RPMI culture medium as before at a concentration of 2 x 
106 cells/ml.
2.3  Cell viability assays and imaging
2.3.1  MTT assay
200pl of cells at a concentration of 0.25 x  106/ml (for the cell lines) and 2 x  106/ml (for 
the  AML/CLL  cells)  were  cultured  with  increasing  concentrations  of  the  antibody 
peptide conjugate, made up to 20pl  in RPMI,  in flat bottom  96 well plates.  At 24, 48 
and 72 hours  lOOpl of cells from each well were transferred into 96 well round bottom 
plates  with  lOpl  of  5mg/ml  3-(4,  5-dimethylthiazol-2-yl)-2,  5-diphenyl  tetrazolium 
bromide  (MTT,  Sigma)208  and  cultured  for  a  further  4  hours  at  37°C.  Plates  were 
centrifuged  at  800 xg  for 5  minutes, the  supernatants  were withdrawn and  100  pi per 
well  of  Dimethylsulfoxide  (DMSO)  were  added.  The  absorbance  of  the  purple 
formazan generated by reduction of MTT by viable  cells  was  quantified by recording 
absorbance at 540 nm on an Anthos plate reader.
862.3.2 Clonogenic assay
1  ml aliquots of cell lines (106.ml"1 ) were incubated at 37°C in the presence or absence 
of antibody-peptide  conjugate  for  48h.  lOpl  of these  suspensions  were  mixed  with 
290pl  of Iscove’s modification of Dulbecco’s medium (Invitrogen) and added to semi­
solid methylcellulose culture medium with recombinant cytokines  (Stem  Cell Factor, 
GM-CSF,  IL-3,  IL-6,  G-CSF,  Eryhtropoeitin)  (Methocult  H4435;  Stem  Cell 
Technologies, Meylan, France).  Triplicate  aliquots  (1  ml) were plated in 35  mm  Petri 
plates and incubated further at 37°C.  Colonies were counted at 7 days using an inverted 
microscope.
2.3.3 Cytospin preparation
Raji and Jurkat cells at a concentration of 0.5 x  106/ml were incubated with lOnM anti- 
CD 19-D  (KLAKLAK)2  for 48  hours.  Cytospin preparations  were  then made  of these 
cells  along  with  untreated controls.  Slides  were  stained  with May  Griimwald  Giemsa 
(MGG) and viewed under the light microscope. Apoptotic cell death was quantified by 
estimating the proportion of cells with condensed  chromatin or fragmented nuclei209  . 
Slides were examined in random order and at least two hundred cells in four different 
fields were counted per cytospin preparation.
2.3.4 Immunofluorescent microscopy
The  biotinylated  amphipathic  peptide  biotin-L  (CGG)  D  (KLAKLAK^  was 
conjugated using the method described in section 2.1.2, to human monoclonal anti body 
at a molar ratio of 1:6.  1   ml of various cell lines at a concentration of 0.5 x  106/ml was 
incubated with  lOnM of the conjugate solution. Cytospin preparations were made at 0,
875,  15,  30  and  60  minutes.  Slides  were  fixed  in  ice-cold  methanol  overnight  and 
rehydrated in PBS containing  1% bovine albumin.  Spots were incubated with either  10 
pi of FITC-conjugated streptavidin (Pharmingen) or  lOOpl of a  1/10 dilution of FITC- 
labelled anti-mouse immunoglobulin (DAKO,  Glostrup, Denmark)  for half an hour in 
the  dark.  Following three  rinses  with PBS,  0.1%  tween 20,  2%  FCS,  the  slides  were 
mounted  in  PBS:glycerol  (1:1),  viewed  and  viewed  in  an  Olympus  1X70  confocal 
microscope.
2.3.5 Electron microscopy
1  ml of cells isolated from the peripheral blood of a patient with CLL at a concentration 
of 2 x  106/ml were incubated with lOnM of anti-CD 19 D(KLAKLAK)2. After 24 hours 
the  cell  suspension  was  transferred  to  a  1.5  ml  microfuge  tube  and  concentrated  by 
centrifugation to a volume of 50pl.  0.5ml of gluteraldehyde was then slowly added to 
the  tube,  whilst  vortexing  gently,  to  fix  the  cells.  Electron  microscopy  was  kindly 
carried out by Jackie Lewin at the Royal Free Flospital.
2.3.6 Flow cytometry of annexin V/Propidium iodide stained cells
Phosphatidylserine  on  the  outer  membrane  of  treated  cells  was  detected  by  flow 
cytometry using a human Annexin V FITC kit (Bender Medsystems, Austria) following 
the manufacturer’s instructions.  1   ml of cells at a concentration of 0.5 x  106/ml (for the 
cell lines) and 2 x  106/ml (for the  CLL cells) were incubated with either no  additions 
(negative  control),  with  lOnM  anti-CD 19  D  (KLAKLAK^  or  20pg/ml  chlorambucil 
(positive  control).  At various time points  (1,  3,  8  and 24 hours)  cells  were  washed  in 
PBS and resuspended in pre-diluted binding buffer at a concentration of 5 x  105/ml. 5pl 
of annexin V-FITC was then added to  195 pi  of the  cell  suspension and incubated forten  minutes  at  room  temperature  in  the  dark.  Cells  were  then  washed  once  in  PBS,
resuspended  in  190pl  of pre-diluted  binding  buffer,  and  lOpl  of 20pg/ml  propidium
iodide  stock  solution  were  added.  Samples  were  immediately  analysed  on  a  Becton
Dickinson flow cytometer using Cell Quest software.  A published equation was used
210 to compute agent-specific apoptosis  .
Specific apoptosis = % apoptosis in treated sample -  %of apoptosis in untreated control
100 -  % of apoptosis in untreated control
2.3.7 Flow cytometry to demonstrate antibody internalisation into Raji cells
1   ml  of Raji  cells  at  a  concentration  of 0.5  x  106/ml  were  incubated  with  either  no 
addition (negative control) or lOnM anti-CD 19 D (KLAKLAK^ for half an hour. Cells 
were then washed with HBSS and resuspended in culture medium. Aliquots were taken 
for flow cytometric analysis immediately (0 hour) and following incubation for 1,3 and 
6  hours.  Cells  were  stained  with  FITC-labelled  anti-mouse  immunoglobulin  either 
directly or following permeabilisation and fixation with IntraStain (DAKO).
Samples were then analysed on a Becton Dickinson flow cytometer using Cell  Quest 
software.
2.3.8  Quantification  of  protein  expression  in  Raji  and  CLL  cells  by  western 
blotting
Western  blotting  was  used  to  quantitate  the  expression  of  various  anti-apoptotic 
proteins in untreated CLL  cells  and also to estimate PARP  cleavage  in Raji  and  CLL 
cells after treatment with anti-CD 19 D(KLAKLAK)2 or  chlorambucil for 24 hours. 
Proteins were extracted from between 2-5 million cells. Cells were washed once in cold 
HBSS,  transferred to microfuge tubes  and resuspended  in  50 to  lOOpl  of lysis  buffer
89(20mM  Hepes-KOH  [pH  7.5],  50mM  NaCl,  2%  nonidet  P40,  0.5%  sodium 
deoxycholate,  0.2%  SDS,  ImM  sodium  vanadate,  lOmM  sodium  fluoride,  ImM 
ethylene glycol tetra-acetic  acid (EGTA)), 0.02M DTT and  ImM PMSF.  The  lysates 
was kept on ice for 15 minutes and centrifuged for 15 minutes at  12,000xg.  Finally the 
supernatant was removed to another microfiige tube and stored at -70°C until use. 
Protein  concentrations  were  estimated  as  described  in  section  2.1.3.1  using  bovine 
serum  albumin  (BSA,Sigma)  as  a  standard.  Western  blots  were  then  prepared  as 
described  in  section  2.1.3.3  using  15pg  of protein  per  well.  Blots  were  blocked  as 
before  with  5% PVP  blocking buffer and  incubated  overnight  with primary  antibody 
(listed  in Table  2.2),  followed  by  washing  and  incubation  with the  appropriate  HRP 
linked secondary antibody (DAKO Denmark,  1/5000 dilution) for  1-3 hours. The ECL 
method was used as before to detect immunoreactive protein bands.
For further antibody staining the blots were  stripped by incubation in stripping buffer 
(162mM Tris  [pH 6.7], 2%  SDS,  lOOmM  P-mercaptoethanol)  for 30 minutes at  50°C. 
Band intensities were determined using Quantity 1   software (BioRad).
Antibody Source
XIAP BD bioscience, Oxford, UK
Bcl-2 Dako, Glostrup, Norway
Mcl-1 Santa Cruz, CA, US
PI 16 PARP Pharmingen, Cowley, UK
P85 PARP Promega, Southampton, UK
Actin Sigma, Poole, UK
Table 2.2 Antibodies used in this study
902.3.9  Zeta-asociated protein 70 (ZAP-70) and IgVH mutation analysis estimation
ZAP-70  expression  CLL  samples  was  carried  out  by  Najeem  Folarin,  using  a  flow 
cytometric method. Mouse monoclonal anti-ZAP-70 clone 2F3-2 (Upstate, Lake Placid, 
NY)  and an  isotype  control  mouse  IgG2A  (Dako,  Glostrup,  Denmark)  were  labelled 
with Alexa Fluor 488  immediately  before  use,  using  a  Zenon  antibody-labelling  kit 
(Invitrogen). The procedure for determination of ZAP-70 expression status was carried 
out as described211.  ZAP-70 mean cell fluorescence was  simultaneously determined in 
the  B  and  T  lymphoid  populations  of CLL  isolates,  distinguished  by  labelling  with 
phycoerythrin-conjugated  anti-CD3  and  PerCP-conjugated  anti-CD 19  (Becton- 
Dickinson, Oxford, UK) respectively.  The  ratio  of ZAP-70 mean cell  fluorescence  of 
the B and T lymphoid populations was determined. A ratio above 0.75  was considered 
to indicate elevated ZAP-70 expression. This cut-off value was determined by analysis 
of B  and  T  lymphocytes  from  20 normal  subjects  and  represents  the  mean plus  two 
standard deviations of the ratio determined for normal B cells.
IgVH  gene  sequencing  was  carried  out  by  Veronique  Duke  using  polymerase  chain 
reaction products obtained by amplification of genomic DNA using Framework Region 
1   and Jh primers as described  .
2.4  Phage display studies
2.4.1  Cell line
A  CD33-Fc  secreting  CHO cell  line was kindly  supplied by Paul  Crocker at Dundee 
University.  Cells were cultured in 80cm2 tissue culture flasks at 37°C  in a humidified 
5% CO2 incubator.  Culture medium consisted of Glasgow’s Modified Eagles Medium 
supplemented for CHO culture with glutamine synthetase (GS) expression system (First 
Link,  Brierley  Hill  UK)  +5%  dialysed  immunoglobulin  depleted  foetal  calf  serum
91(Gibco, Life Technologies) +200pM methionine sulfoximine (Sigma). Supernatant was 
removed weekly and stored in 50ml aliquots at -20°C.
2.4.2 ELISA for CD33
lOOpl  of  protein  AG  (5pg/ml)  was  placed  in  the  wells  of  a  protein  immobiliser 
micro  well  plate  (Exiqon,  Vedbaek,  Denmark)  for  2  hours  on  an  agitator  at  room 
temperature. Plates were then washed 3 times with TBS  + 0.1% Tween 20, to remove 
any unbound protein. lOOpl of CD33-Fc containing supernatant were then added to each 
well and the plate placed on the agitator for a further 2 hours.  After another 3  washes 
with TBS-Tween,  non-specific  protein binding  was  blocked  by  filling  the  wells  with 
TBS-Tween + 10% foetal calf serum for 1 hour. Murine anti-human CD33 clone Him-3 
(Pharmingen) (lOOpl of a  1:2000 dilution in TBS-tween/FCS) was then added to each 
well and  incubated  for  1   hour.  After 3  further washes,  1  OOpl  of a  1:2000  dilution  of 
HRP-conjugated goat anti mouse immunoglobulin (Dako) was added to each well and 
incubated for an hour. The wells were washed a further 3 times with TBS-Tween /FCS 
and lOOpl of substrate reagent (R&D Systems catalogue number DY999) were added to 
each well. The reaction was stopped after 10 minutes on the agitator using  lOOpl of 2N 
sulphuric acid solution. The plates were then read spectrophotometrically at 450 nm on 
an Anthos plate reader.
2.4.3 Phage display biopanning
The CD33-Fc containing supernatant was dialysed into 0.1M NaHC0 3  (pH 8.6).  150pl 
of this solution was added to a single well of a 96 well flat bottom plate and incubated 
overnight at 4°C in a humidified container. The excess supernatant was removed with a 
pipette and the well was filled with blocking buffer (0.1M NaHCC>3 pH  8.6 + 5mg/ml
92BSA + 0.02% NaNs) and left for one hour at 4°C. This was then discarded and the well 
was washed 6x with TBS Tween 20 0.1% + 0.1% BSA. A phage display library (Ph.D 
7mer peptide library, New England Biolabs, Ipswich, US) was used to pan the protein 
to  select  phage  that  bound  to  CD33.  lOOpl  of phage  medium  consisting  of  1  Oj l x I  of 
phage,  20pl  of human IgG  (Sigma) and  70pl  of TBS  Tween  0.1%  were  added to  the 
well. After an hour on the agitator the excess medium  containing unbound phage was 
pipetted off and the well was washed ten times with TBS Tween as before. The bound 
phage were then eluted by adding  lOOpl of 0.2M glycine HCL pH2.2 +1 mg/ml BSA to 
the  well  for  8  minutes.  The  eluate  was  then  transferred  into  a  microfuge  tube  and 
neutralised with 15pl of 1M Tris HCL pH9.1.
A  small  amount  of the  eluted  phage  was  then  titred  as  follows:  dilutions  of phage 
(101,102,103  and  104)  were prepared in LB  media  .E.coli  ER2738  culture,  in mid  log 
phase was dispensed into four microfuge tubes and lOpl of diluted phage added .One at 
a  time  ,  the  infected  cell  suspensions  were  transferred  to  culture  tubes  containing 
melted  agarose  top.  The  tubes  were  vortexed  quickly  and  the  media  immediately 
poured onto pre-warmed LB/IPTG/Xgal plates.  The plates were  allowed to  cool  for 5 
minutes before inverting and incubating at 37°C overnight. The number of blue plaques 
were then counted.
The  remainder  of the  phage  from  biopanning  was  amplified  by  adding  to  20  ml  of 
E.coli culture in early log phase. The culture was incubated with vigorous shaking for
4.5  hours.  The  culture  was  then  transferred  to  a  centrifuge  tube  and  centrifuged  at 
10,000 xg at 4°C  for  10 minutes.  The  supernatant was  transferred to  a fresh tube  and 
centrifuged again.  The upper 80% of supernatant was then transferred to a fresh tube, 
1/6  volume  of  PEG/NaCl  was  added  and  the  solution  kept  a  4°C  overnight  to 
precipitate the phage.
93The following day another culture of ER2738 was set up in order to titre the amplified 
phage.  Again,  four  LB/IPTG/Xgal  plates  were  placed  in  an  incubator  at  37°C  and 
agarose top was melted and kept at 45°C until required.
The  amplified  phage  precipitated  overnight  was  centrifuged  at  10,000  xg  for  15 
minutes.  The  supernatant  was  removed  and  the  phage  centrifuged  briefly.  Residual 
supernatant was removed with a pipette. The phage pellet was resuspended in  1ml TBS 
and transferred to  a microfuge tube.  It was  centrifuged for  5  minutes  at 4°C  to pellet 
any residual cells and the supernatant transferred to a fresh microfuge tube. The phage 
was reprecipitated by adding  1/6 volume of PEG/NaCl and leaving on ice  for  1  hour. 
The  precipitated  phage  was  centrifuged  for  10  minutes  at  4°C,  the  supernatant 
discarded and the phage briefly re-centrifuged. The remaining supernatant was removed 
with  a  pipette.  The  phage  pellet  was  resuspended  in  lOOpl  TBS  +0.02%  NaN 3.The 
phage solution was centrifuged for one minute to remove any insoluble matter and the 
supernatant transferred to a fresh tube for storage at 4°C. The amplified eluate was then 
titered as before, but this time using dilutions of 108-10n fold.
Three  further  rounds  of  biopanning  were  performed  in  this  way,  each  time  using 
approximately 2xlOn pfu (plaque forming units) of amplified eluate from the previous 
round as  input phage.  The method for subsequent rounds was  exactly the  same  as  for 
the first except that the concentration of TBS Tween was raised to 0.5%.
942.4.4  Sequencing of selected phage clones
After the fourth round of biopanning, clones were picked from the plate that had been 
used to titre the unamplified phage  .Ten blue plaques were picked from the plate that 
contained  less  than  100  colonies  and  that  had  been  incubated  for  not  more  than  16 
hours.  The  plaques  were  transferred  to  separate  tubes  containing  a  culture  of E.coli 
ER2738  in  10ml  LB  medium,  and  incubated  at  37°C  with  vigorous  shaking  for  4.5 
hours.  Cultures  were  then  transferred  to  centrifuge  tubes  and  centrifuged  for  30 
seconds.500pi  of  the  phage-containing  supernatants  were  then  transferred  to  large 
microfuge  tubes  to  which  200pl  of PEG/NaCl  were  added,  and  allowed  to  stand  at 
room  temperature  for  10  minutes.  After  discarding  the  supernatant  each  pellet  was 
suspended in lOOpl of Iodide buffer (lOmM Tris-HCl pH8.0,  ImM EDTA, 4M Nal), to 
which  250pl  of ethanol  were  added  and  left  for  10  minutes  at  room  temperature  to 
precipitate  the  phage  DNA.  The  samples  were  then  centrifuged  for  10  minutes,  and 
after discarding the supernatant, the remaining pellets were washed in 70% ethanol and 
dried briefly under vacuum. The pellets were then suspended in 30pl TE buffer (lOnM 
Tris-HCl pH8.0,  ImM EDTA).
PCR mixture for each clone to be sequenced was prepared with 2pl -96 gill sequencing 
primer (lOpmol/pl),  lpl Big Dye Perkin Elmer, 7pl dilution buffer and 8 pi water.2pl of 
DNA in TE buffer were added to each PCR reaction tube. PCR was carried out for 25 
cycles:  96°C  for  10  seconds,  50°C  for  5  seconds,  60°C  for  4  minutes.  The  PCR 
products  were  then  transferred  to  0.7ml  tubes  and  precipitated  by  adding  2pl  of Na 
Acetate  3M  and  50pl  100%  Ethanol to  each tube.  These  were  then left on ice  for  30 
minutes, centrifuged for 30 minutes at full speed before removing the supernatant. The
95DNA  was  washed  with  150  pi  of  70%  ethanol,  centrifuged  for  10  minutes.  After 
removing the ethanol, pellets were allowed to air dry.
An acrylamide  gel was prepared for sequencing.  Loading buffer was prepared using a 
lin  6  dilution  of concentrated  loading  buffer  in  formamide.  For  each  reaction  tube, 
4.5pi  of  loading  buffer  were  added  and  after  vigorous  vortexing  the  DNA  was 
denatured at 95°C for 2 minutes. Prior to loading the denatured DNA was kept on ice  . 
2pl  samples  were  loaded  onto  the  acrylamide  gel  and  the  DNA  sequencer  (Applied 
Biosystems, Foster City, US) was run overnight to sequence the selected phage.
2.5  Statistical methods
Statistical analyisis were carried out using Prism software.
The apoptotic and loss of viability data in chapter 4 were evaluated using a two-tailed 
Student  /-test  for  paired  samples.  Two-tailed  test  was  used  because  the  results  were 
interesting  in  either direction.  A two-tailed test is  a hypothesis  test  in  which the  null 
hypothesis is rejected if the observed sample statistic is more extreme than the critical 
value  in  either  direction  (higher  than  the  positive  critical  value  or  lower  than  the 
negative critical value).  Two-tailed Pearson parametric correlation statistical test was 
used  to  determine  the  relationship  between  two  independent  variables  based  on  the 
assumption  that  both  X  and  Y  values  are  sampled  from  populations  that  follow  a 
Gaussian  distribution,  at  least  approximately.  Nonparametric  two  tailed  Spearman 
correlation  statistical  test  was  used  to  determine  the  relationship  between  two 
independent variables based on ranks, not the actual values.
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Synthesis and characterization of antibody -D  (KLAKLAK) 2 conjugates
3.1 Introduction
In  order  to  create  conjugates  that  were  selectively  cytotoxic  to  haematological 
malignant cells, we conjugated D(KLAKLAK)2  to commercially available monoclonal 
antibodies with specificities against antigens expressed on lymphoid and myeloid cells.
3.1.1 Choice of antibody
Anti-CD 19 and anti-CD33 were chosen for this purpose, as they are expressed on early 
lymphoid  and  myeloid  progenitors  cells  respectively  (Fig.  3.1).  Neither  of  these 
antigens  are  expressed  on  the  pluripotent  stem  cell,  thus  theoretically  allowing 
repopulation of bone marrow haemopoetic cells post-treatment. They also both have the 
additional favourable characteristics of internalising on binding to the ligand, providing 
a method of delivery of the cytotoxic peptide to the cytosol.
Myeloid
Myeloid stem cell 
CD33 + CD 33+
Myeloblast
CD 33+
Myelocytes 
CD33 +
Pluripotent 
Stem cell 
CD 19 - 
CD 33 -
Lymphoid Pro B-cell 
CD19 +
Pre B-cell 
CD 19+
B-cell 
CD 19 + stem cell 
CD 19 -
Lymphoid
Fig 3.1 Expression of CD19 and CD33 on maturing haemopoietic cells
973.1.2  Choice of linker molecule
Antibodies can be chemically linked to peptides via cross-linking reagents. Most cross 
linking reagents have two reactive groups connected by a flexible spacer arm; reagents 
differ in their spacer arm  length,  cleavability  and  reactive  groups.  Homo-bifunctional 
linkers have the same reactive group at both ends and which can lead to high levels of 
polymerisation; alternatively bifunctional reagents have different reactive groups at the 
ends. Most protein cross-linking reactions are side chain reactions and are nucleophillic 
and pH dependent. Most proteins including antibodies have lysine residues available at 
the surface of the proteins, providing primary amines; many proteins also have cysteine 
residues that are not involved in disulphide bonds providing free  sulfydryls.  These are 
the two most commonly used groups  in protein cross-linking  strategies.  Cross-linking 
strategies may also use carbohydrates, carboxyls or other reactive functional groups.206 
N-Succinimidyl  3-(2-pyridyldithio)  propionate  (SPDP)  is  a  cleavable 
heterobifunctional  cross-linking  agent  which  contains  one  N-hydroxysuccinimide 
(NHS) residue and one pyridyl disulphide residue which react with primary amines and 
sulfydryls respectively207(Fig. 3.2).
The  conjugation of D  (KLAKLAK) 2  to  anti-CD33  and  anti-CD 19  using  SPDP  as  a 
cross-linker, was carried out using a method adapted from a published protocol ,206
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Fig 3.2 SPDP (Ar -Succinimidyl 3-(2-pyridyldithio) propionate conjugation
Step 1, the activated NHS end of the SPDP reacts with amino groups on lysine residues 
of the antibody.
Step 2, the 2-pyridyldithiol group at the other end of the SPDP moiety reacts with 
sulfydryl residues on the peptide releasing Pyridine-2-thione in the process.Pyridine-2- 
thione can be detected spectrophotometrically at 343nm,allowing the monitoring of the 
progress of the conjugation.
The molar extinction coefficient  of pyridine-2-thione at 343nm is 8.08 x 103M‘1cm'1
Adapted from ref206.
993.2  Results
3.2.1  Spectrophotometric monitoring of the conjugation reaction.
The concentration of pyridine-2-thione released during the conjugation reaction (step 2 
fig.  3.2)  was  determined  by  measuring  the  change  in  absorbance  in  a  u.v. 
spectrophotometer at 343nM. The molar extinction coefficient of pyridine-2-thione was 
used to  calculate the  number of SPDP  molecules  attached per antibody molecule  and 
hence  the  final  stoichiometry  of  the  conjugation  reaction  (assuming  the  SPDP:  D 
(KLAKLAK) 2 ratio to be  1:1).  Fig  3.3  illustrates the  change  in absorbance occurring 
during the reaction of lmg antibody (6.67 xlO'9 mols) with SPDP in 3  different molar 
ratios.
Example of calculation (see fig 3.3)
Increase in absorbance at 343nm at peptide: antibody molar ratio 18:1  =0.1 
Molar extinction coefficient of pyridine -2-thione at 343nm =  8.08 x 103/M/cm 
Standard u.v cuvette path length = 1   cm
0.1/ (8.08x  103) =1.24 xlO'5  molar increase in concentration =1.24x1 O’5/litre
The  volume  of the  cuvette  is  500pl  therefore  moles  of pyridine-2-thione  released  in
500pl = 6.2 x 10*9.
Ratio of antibody to SPDP = 6.67:6.2  approximately 1:1
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Fig. 3.3 Effect of increasing the peptide/SPDP : antibody ratio
Increasing the peptide/SPDP : antibody ratio results in a 
corresponding increase in the  change in A343nm and hence in the 
number of peptides incorporated  per antibody molecule.
101An SPDP to antibody ratio of only 1:1 using an 18:1 molar ratio of peptide to antibody 
was an unexpectedly low efficiency. To determine the reason for this we first estimated 
the protein loss during the conjugation reaction by biorad assay of pre and post 
conjugation samples compared to a standard curve generated using known 
concentrations of anti-CD45. This was found to be approximately 30% and therefore 
did not account for the poor conjugation efficiency.
3.2.2  Effect of pH on the efficiency of the conjugation reaction
In  our  initial  conjugation  protocol  adapted  from  a  standard  published  method  a 
conjugation buffer with pH  7.2  was  used.  However  other methods  in the  literature213 
noted an increased  efficiency of SPDP  conjugation  efficiency  at pH  between  8.0  and 
8.5.  We  investigated  this  by  repeating  the  conjugation  reaction  in  three  buffers  of 
varying pH  (7.0,  8.0,  8.5)  using the  same  molar ratio  of SPDP  to  antibody of 6:1  in 
each experiment (Fig.3.4).  In these reactions DTT was used instead of D(KLAKLAK)2 
to reduce the disulphide bond and release the pyridine-2-thione (step 2 Fig 3.2).
The  results  of  these  experiments  demonstrated  a  conjugation  efficiency  of 
approximately 50% (i.e.  final  SPDP antibody ratio 3:1  using initial molar ratio of 6:1) 
using  buffers  with pH  8.0  and  8.5  compared to  7%  with the  buffer at pH  7.0.  These 
calculations took into account the 30% protein loss during conjugation as estimated by 
biorad assay above.
The  conjugation  protocol  was  modified  accordingly  and  a  pH  of 8  was  used  in  all 
subsequent conjugations.
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Fig.3.4 Effect of pH on the SPDP conjugation reaction
Small changes in the pH of the reaction buffer resulted in relatively large 
increases in efficiency of the conjugation reaction.
1033.2.3 Characterization of conjugates
3.2.3.1  Gel electrophoresis of antibody conjugates
In addition to spectrophotometric monitoring, the stoichiometry of the final conjugates 
was assessed by gel electrophoresis (Fig.3.5).  5  pi of peptide conjugates of anti-CD45 
(CD45K),  and  20  pi  of anti-CD33  (CD33K)  and  anti-CD 19  (CD19K),  and  known 
amounts  of unconjugated  peptide  and  unconjugated  anti-CD45  were  fractionated  by 
SDS-  PAGE.  The  gel  was  stained  with  Coomassie  blue.  Intensities  of bands  were 
quantified using Quantity 1  software (BioRad).
These values were then used to estimate the concentration of the antibody conjugates 
and the number of D(KLAKLAK)2 peptides per antibody molecule as follows:
i.  Standard unit from known amounts of anti-CD45 control
Total pg antibody 
applied to lane
Absorbance units/pg antibody =
(absorbance of heavy chain + absorbance of light chain) 
pg antibody applied to lane
20ng 27.7+ 12.24/20  =  2
10ng 13.08 + 6.86/ 10  =  1.99
5|ug 7.27 + 3.77/5  =  2.21
For further calculations it was assumed that a total absorbance of 2 corresponded to lpg 
of antibody.
104ii. Calculation of concentrations of antibody conjugates
e.g. anti-CD33K :  7.18 + 3.6/2 = 5.39pg in 20pl .
Therefore the antibody concentration is 0.27pg/pl, (a value of 0.3pg/pl was obtained by 
biorad assay of the same conjugate).
iii. Estimation of the proportion of the ratio of D(KLAKLAK)2 to antibody
Absorbance of [D(KLAKLAK)2 /(heavy chain + light chain + D(KLAKLAK )2 ]  * 100 
For example, this was computed at 9.9% for the anti-CD33-D(KLAKLAK)2 conjugate. 
Molecular weight of D(KLAKLAK )2 = 2000 
Molecular weight of unconjugated antibody = 150 000
Using the formula =  [2000x /(150 000 +2000x) ]  *  100 = 9.9 , where jc represents the 
number of molecules of D(KLAKLAK)2  per molecule of antibody.
This represents approximately 8 D (KLAKLAK)2 peptides per antibody molecule. 
Spectrophotometric  monitoring  of  the  same  conjugate  estimated  a  conjugation 
stoichiometry of 10 peptide molecules per antibody molecule.
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D(KLAKLAK)2 0.73  1.19 0.92 2.14 0.86  0.34
Fig.3.5 Gel electrophoresis of antibody conjugates
Peptide  conjugates of anti-CD45 (CD45K), anti-CD33 (CD33K) and anti-CD19 (CD19K), unconjugated peptide and 
unconjugated anti-CD45  were fractionated by SDS- PAGE. The gel was stained with Coumassie blue. Intensities of bands 
were quantified and are presented in the table.
H,heavy chain  L,light chain  K, D(KLAKLAK)23.2.3.2  Western blot analysis of antibody conjugates
Conjugates were also characterised by western blotting (Fig 3.6).  In these experiments 
anti-CD33 was conjugated to a peptide consisting of D(KLAKLAK)2  with the addition 
of a biotin tag  .  This was  fractionated by  SDS-PAGE  along with a similar amount of 
unconjugated anti-CD33  and two concentrations of unconjugated biotinylated peptide. 
All  the  samples  were  reduced by heating to  70°C  with  170mM  DTT.  The  blots  were 
probed  sequentially  with  anti-mouse  immunoglobulin  and  streptavidin-HRP.  As 
expected, the  anti-mouse  immunoglobulin recognised  bands  in regions  corresponding 
to  the  heavy  and  light  chains  of both  the  unconjugated  antibody  and  the  antibody- 
peptide  conjugate.  The  streptavidin  -   HRP  also  recognised  bands  in  the  regions 
corresponding  to  the  heavy  and  light  chains  of the  antibody  conjugate  as  well  as  a 
further band of lower molecular weight corresponding to the biotinylated peptide that 
had  been  released  by  the  reducing  conditions.  The  same  probe  recognised  multiple 
bands  in  the  same  position  for  the  two  unconjugated  biotinylated  peptide  samples. 
These results  indicate that the reducing conditions  used were not sufficient to prevent 
the D(KLAKLAK)2 -  biotin forming dimers or to release all of the peptide conjugated 
to the heavy and light chains of the antibody. A similar blot (not shown) using the same 
samples  seen  without  prior  reduction  showed  no  free  peptide  band  in  the  antibody 
conjugate lane.
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Fig.3.6 Western blot analysis of biotinylated antibody conjugate
Unconjugated  anti-CD33, anti-CD33 conjugated to biotinylated  D(KLAKLAK) 2 (anti-CD33 KB) and unconjugated biotinylated 
D(KLAKLAK) 2 were reduced with DTT and  fractionated by SDS-PAGE, transferred to a Hybond membrane and analyzed using 
anti-mouse immunoglobulin (upper) or sterptavidin- HRP (lower).
H, heavy chain  L, light chain  KB, biotinylated D(KLAKLAK) 23.3  Discussion
90  f\
Using a modified published protocol  we have developed a method which allows the 
conjugation  of  a  predictable  number  of  peptides  per  antibody  molecule  and 
demonstrated  reliable  stoichiometry  by  spectrophotometric  monitoring  of  the 
conjugation  reaction  and  SDS-PAGE  electrophoresis.  A  western  blot  probed  with 
streptavidin-HRP  showed  that  while  there  was  no  free  peptide  in  the  unreduced 
conjugation sample, it was partially released by heating with 170mM DTT.
NHS ester reactions (step  1   Fig 3.2) are normally carried out at pH 7.0-9.0. Reactivity 
of the lysine group increases as the pH increases to 9.0, but competing NHS hydrolysis
1  1*7
also  is  favored  with  pH  increase  .  Many  of  the  published  protocols  for  SPDP 
conjugation  (including  the  manufacturers’  recommendations)  recommend  an  initial 
buffer pH of between 7.0 and 7.5 with a reaction time of at least half an hour and up to 
twelve  hours137,206,207,214.  However  in  our hands,  a  higher pH  of 8-8.5  with  a  shorter
91^
reaction time  of five minutes  as described by Peeters  et al  gave  significantly better 
conjugation efficiency.
Summary
D(KLAKLAK)2  was  conjugated  to  monoclonal  antibodies  with  specificities 
against  antigens  expressed  on  lyphoid  and  myeloid  cells  (CD19  and  CD33 
respectively). Conjugation of the peptide to the antibody was carried out using the 
heterobifunctional  cross-linking  agent  SPDP  from  a  method  adapted  from  a 
published  protocol which was  optimised  by  altering the  reaction  conditions.  The 
resulting  conjugate  was  characterised  spectrophotometrically,  by  gel 
electrophoresis  and  Western  blotting  under  reducing  conditions.
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Cytotoxicity of D (KLAKLAK) 2 antibody conjugates towards leukaemia cell lines
4.1  Introduction
In  order  to  assess  the  cytotoxicity,  potency  and  specificity  of  D  (KLAKLAK)  2  - 
antibody conjugates we used a number of cell lines of haematological origin.
Cell lines were selected on the basis of the cell  lineage and expression of the relevant 
antigen. (Table 4.1)
Cell line Cell of origin Morphology CD33 CD19 Ref.
Jurkat T-cell leukaemia T-lymphoblast no yes
215
Raji Burkitt’s
lymphoma
B-lymphoblast no yes
216
Daudi Burkitt’s
lymphoma
B-lymphoblast no yes
217
721 221 HLA deficient 
lymphoblast
B-lymphoblast no yes
218
THP1 Acute monocytic 
leukaemia
Monoblast yes no
219
HL60 Acute
promyelocytic
leukaemia
Myeloblast yes no ~120....
U937 Histiocytic 
lymphoma (pleural 
effusion)
Histiomonoblast yes no
221
K562 CML  in blast 
crisis
(pleural effusion)
Erythromyeloblast no no
222
Table 4.1 Characteristics of cell lines used in this study
1104.2 Results
4.2.1 Assessment of cytotoxcity of D(KLAKLAK)2 conjugates
4.2.1.1  Anti-CD33-D (KLAKLAK^ has cytotoxic activity against a CD33 positive 
cell line as assessed by MTT  and clonogenic assay
CD33  expression  was  first  checked  by  immunophenotyping  by  flow  cytometry  and 
alkaline  phosphatase-anti-alkaline  phosphatase  (APAAP)*  staining  of  cytospin 
preparations  of  cells.  The  cytotoxicity  of  the  anti-CD 3 3 -D(KLAKLAK )2  conjugate 
(antibody:  peptide ratio  1 :6 ) was  assessed by incubation of increasing concentrations of 
the conjugate with a CD33 positive cell line  (THP1) and three CD33  negative cell lines 
(Jurkat, Raji and K562). MTT assays were performed at 24, 48  and 72 hours.  All MTT 
assays  were  performed  in  duplicate.  In  the  case  of the  THP1  cell  line,  the  maximal 
decrease in cell viability of 93% was noted at 24 hours (Fig 4.1) with no further decrease 
at 48 or 72 hours. The IC50 at 24 hours for THP1  cells was 2.53  nM in this experiment, 
with no  decrease  in cell  viability  at these  doses  being  noted  in the  CD33  negative  cell 
lines (Fig. 4.1).
Two other CD33 positive cell lines were also assayed after incubation with anti-CD33- 
D(KLAKLAK)2  and showed no decrease in cell viability at 24-72 hours. This will be 
discussed later in the chapter (section 4.2.3)
* APAAP  staining was kindly carried out by Faith Wright of the  immunophenotyping 
laboratory at the Royal Free Hospital.
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Fig 4.1 Action of anti-CD33 D(KLAKLAK)2 on malignant haemopoietic cell lines
Dose response curve for action of anti-CD3 3 -D(KLAKLAK )2 on CD33 positive 
(THP1) and CD33 negative (Jurkat,Raji and K562) cell lines. Cell lines were incubated 
with increasing concentrations of the conjugate. Cell viability was assessed by MTT 
assay at 24 hours
Data are representative of four independent experiments.
Error bars represent SEM of duplicate determinations.
112To ensure that the  results  for the  MTT  cell viability  assay above  correlated with true 
cell death and loss of proliferative potential,  a clonogenic  assay and MTT assay were 
performed in parallel.  THP1  cells,  either untreated or treated with  10  nM  anti-CD33- 
D(KLAKLAK)2  were incubated for 24 hours, at which time  1  OOpl  samples were taken 
for  MTT  assay  (  in  duplicate  ).  The  remaining  cells  were  suspended  in  semi  solid 
culture  medium  in  methylcellulose  with  recombinant  cytokines  (see  section  2.3.2), 
plated  in triplicate  Petri  dishes  and  incubated  at  37°C.  Colonies  were  counted  at  one 
week. The results of this experiment demonstrated equivalent decreases in cell viability 
of treated cells as compared to  untreated controls  as measured by both assays:  70.4% 
decrease in cell viability by clonogenic assay and 66.5% by MTT assay (Fig.4.2).
The effect of altering the antibody to peptide ratio on the cytotoxicity of the conjugates 
towards  cell  lines  was  investigated  by  incubating  THP1  cells  with  two  anti-CD33- 
D(KLAKLAK)2 conjugates.  One of the conjugates had an antibody to peptide ratio of 
1:3 and the other of 1:9. MTT assays were performed at 24 hours (Fig 4.3). The results 
of  this  experiment  indicated  that  increasing  the  number  of  peptides  per  antibody 
molecule had no effect on the maximum  decrease  in cell viability observed:  83% and 
81%  for  the  1:3  and  the  1:9  conjugate  respectively.  However  the  conjugate  with  a 
higher number of peptides per antibody molecule was more potent, with an IC50 of 6.3 
nM compared to 12.5 nM for the  1:3 conjugate.
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Fig 4.2 Cytotoxicity of anti-CD33-D(KLAKLAK)2 to THP1 cells as assessed by 
clonogenic  (A) and MTT (B) assays
THP1 cells were either untreated (control) or incubated with 10 nM anti-CD33 
D(KLAKLAK)2 for 24 hours. Clonogenic assay (A) and MTT assay (B) were then 
performed in parallel.
A. Clonogenic assay. Colonies were counted at 1   week
B. MTT assay was at 24 hours
Data are representative of two independent experiments.
Error bars represent SEM of triplicate determinations.
Statistical evaluation was by paired Student’s t-test.
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Fig.4.3 Effect of varying the antibody: peptide ratio on cytotoxicity of conjugates
Dose response curves for action of two anti-CD3 3 -D(KLAKLAK)2  conjugates with 
varying antibody to peptide ratios on THP1 cells. THP1  cells were incubated with 
increasing concentrations of the two anti-CD33 D(KLAKLAK )2 conjugates, one with 
an  antiboby : peptide ratio of 1:3 and the other with a ratio of 1:9.
Cell viability was assessed by MTT assay at 24 hours.
Data are representative of two independent experiments.
Error bars represent the SEM of duplicate determinations.
1154.2.1.2  Anti-CD 19-D(KLAKLAK)2  has  cytotoxic  activity  against  CD19  positive 
cell lines as measured by MTT assay and clonogenic assay
Cytotoxicity  of  anti-CD 19-D  (KLAKLAK)  2  (antibody:  peptide  ratio  of  1:6)  was 
assessed  by  incubation  of increasing  concentrations  of the  conjugate  with  four  cell 
lines, three of which expressed the CD 19 antigen (Raji, Daudi and 721  221) and one of 
which did not (Jurkat). CD 19 expression was first assessed by immunophenotyping by 
flow cytometry  and APAAP  staining  of cytospin preparations  of cells.  Samples  were 
taken for MTT assay at 24, 48 and 72 hours. At 24 hours the decrease in cell viability 
for  the  three  CD19  positive  cells  was  between  37-  83%,  mean  61.6%  (not  shown). 
Maximal decrease in cell viability 75-97%, mean 87.4%, was observed at 48 hours (Fig
4.4  A). No further decrease in cell viability was noted at 72 hours.  IC50S for the three 
CD 19  positive  cell  lines  after 48  hours  incubation  were  in  the  low nanomolar range 
(2.04-5.07nM, mean 3.66nM).  Jurkat cells  showed no  decrease  in cell viability at the 
doses of conjugate used in this experiment.
Clonogenic  assay confirmed the dose  dependent decrease  in cell viability of Raji cell 
treated with three different concentrations  of anti-CD 19  D(KLAKLAK)2. (Fig 4.4 B). 
The resistance of Jurkat cells to anti-CD 19 conjugate was also confirmed by clonogenic 
assay (data not shown).
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Fig 4.4 Action of anti-CD19 D(KLAKLAK)2 on malignant haemopoietic cell lines
A. Dose response curve for action of anti-CD 19 D-(KLAKLAK ) 2  on  three CD 19 
positive (Raji,721  221  and Daudi) and one CD 19 negative (Jurkat) cell lines. Cell lines 
were incubated with increasing concentrations of the anti-CD 19 D(KLAKLAK)2 
conjugate. Cell viability was assessed by MTT assay at 48 hours.
B. Clonogenic assay of Raji cells treated with anti-CD19 D(KLAKLAK)2 
Raji cells were incubated with three different concentrations of the anti-CD 19 
D(KLAKLAK)2  conjugate for 48 hours. Colonies were counted at one week.
Data are representative of two independent experiments.
Error bars represent SEM of triplicate determinations.
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1174.2.1.3 Cytotoxicity of  unconjugated antibodies
Raji  and  THP1  cells  were  incubated  with  unconjugated  anti-CD 19  and  anti-CD33 
respectively, at the same dose ranges used in the experiments using conjugate. Samples 
for MTT assay were taken at 48 hours for the anti-CD 19 (Fig 4.5 A) and  at 24 hours for 
the  anti-CD33  antibodies  (Fig  4.5B).  Neither of the  unconjugated  antibodies  had  any 
significant cytotoxic effect on the cell lines which expressed the relevant antigens at the 
concentrations used.
4.2.1.4 Cytotoxicity of  unconjugated peptide
Five  cell  lines  were  incubated  with  increasing  concentrations  of  unconjugated 
D(KLAKLAK)2  , samples were taken for MTT assay at 24 hours ( Fig.4.6). All of the 
cell  lines  were  susceptible  to  the  cytotoxic  action  of the  unconjugated  peptide  with 
decreases in cell viability of at least 97%. IC50S were in the low micromolar range (6.5- 
19.6pM).  Therefore  the  concentrations  of unconjugated  peptide  required  to  decrease 
cell viability by 50% were  substantially greater than when the peptide was conjugated 
to an appropriate internalising antibody.
4.2.1.5 Cytotoxicity of a mixture of unconjugated peptide and antibody
Finally  Raji  cells  were  incubated  with  a  mixture  of  unconjugated  peptide  and 
unconjugated  anti-CD 19  in  the  same  molar  proportions  as  an  anti-CD 19- 
D(KLAKLAK)2 conjugate  (antibody:  peptide ratio  1:6 ).  After 48  hours there  was no 
decrease  in cell viability  as  assessed by MTT  in the  cells treated with the  mixture  of 
agents (Fig.4.7).
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Fig 4.5 Action of unconjugated antibodies on haemopoeitic cell lines
A Dose response curves of the action of unconjugated anti-CD 19 and anti-CD 19 
D(KLAKLAK)2 on Raji cells. Cell viability was assessed byMTT assay at 24 hours.
B.  Dose response curve of the action unconjugated anti-CD33 and anti-CD33 
D(KLAKLAK)2  on THP1  cells (B). cell viability was assessed by MTT assay at 48 
hours.
Data are representative of two independent experiments.
Error bars represent the SEM of duplicate determinations.
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Fig.4.6 Action of unconjugated D(KLAKLAK)2 on malignant haemopoietic cell 
lines
Dose response curve for action of unconjugated D(KLAKLAK) 2  on  five cell lines. 
Cells were incubated with increasing concentrations of unconjugated peptide.
Cell viability was assessed by MTT assay at 24 hours.
Data are representative of three independent experiments.
Error bars represent the SEM of duplicate determinations.
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Fig 4.7 Action of a mixture of anti-CD19 and D(KLAKLAK)2  peptide on Raji 
cells
Dose repsonse curve for the action of a mixture of anti-CD 19 and D(KLAKLAK) 2  
peptide in a molar proportion of 1:6 on Raji cells. Raji cells were incubated with 
increasing concentrations of a mixture of unconjugated peptide and unconjugated anti- 
C D ^ in the same molar proportions as an anti-CD 19 D(KLAKLAK)2 conjugate.
Cell viability was assessed by MTT assay at 48 hours. Data representive of two 
independent experiments.
Error bars represent SEM of duplicate determinations.
1214.2.2 Mechanism of action of D(KLAKLAK)2 conjugates
4.2.2.1  D(KLAKLAK)2  conjugates internalise into cells that express the relevant 
antigen
i .  Anti-CD33-D(KLAKLAK)2 conjugates are internalised by CD33 positive cells.
Two  CD33  positive  cell  lines  (THP1,  HL60)  and  one  CD33  negative  cell  line  (Raji) 
were incubated with a conjugate of anti-CD33-biotinylated D(KLAKLAK)2  (antibody: 
peptide ratio  1:9).  Cytospin preparations  were  made  and  fixed  after 0,  15,  30  and 60 
minutes incubation.  Slides were then stained with streptavidin-FITC and visualised on 
the confocal microscope. At  15 minutes, internalisation of the biotinylated peptide into 
vesicular structures was demonstrated in both the cell lines which expressed CD33 but 
not in the negative control Raji cells. Data not available for HL60 cells. Data for THP1 
cells (Fig 4.8).
ii.  Anti-CD 19-D(KLAKLAK)2 conjugates are internalised by CD19 positive cells.
A similar experiment using a CD 19 positive cell line (Raji) incubated with anti-CD 19- 
biotinylated  D(KLAKLAK)2  ,  stained  with  streptavidin  -  FITC  and  viewed  on  the 
confocal  microscope  did  not  yield  clear  results  due  to  a  high  level  of background 
staining obscuring visualisation of the biotinylated antibody conjugate (not shown).
To  investigate  the  cause  for  this  high  level  of background  staining  a  Western  blot 
analysis  of  the  lysate  of  Raji  cells  incubated  with  anti-CD 19-biotinylated 
D(KLAKLAK)2  was  performed  as  in  section  2.1.3.3  (Fig  4.9).  Staining  with 
streptavidin-HRP  revealed  a  strongly  reactive  biotin  containing  protein  which  was 
constitutively  present  in  both  treated  and  untreated  Raji  cells.  A  much  fainter  band 
detected  only  in  the  treated  cells  which  co-migrated  with  a  band  reactive  with  anti­
mouse  immunoglobulin-HRP  represented  the  biotinylated  anti-CD 19  conjugate.
122In view of these findings a different staining method was employed using FITC-labeled 
anti-mouse immunoglobulin to detect the antibody portion of the conjugate rather than 
the  biotinlyated  peptide  moiety.  In  these  experiments  cells  were  also  incubated  with 
10pl of Hoechst 33342 as per manufacturers instructions prior to confocal microscopy 
to  allow  visualisation  of the  cell  nuclei.  When  viewed  on  the  confocal  microscope, 
control  cells  showed no  green  fluorescence  (Fig.4.10  A)  but cells  incubated with the 
conjugate showed evidence of antibody internalisation into vesicle-like structures at 30 
minutes (Fig. 4.10 B). These cells were then washed free of conjugate and incubated for 
a further 6  hours, at which point cellular labeling was substantially reduced, compatible 
with degradation of the immunoglobulin moiety of the conjugate (Fig 4.10C).
Further  evidence  of  anti  CD 19-conjugate  internalisation  was  obtained  by  a  flow 
cytometric analysis of Raji cells incubated with anti-CD 19 D(KLAKLAK)2 and stained 
with FITC-labeled anti-mouse  immunoglobulin  (Fig.  4.11).,  Cells  were  left untreated 
(control)  or  were  incubated  with  anti-CD 19  conjugate  for  30  minutes  at  37°C  after 
which cells were washed in Hanks saline and resuspended in culture medium. Aliquots 
were  taken for analysis  at  0,1,3  and  6   hours.  At  each time  point  cells  were  analysed 
without permeabilisation (Fig 4.12 A) or following permeabilisation and fixation with 
IntraStain  (DAKO,  Glostrup,  Norway)(Fig  4.11  B).  Analysis  of  intact  Raji  cells 
incubated  with  the  conjugate  for  30  minutes  showed  cell  surface  labeling  which 
persisted  for  one  hour  after  the  initiation  of a  “chase”  period  with  medium  alone. 
However, cell  surface labeling was not detectable  at 3  or  6  hours.  Parallel  analysis of 
permeabilised  and  fixed  cells  also  provided  evidence  of  cell-associated  anti-CD 19 
conjugate, which declined  slowly over a  6  hour “chase” period.  The presence of anti- 
C D ^   reactivity  in  permeabilised  cells  at  3  and  6   hours,  at  which  time  cell  surface 
labeling was undetectable strongly suggested internalisation of the conjugate.
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Fig 4.8 Internalisation of anti-CD33D(KLAKLAK) 2 by THPl cells
Confocal microscopy of CD33 positive (THPl) and CD33 negative (Raji) cells treated with anti-CD33 
D(KLAKLAK)2biotin (KB)
Conjugate internalisation into intracellular vesicular like structures indicated by green arrow.+anti 
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Fig 4.9 Western blots analysis of the lysate of Raji cells treated with anti-CD19 biotinylated D(KLAKLAK) 2
Staining with steptavidin- HRP reveals two bands:a stongly reactive biotin containing protein constitutively present in Raji cells 
(open arrow) and the biotinylated peptide moiety of the anti-CD 19 conjugate (closed arrow).
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46Fig 4.10 Internalisation of anti-CD19 D(KLAKLAK) 2 by Raji cells
Cytospin preparations were stained with FITC labelled anti-mouse immunoglobulin 
A Control cells
B Cells incubated with anti-CD 19 D(KLAKLAK) 2 for 30 minutes.
C Cells incubated as in B then washed and cultured in medium alone for an additional 6 hours 
Bar = 5pmA. Intact cells
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Fig 4.11 Flow cytometric analysis of Raii cells treated with anti-CD19 
D(KLAKLAK)2
Raji cells were left untreated (control) or treated with anti-CD 19 D(KLAKLAK) 2 for 
30 minutes at 37°C. Cells were washed with Hank’s saline and resuspended in culture 
medium. Aliquots were taken for flow cytometric analysis immediately (0 hour) or 
following incubation for 1, 3, or 6  hours. Cells were stained with FITC anti-mouse 
immunoglobulin either directly (A) or following permabilisation and fixation with 
Intrastain.(B).
Results are typical of two experiments.
1274.2.2.2  D(KLAKLAK)2  conjugates  induce  apoptosis  in  cells  which  express  the 
relevant antigen
Raji  and  Jurkat  cells  were  incubated  with  lOnM  anti-CD 19-D  (KLAKLAK)  2  for 48 
hours.  Cytospin  preparations  were  then  made  of  these  cells  along  with  untreated 
controls.  Slides  were  stained with May  Griimwald  Giemsa (MGG)  and viewed under 
the  light  microscope  (Fig  4.12).  For  each  slide,  the  number  of cells  with  apoptotic 
morphology as characterised by cell shrinkage, nuclear condensation or the presence of 
apoptotic  bodies  were  counted  in  three  separate  fields  (Fig  4.13).  Mitotic  cells  were 
also counted in the same way. Statistical evaluation was by Student’s t test. 
Morphological  evidence  of apoptotic  cell  death  was  seen  in  all  slides  at  background 
levels  of  between  2-12%.  The  slides  of  the  CD 19  positive  Raji  cells  showed  a 
significant increase in the mean percentage of apoptotic cells per field in the treated vs. 
the untreated controls (27.3%, vs. 3.7%; p=0.04). In the CD19 negative Jurkat cells, the 
difference was not significant (10% vs.  8 %; p=0.64).
The  percentage  of mitotic  cells  per  field  was  also  counted.  The  untreated  Raji  cells 
showed a background  level  of 2.1% mitotic cells.  In contrast, no mitotic figures were 
seen  in  the  slide  of the  treated  cells.  For  the  Jurkat  cells  the  difference  between  the 
treated cells and the controls was insignificant (2 .1% vs.  1.2 %; p=0.62).
Further  evidence  for  an  apoptotic  mode  of cell  death  was  provided  by  western  blot 
analysis of the lysate of Raji cells incubated with anti-CD19 D(KLAKLAK)2  for three 
hours and probed with antibodies specific for the pi 16 and p85 fragment of PARP. The 
p85 fragment is generated from the larger pi 16 fragment by the action of the apoptotic
'y j'i
protease caspase 3  . PARP cleavage was seen in cells incubated with conjugate for 3
hours but was not evident at 1 hour or in untreated control cells.(Fig 4.14).
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Fig.4.12 Morphology of cell lines incubated with anti-CD19 D(KLAKLAK) 2
Cell were incubated in the presence or absence of anti-CD 19 D(KLAKLAK) 2 for 48 hours 
Cytospin preparations were stained with MGG and representative fields were photographed.nn Untreated 
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Fig 4.13 Percentage of cells on cytospins with A, apoptotic or B,mitotic 
morphology.
Raji and Jurkat cells were either untreated (control) or incubated with lOnM anti-CD 19 
D(KLAKLAK)2 for 48 hours. Cytospin preparations were made and stained with MGG. 
The number of cells with either apoptotic or mitotic morphology was counted in three 
separate fields at low power.
Error bars represent SEM of triplicate determinations.
Statistical evaluation was by Student’s t test.
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Fig 4.14 Western blot analysis of lysates of Raji cells treated with anti-CD19D(KLAKLAK)2
Raji cells were incubated in the prescence or absence of anti-CD 19 D(KLAKLAK)2 for 1 or 3 hours. Lysates were 
analysed by Western blotting. Results are typical of four experiments.4.2.3  Some CD33 positive cell lines are resistant to anti-CD33-D(KLAKLAK)2 but 
are susceptible to other CD33 immunoconjugates
4.2.3.1 Resistance of myeloid cell lines to anti-CD33 D(KLAKLAK)2
Four  myeloid  cell  lines,  (THP1,  HL60  ,  U937  and  K562)  were  incubated  with 
increasing doses of anti-CD 3 3 -D(KLAKLAK)2 . CD33 expression was first assessed by 
immunophenotyping  by  flow  cytometry  (upper  panel  Fig  4.15).  Sample  for  MTT 
assays  were  taken  at  24,  48  and  72  hours.  As  before  the  maximal  decrease  in  cell 
viability for THP1  cells was noted at 24 hours (Fig 4.15). None of the other cell lines 
showed any significant decrease in cell viability at the doses of antibody used.  In the 
case of K562 the resistance is accounted for by the lack of surface expression of CD33. 
However U937 and HL60 cells expressed CD33 at levels comparable to THP1.
4.2.3.2 Susceptibility of myeloid cell lines to anti-CD33 calicheamicin
We  obtained  a  small  volume  (50pl)  of anti-CD33-calicheamicin.  This  was the  excess
79
drug from a vial that had been used as part of the MRC AML  15 trial  . The data sheet 
stated that the concentration of the conjugate was  1 mg/ml with approximately 50% of 
the  anti-CD33  being  conjugated  to  calicheamicin  derivatives  with  an  antibody: 
calicheamicin ratio  of 1:  4-6224.  An  equivalent anti-CD3 3 -D(KLAKLAK)2  conjugate 
was  selected  for  comparison,  with  a  concentration  (  estimated  by  biorad  assay)  of 
1  mg/ml  and  an  antibody  to  peptide  ratio  of  1:6.  Concentrations  of  anti-CD33- 
calicheamicin that  had  been  used  in published  in-vitro  cell  line  experiments225  were 
noted to be in the same range as the concentration we had previously established for the 
use of anti-CD 3 3 -D(KLAKLAK)2 , with the majority of the molecular weight of both 
compounds  being  made  up  by  the  antibody  portion.  Two  CD33  positive  cell  lines 
(HL60 and THP1) were  incubated with either anti-CD33-calicheamicin or anti-CD33-
132D(KLAKLAK)2  at  equivalent  concentrations  and  samples  for  MTT  assay  were 
analysed at 24,48,72 and 96 hours (Fig.4.16). The results showed that THP1  cells were 
susceptible  to  the  cytotoxic  action  of  both  agents,  with  maximal  decrease  in  cell 
viability occurring by 24 hours with the anti-CD 3 3 -D(KLAKLAK)2  conjugate  and at 
96  hours  with  anti-CD33-calicheamicin.  HL60  cells  showed  a  similar  pattern  of 
maximal  decrease  in  cell  viability  at  96  hours  with  the  anti-CD33-calicheamicin  but 
were completely resistant to the cytotoxic effect of anti-CD3 3 -D(KLAKLAK)2.
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Fig 4.15 action of anti-CD33 D(KLAKLAK)2 on four myeloid cell lines
Upper panel
FACScan analysis for the expression of CD33 by four myeloid cell lines 
Lower panel
The same cell lines were incubated with increasing concentrations of anti-CD33 
D(KLAKLAK)2.  Cell viability was assessed by MTT assay at 24 hours.
Results are representative of three independent experiments.
Error bars represent SEM of duplicate determinations.
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Fig 4.16 Action of anti-CD33-calicheamycin and anti-CD33-D(KLAKLAK)2 on 
THP1 and HL60 cells.
THP1  and HL60 cells were incubated with equivalent concentrations of either anti- 
CD33 D(KLAKLAK)2  or anti-CD33 calicheamicin. MTT assays were performed at 
24,48,72 and 96 hours.
Only one experiment was performed with single MTT assays at each time point due 
to the limited availability of the anti-CD33 calicheamicin.
1354.3 Discussion
We  have  demonstrated  that  the  antibody-D(KLAKLAK)2  conjugates  synthesised  as 
described  in  Chapter  3  have  selective  cytotoxic  actions,  at nanomolar concentrations, 
on many (but not all) of the cell lines tested, that express the relevant antigens. All cell 
lines  were  susceptible  to  the  cyotoxic  actions  of the  unconjugated  peptide  alone,  but 
only  at  micromolar  concentrations  i.e.  approximately  one  thousand  times  the 
concentration  required  with  the  targeted  peptide.  None  of the  cell  lines  showed  any 
decrease  in  cell  viability  following  incubation  with  unconjugated  antibody  in  the 
concentration ranges used.
Internalisation of the antibody conjugates into cells expressing the relevant antigen was 
demonstrated  by  flow  cytometry  and  by  confocal  microscopy  using  either  FITC- 
streptavidin  to  label  the  biotinylated  peptide  portion  of the  conjugate  or  FITC-  anti­
mouse immunoglobulin to label the antibody moiety.
Apoptotic  morphology  was  noted  on  cytospin  preparations  of conjugate  treated  Raji 
cells,  as  well  as  a  decrease  in  the  mitotic  index.  Unconjugated  anti-CD19  and  anti- 
CD 19-immunotoxins  have  also  been  noted  to  cause  cell  cycle  arrest  in  in-vitro 
experiments with CD 19 positive  cell  lines226.  Further evidence  of apoptosis  induction 
was  obtained  by  demonstrating  the  caspase-mediated  cleavage  of poly(ADP-ribose) 
polymerase in anti-CD 19 D(KLAKLAK )2 treated cells.
The principal measure of cell viability used in these  experiments was the MTT assay. 
This assay is based on the ability of metabolically active cells to reduce  a tetrazolium 
compound to a blue formazan product. As such it is specifically a test of mitochondrial 
oxidative  phosphorylation.  The  clonogenic  assay  that  measures  the  proliferative 
potential  of cells  and their ability to  form colonies  is a truer measure of cell viability
997
and  is  generally regarded as the  “gold  standard” assay  .  However clonogenic  assays
136are  much  more time consuming than MTT assays  and require  using  larger amounts of 
drug. The correlation between MTT and clonogenic assay results vary depending on the 
drug  being tested"”8.  In  the  case  of our antibody-D(KLAKLAK )2  conjugates,  we  have 
demonstrated that both tests yield comparable results.
All  of the CD 19  positive cell  lines tested were  sensitive to anti-CD 19D(KLAKLAK)2. 
In contrast only one out of three of the CD33 positive cell lines tested (THP1) showed a 
significant decrease  in cell viability after incubation with anti-CD33-peptide conjugate. 
Nevertheless  we  were  able  to  demonstrate  peptide  internalisation  into  HL60  cells  as 
well  as  THP1  cells,  indicating  that  differences  in  sensitivity  may  reflect  different 
molecular  responses  to  the  peptide  by  the  two  different  cell  lines,  rather  than  a 
differential  ability to  internalise anti-CD33.  We  found  that  both HL60 and THP1  cells 
were sensitive to anti-CD33-calicheamicin, again  implying that the resistance of HL60 
cells to anti-CD 3 3 -D(KLAKLAK )2 was not explained by an inability to internalise the 
conjugate.  Amico et al  also described decreases  in cell  viability of these two cell  lines 
in  response  to  anti-CD33-calicheamicin  as  measured  by  thymidine  uptake.  They 
demonstrated  that  the  drug  induced G2 cell  cycle  arrest  in  both cell  lines  but that this 
was only  followed by apoptosis in the HL60 cells.  They also demonstrated that another 
myeloid cell  line (K G 1) cells were resistant to the cytotoxic action of this conjugate229. 
They  found  no  correlation  between  these  responses  and  the  expression  of CD33  or 
multiple drug resistance proteins by these cell  lines, although K G 1  cells were shown to 
have  a  high  cyclosporine  inhibitable efflux  activity,  possibly  explaining  the  resistance 
of this  cell  line  to  the  calicheamicin conjugate.  They  postulated  that  these  findings  go 
some  way  to  explaining  the  heterogeneity  of  response  to  anti-CD33-calicheamicin 
observed in AML patients.
137In  summary  we  have  show  that  internalisation  of  the  amphipathic  peptide 
D(KLAKLAK):  into malignant B  lymphoid cell  lines efficiently induces killing via an 
apoptotic  mechanism.  However  the  strategy  was  less  successful  against  myeloid  cell 
lines.
Summary
We have demonstrated  that the antibody-  D(KLAKLAK)2 conjugates synthesised 
in  the previous chapter have selective cytotoxic activity against  haemopoeitic cell 
lines.  An  anti-CD19  conjugate  effectively  killed  three  out  of three  lymphoid  cell 
lines, however an anti-CD33 conjugate was cytotoxic towards only one out of three 
myeloid  cell  lines.  Cell viability was assessed  by  MTT and clonogenic assays with 
IC50 in  the  low  nanomolar  range.  Internalisation  of the  antibody  conjugate  into 
cells  expressing  the  relevant  antigen  was  demonstrated  by  confocal  microscopy 
and  flow  cytometric  methods. An apoptotic mode of cell death was  inferred  from 
the  characteristic  morphology  of treated  cells  viewed  by  direct  microscopy  and 
Western blot analysis of PARP cleavage.
138Chapter 5
Cytotoxicit>r   of  D(KLAKLAK )2  antibody  conjugates  towards  mononuclear  cells 
isolated  from  patients  with  chronic  lymphocytic  leukaemia  (CLL)  and  acute 
myeloid leukaemia (AML)
5.1  Introduction
5.1.1  B-CLL
B-CLL  is  the  most  common  leukaemia  in  the  western  hemisphere  and  has  a  peak 
incidence  between  60  and  80  years  of age.  The  aetiology  is  unknown.  It  is  a  disease 
characterised  by  the  accumulation  of  relatively  mature  B-cells  in  the  blood,  bone 
marrow, liver, spleen and lymph nodes as a result of prolonged lifespan and impairment 
of normal  apoptosis  in  vivo230.  The circulating cells  are  characteristically  CD 19,  CD5 
and CD23 positive with weak expression of surface immunoglobulin.
Poor prognostic  factors in B-CLL include Binet stage (B, C) (table 5.1), male sex, rapid 
lymphocyte doubling time, dysfunction of the p53  pathway231, high expression of anti- 
apoptotic  proteins  especially  Bcl-2232  ,  chromosomal  abnormalities  (such  as  13q  del) 
the presence of unmutated VH immunoglobulin genes233,234 and the elevated expression 
ofZA P70 protein tyrosine kinase235,236.
Stage Clinical features at diagnosis
A Lymphocytosis and <3 areas of palpable lymphoid tissue enlargement.
B Lymphocytosis and 3 or more areas of palpable lymphoid tissue enlargement.
C As B  but with anaemia or thrombocytopenia
Table 5.1  Binet Clinical Staging System
139Although  Bcl-2  gene  rearrangements  are  rare  in  B-CLL,  more  than  85%  of  B-CLL 
express  high  levels  of  Bcl-2  protein232,  possibly  associated  with  hypomethylation  of
BC1-2 gene237.  In addition, elevated levels of Mcl-1  protien expression occurs in nearly
^ ^   8 half of CLL  B-cells~  .However  in vitro,  B-CLL  cells  undergo  spontaneous  apoptosis 
which  suggests  that  in  B-CLL  cells  the  apoptotic  mechanism  is  influenced  by 
interaction  with  the  microenvironment239  in  vivo.  In-vitro  data  suggest  that  several 
cytokines such as IL-4 and cell to cell interaction with stroma and blood derived nurse- 
like  cells  inhibit  B-CLL  cell  apoptosis  and  may  be  accompanied  by  preservation  or 
upregulation of Bcl-2 protein 240,241  .
B-cell  VH  genes  undergo  somatic  hypermutation  in  germinal  centres of lymph  nodes. 
In  CLL  the  VH  genes  are  hypermutated  in  approximately  60%  of cases  suggesting 
origin  from  the  post  germinal  follicle centre cells.  These patients are more  likely to be 
in  stage  A  with  stable  disease  and  typical  morphology  with  median  survival  of 25 
years, whereas patients  with unmutated VH genes are  more likely to have an advanced 
stage, atypical  morphology,  progressive disease, and a poorer prognosis with a median 
surv ival  of about  8  years233,234.  Studies  have  shown  a  strong  correlation  between  the 
presence  of  unmutated  VH  genes  and  elevated  expression  of  ZAP70  protein 
kinase235 236.  M alignant  cells  isolated  from  this  group  of  poor  risk  patients  are 
characteristically  defective  in the induction of the  p53  dependent pathway  in  response 
to  DNA  damage,  either due  to mutation or deletion  of the  p53  genes themselves or to 
defects in the ATM  protein kinase, which is an upstream mediator of this pro-apoptotic 
pathway242,243.
140Both  defects  in  the  p53  pathway  and  elevated  expression  of anti-apoptotic  proteins 
(Bcl-2,  Mcl-1  and  XIAP)  are thought to  contribute  to  resistance  of CLL  cells  to  both 
conventional cytotoxic drugs238,244*247 or to Rituximab248.
CLL  is  not  curable  by  conventional  cytotoxic  chemotherapy230.  While  cure  may  be 
achieved  by  allogeneic  stem  cell  transplantation,  this  procedure  is  associated  with  a 
high  rate  of transplant  related  morbidity  and  mortality249  and  is  usually  reserved  for 
younger  patients.  Standard  therapy  for  CLL  includes  conservative  management  and 
drug therapy with alkylating agents, purine analogs, corticosteroids or combinations of 
these  drugs.  Therapy  with  unconjugated  monoclonal  antibodies  such  as  Campath  1H 
(anti-CD52)  and  Rituximab  (anti-CD20)  also  produce  responses  in  a  proportion  of 
patients250,251.
5.1.2 AML
Acute  myeloid  leukaemia  is  a clonal disorder of haemopoeitic  tissue  characterised  by 
proliferation of abnormal blasts in the bone marrow and impaired production of normal 
blood  cells,  resulting  in  anaemia  and  thrombocytopenia  and  in  some  cases  tissue 
infiltration  with  tum our  cells.  AML occurs  in  all  ages  and  is  the  commonest  form  of 
acute  leukaemia  in  adults;  however  it  forms  only  a  minor  fraction  ( 1 0   -   15%)  of 
childhood  leukaemias.  Established  causative  agents  in  AML  include  high  dose 
radiation,  chronic  benzene  exposure  and  treatment  with  alkylating  agents  and  other 
chemotherapeutic  drugs.  AML  may  also  develop  from  myelodysplasia,  chronic 
myeloproliferative disorders and other haematological  diseases.  Classification of AML 
is based on the  W orld  Health Organisation histological  classification of AML252  which 
incorporates  and  interrelates  morphology,  cytogenetics,  molecular  genetics  and 
immunological  markers.  This  has  supplanted  the  still  widely  used  French  American
141British  (FAB)  scheme  in  which  the  emphasis  was  more  on  morphological  and 
immunophenotypic characteristics which were used to classify AML into eight variants 
(M0-M7). For the purposes of decription in this chapter the FAB scheme has been used. 
The  typical  AML  immunophenotype  is  CD13+,  CD33+  and  TdT  negative  with 
additional antibodies  being useful for the diagnosis of specific  FAB  subtypes (MO, M 6  
and M7). Cytogenetic  abnormalities are present in about half of patients at presentation 
and  have  a  major  intluence  on  prognosis.  The  most  frequent  genetic  changes  result 
from  chromosomal  translocation  involving  core  binding  factor  (CBF),  retinoic  acid 
receptor a  gene, MLL gene and transcriptional co-activators.
Treatment  for  AML  includes  supportive  therapy  and  intensive  chemotherapy  with 
agents  such  as  cytosine  arabinoside,  daunorubicin,  idarubicin,  6 -thioguanine, 
mitoxantrone  or  etoposide.  Allogeneic  stem  cell  transplantation  is  considered  in 
younger patients with poor risk disease and is generally performed in first remission. 
The  place  of targeted  monoclonal  antibody  therapy  with  anti-CD33-calicheamicin  is
77
currently  being  investigated  as  part  of  the  AML  15  trial  ",  and  may  prove  to  be 
especially  useful  for patients over the age  of 60  years old, who  form  a  group who  are 
particularly  difficult  to  manage  due  to  both  primary  disease  resistance  and  poor 
toleration  of intensive  chemotherapy.  Several  cellular  drug  resistance  mechanisms  in 
AML  cells have  been  described, such as  P-gp (P-glycoprotein),  LRP  (vault-transporter 
lung  resistance  protein)  and  MRP (ABC  transporter multidrug  resistance  protein)  354. 
P-gp, w hich is a multidrug resistance protein and a product of the m drl gene (multidrug 
resistance-1),  has  been  shown  to be  involved  in  AML  resistance  against  spontaneous 
and drug induced apoptosis.
1425.2 Results
5.2.1 Assessment of cytotoxicity of anti-CD19-D(KLAKLAK)2 against cells isolated 
from patients with CLL
CLL  was  diagnosed  by  established  clinical  criteria  and  confirmed  by 
immunocytochemical  analysis  for  the  expression  of CD5,  CD 19  and  restricted  cell- 
surface immunoglobulin.253
Mononuclear cells were  isolated from  the peripheral  blood of 20 patients with CLL  by 
Ficoll  density  gradient  (see  chapter  2  section  2.2.2).  Three  of these  patients  donated 
samples on more than one occasion. The characteristics of the patients are summarised 
in table 5.2. O f the  18 patients on whom ZAP70 expression data were available, 5 were 
classified  as  being  in  the  poor  risk  category  as  defined  by  elevated  ZAP 
expression21 1 235’236.  For  12 of these patients, prognosis was additionally established by 
sequencing of immunoglobulin VH genes.  Patients with  less than 2% divergence  from 
germline sequence were classified as poor risk212,233’234.
5.2.1.1  Anti-CD 19-D(KLAKLAK>2  has  cytotoxic  activity  against  CD19  positive 
CLL cells as assessed by MTT assay
Cytotoxicity  of anti-CD 19-D(KLAKLAK>2 (antibody:  peptide  ratio  1:6)  was  assessed 
by  incubation  of  increasing  concentrations  of the  conjugate  with  mononuclear  cells 
isolated  from  the  peripheral  blood  of  12  patients  with  CLL.  Samples  for  MTT  assay 
were taken at 24, 48 and 72 hours.  Figure 5.1  illustrates the dose response curve of the 
action of anti-CD19  D(KLAKLAK )2  on  three  representative  CLL  samples.  All  MTT 
assays  were  performed  in  duplicate.  In  each  experiment  a  positive  control  of CD 19 
positive  Raji  cells and  a  negative  control  of CD 19  negative Jurkat cells were  used.  As 
was  noted  in  the  previous  chapter,  the  anti-CD 19  conjugate  had  maximal  effects  after
14348 hours incubation, with mean decreases in cell viability at 24 hours of 75.2%  (range 
40.3%-96.1%) and of 84.2% (range 40.3%- 97.5%) at 48 hours. At 72 hours incubation 
there  was  generally a high  level of spontaneous cell  death in the control  wells making 
assessment  of the  cytotoxic  action  of the  conjugate  at  this  time  difficult.  As  with  the 
cell  line  experiments  the  IC 50 values  at  48  hours  determined  using  cells  from  twelve 
patients were in the low nanomolar range with a mean value of 1.8nM (range  1.6 to 4.6 
nM  ).  The mean  IC 50  for the cells  from  four poor risk  patients (2.3  +  1.6 nM)  was  not 
significantly  different  from  that  for  eight  good  prognosis  patients  (1.6  +  0.8  nM; 
p=0.36; Student t test for unpaired samples).
Three of the  patients donated  samples of peripheral  blood on more than one occasion, 
several  months  apart.  This  allowed  us  to  assess  the  reproducibility  of our  assay  over 
time.  Figure  5.2  illustrates  the  dose  response  curve  of  the  action  of  anti-CD 19- 
D(KLAKLAK )2 on cells isolated from the peripheral blood of a single patient,taken six 
months  apart.  The  patient had  received  no  treatment  during  this  time  period.  The  two 
dose response curves are similar with both IC50S (2.0 and 2.7nM) above the mean value 
for the sample population as a whole and at the upper end of the range.
144Patient
Number
Age/sex Binet stage Risk
category
Treatment
history
1 81/M B Poor* chi
2 85/F C Good* chi
3 73/M B Poor* eye
4 62/F A Good* NA
5 63/F C Good* Untreated
6 57/M B Good* chi
7 98/M A Good* Untreated
8 75/F B Good* chi
9 43/M C Poor chi
1 0 72/M A Good chi
11 75/M A Good Untreated
1 2 67/M C Poor* chi
13 75/M A Good Untreated
14 90/M A Good* Untreated
15 77/M A Good Untreated
16 69/M NA NA chi
17 73/F C Good* Untreated
18 72/M A NA chi
19 49/M A NA Untreated
2 0 67/M C Poor* chi
2 1 62/F NA Good* NA
2 2 74/M A NA Untreated
23 82/M A NA Untreated
Table 5.2 Clinical characteristics of CLL patients.
Risk categories were assigned on the basis of FACScan determination of ZAP70 
expression. Asterisks denote that the risk category was additionally confirmed by 
immunoglobulin heavy chain sequencing. Previous treatment with chlorambucil (chi) 
or cyclophosphamide (eye) is indicated.  NA, data not available.
Patient number  10 and  18,  11  and  13,  12 and 20 samples come from the same patient 
taken several months apart.
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Fig 5.1  Cytotoxicity of anti-CD19 D(KLAKLAK)2 towards CLL cells
Dose response curv es for the action of anti-CD 19 D(KLAKLAK )2 on three 
representative CLL cell isolates.
Cell viability was determined by MTT assay following 24 and 48h incubation. 
Error bars represent SE:M of duplicate determinations.
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Fig 5.2 Action of anti-CD19 D(KLAKLAK)2 on cells isolated from a 
single CLL patient, taken 6 months apart
Dose response curves for the action of anti-CD 19 D(KLAKLAK ) 2 on cells 
isolated from a single CLL patient, taken 6  months apart. M TT assay at 48 
hours.
Error bars represent SEM  of duplicate determinations
1475.2.1.2  CD2 positive T-cells are resistant to the cytotoxic action of anti-CD19- 
D(KLAKLAK)2
The percentage of CD2  positive  cells  in the  mononuclear preparation  was assessed by 
flow  cytometry  prior  to  incubation  with  the  cytotoxic  agents.  The  range  of  CD2 
positive cells was wide, ranging from 0.6% to 38.7%.
A strong positive correlation (p=0.0004) was noted between the percentage of cells that 
were resistant to the effects of the anti-CD 19 conjugate and the percentage of cells that 
were  CD2  positive  (Fig.5.3),  suggesting  that  the  anti-CD 19  conjugate  had  specific 
cytotoxic  action  on  the  CD 19  positive  B-cells  in the  samples  and  the  CD 19  negative, 
CD2 positive T-cells in the mononuclear preparation remained unaffected.
Further  evidence  for  the  sparing  of CD2  positive  T-cells  came  from  flow  cytometric 
analysis of CD2 count on a single patient, both pre and post treatment with anti-CD 19- 
D(KLAKLAK >2 (Fig 5.4)  Pre-treatment  flow cytometric analysis of mononuclear cells 
showed  92.4%  of cells  in  the  live  cell  gate  defined  by  forward  and  side  scatter  as 
described254  .  O f  these  live  cells  6.2%  were  CD2  positive.  Following  24  hours 
incubation with 5nM anti-CD 19-D(KLAKLAK)2,  a decrease in cell viability was noted 
, with only 48.1% of cells  in the live cell gate. CD2-positive cells accounted for  14.8% 
of  events  within  this  gate,  consistent  with  the  resistance  of  T  lymphocytes  to  the 
conjugate.  The  low  yield  of  cells  following  48h  incubation  with  the  conjugate 
precluded FACScan analysis at this later time point.
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Fig 5.3 Relationship between anti-CD19 D(KLAKLAK)2 resistance and CD2 
count.
Correlation between percentage of cells isolated from a patient with CLL that are 
resistant to the cytotoxic effect of anti-CD19 D(KLAKLAK )2 and the CD2 count as 
estimated by flow cytometry on the same samples prior to treatment.
Pearsons parametric test was used for statistical analysis since the data was normally 
distributed.
149Pre-treatment
1   1103 001
Post-treatment
>  * ■  • -  '•  •• •) v.
r
_____________________R1°9X4%
2io  '  '460  iid ' ' '•Ao  J “  1000
FSC-HdgtM
1   1103  002
•L r.-V v * ' •   V  ■
v. 'J X riJ S  •   .•"•••/:'v- :n:-:
K £
R1=4H1%
1.11.03.001
n  
I  1 M 1*6.2%
1  1
/   \ 1   Ml  1
10 ’
C02FITC
10 10^
M 1=14 8 * /.
M l
CD2FITC
Fig 5.4 Enrichment of CD2-positive T lymphocytes in the anti-CD19 
D(KLAKLAK)2-resistant population
A CLL isolate was incubated with 5 nM anti-CD 19 D(K.LAKLAK>2  for 24h. Untreated 
and treated cell populations were subjected to FACScan analysis  The percentage of 
cells within the live gate (Rl) that were reactive with FITC-labelled anti-CD2  was then 
quantified Ml.
1505.2.1.3 Cytotoxicity of unconjugated anti-CD19
Mononuclear cells isolated from the peripheral blood of patients CLL1  and CLL2 were 
incubated  with  unconjugated  anti-CD 19  in  the  same  dose  range  as  was  used  in  the 
initial experiment with the conjugated peptide (section 5.2.1.1). Samples for MTT assay 
were  taken  at  48  hours  (Fig.  5.5A).  A  high  concentration  of the  antibody  (30  nM) 
resulted  in  approximately  30%  loss  of viability.  The  IC 50S  of the  conjugate  towards 
these  isolates  were  1.6  and  2.0  nM  respectively.  These  levels  of the  antibody  alone 
resulted in no killing of the CLL2 isolate and  11% loss of viability of CLL1.
5.2.1.4 Cytotoxicity of uncongugated peptide
The same mononuclear CLL samples were incubated with increasing concentrations of 
unconjugated  D(KLAKLAK )2  Samples  for  MTT  assay  were  taken  at  48  hours  (Fig. 
5.5B).  As  was  noted  in  the  cell  line  experiments  (section  4.2.1.5),  both  samples  were 
sensitive to the peptide, with IC50S in the micromolar range.  In contrast to the cell lines, 
which all  showed  1 0 0 % decreases  in cell  viability  when  incubated with the  peptide,  a 
percentage of CLL  cells (8.8-23.6 %.) remained  resistant to the cytotoxic  effect of the 
peptide.  Although  the  sample  size  was  only  two,  there  was  no  apparent  correlation 
between the percentage of resistant cells and the CD2 count as was noted with the anti- 
CD 19 conjugated peptide.
5.2.1.5 Cyotoxicity of anti-CD33-D(KLAKLAK)2 conjuagte
The  same  mononuclear  CLL  samples  as  were  also  incubated  with  increasing 
concentrations of anti-CD33-D (KLAKLAK)2. As before samples for MTT assay were 
taken  at  48  hours  (Fig.5.5C).  No  decreases  in  cell  viability  were  noted  at  the 
concentrations of anti-CD33 conjugate used.
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Fig 5.5 Actions of unconjugated anti-CD19 (A), unconjugated D-(KLAKLAK)2 (B) 
and (C) anti-CD33-D-(KLAKLAK)2 on cells isolated from two CLL patients
Cells isolated from two patients with CLL were incubated with increasing 
concentrations of  unconjugated anti-CD 19 (A), unconjugated D-(KLAKLAK ) 2 (B) and 
(C) anti-CD33-D-(KLAKLAK)2.
Cell viability was determined by MTT assay following 48h incubation.
Error bars represent SEM of duplicate determinations.
1525.2.1.6  Killing  of  CLL  cells  by  anti-CD19  D(KLAKLAK)2  is  via  an  apoptotic 
mechanism.
Apoptotic  cell  death  is  associated  with  the  induced  expression  of cell-surface  signals 
which  mediate  recognition  and  engulfment  of  the  dying  cell  by  phagocytes.  These 
signals  include  the  extemalization  of  phosphatidylserine156.  Since  engulfment  of 
apoptotic  cells  circumvents  the  release  of  cellular  contents  and  consequent 
inflammatory  reactions,  it  was  important  to  demonstrate  that  anti-CD 19 
D(KLAKLAK)2- induced killing of CLL cells was by an apoptotic mechanism. 
Mononuclear cells isolated  from the peripheral blood of two CLL patients were treated 
with  either  nothing  (negative  control),  5nM  anti-CD 19-D(KLAKLAK )2  or  20pg/ml 
chlorambucil  (positive  control).  At  various  time  points  samples  were  stained  with 
annexin  V  and propidium  iodide and analysed by  flow cytometry.  The  flow cytometry 
plots  for one patient (CLL  17) are illustrated  in  Fig 5.6. The control  samples  shown in 
the  left  hand  panel  of  this  Figure  illustrate  the  levels  of  background  spontaneous 
apoptosis  occurring  in  the  untreated  CLL  cells,  with  a  baseline  level  of  live  cells 
(annexin  v/PI  negative)  of 70%  at  1   hour  decreasing  to  only  34%  viable  cells  at  24 
hours.  The  treated  cells  (both  anti-CD 19-conjugate  and  chlorambucil)  showed 
decreased  levels of viable cells and increased  levels of both apoptotic cells (annexin V 
positive.PI  negative)  and  secondary necrotic  cells  (annexin  V  positive  ,  PI  positive)  at 
every time point as compared to the untreated controls.
Results  were  more  clearly  expressed  in  graphical  form  (Fig  5.7),  employing  a 
calculation  modified  from  one  used  by  Posovsky  et  al  255  which  quantifies  specific 
apoptosis  and  specific  cell  death  that  is  attributable  solely  to  the  cytotoxic  agent  and 
that factors out the effects of background levels of spontaneous apoptotic cell death
153Specific apoptosis = % apoptosis in treated sample -  %of apoptosis in untreated control
100 -  % of apoptosis in untreated control
These  plots  demonstrated  that  although  the  action  of both  drugs  led  to  levels  of 
apoptotic  cell death  above  background  levels, the dynamics  of cell  death appeared 
to  be  different.  The  antibody conjugate  reached a peak  activity  at  between  one  to 
three hours and then maintained a fairly constant level of specific apoptosis and cell 
death  up  to  24 hours.  In  contrast the  plots  for the  action  of chlorambucil  showed 
that  most  of the  cytotoxic  activity  of the  drug  occurred  between  8  and  24  hours, 
w ith a steeper curve and a more complete cytotoxic affect at this time (almost  1 0 0% 
cell  death).  These  results  would  be  consistent  with  the  different  mechanisms  of 
action of the two drugs. Chlorambucil is able to enter cells rapidly by free diffusion, 
where  its  active  metabolite  leads  to  DNA  strand  breaks  and  cross-linking.  In 
contrast,  entry  of anti-CD 19 D(KLAKLAK )2 into  cells  depends  upon  the  level  of 
expression of the CD 19 antigen and the efficiency of CD 19 internalisation ,which is 
a dynamic process  w ith only a proportion of cells expressing the required levels of 
antigen at any one time.
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Fig 5.6 Induction of apoptosis by anti-CD19 D(KLAKLAK)2
Flow cytometric analysis of annexin V/propidium iodide stained CLL cells, at various time 
points after being treated with anti-CD19-D(KLAKLAK)2or chlorambucil.
No gating was used in the FACScan analysis.CLL 16  Antf-CD19 D(KLAKLAK). Chlorambucil
  ..  i
20
Hours incubation
‘ -specific death 
specific apoptotic
30
100-1
75
J2
3  50- 
*  25 
0- 
-25
20
Hours incubation
— i
30
CLL 17  Anti-CD19 D(KLAKLAK)2 Chlorambucil
100-1
75
JB
I 50-
25
0-
-25
0
‘  specific death 
specific apoptosis
  — i...........  i
10  20
Hours incubation
30
100-1
75
Jfl
$  50- 
^   25
-25
0 10 20 30
Hours incubation
Fig.5.7 Agent specific apoptosis and death in CLL cells
Graph illustrating the specific death and specific apoptosis of cells isolated from the 
peripheral blood of two CLL patients after treatment with anti-CD 19 D(KLAKLAK )2  
or chlorambucil.
156Activation of the apoptotic protease caspase 3 results in cleavage of the  116 kDa PARP 
with the consequent generation of an 85  kDa fragment, providing a stringent molecular 
criterion for apoptotic cell death223.
Mononuclear cells  isolated  from the peripheral blood of a CLL  patient were  incubated 
for 24 hours with either nothing (negative control), 5nM of anti-CD 19-D(KLAKLAK)2 
or  2 0 pg/ml  chlorambucil  (positive control).At this  time,  protein  lysates  were  prepared 
and  fractionated  by  SDS-PAGE.  The  blots  were  probed  with  anti-P116  PARP-  HRP, 
anti-P85  PARP  -HRP  and  anti-actin-HRP  to  ensure  equal  loading  (Fig5.8).  Results 
were expressed as the proportion of total PARP that was represented by the cleaved p85 
fragment.
i.e.:  p85PARP  x  100
(p85 PARP + pi 16 PARP)
In this patient very  little spontaneous apoptosis was  noted, with the untreated negative 
control  showing  only  10%  cleavage  of the  pi 16  PARP  fragment  at  24  hours.  Both 
treated  samples  showed  significant  PI 16  PARP  cleavage  at  24  hours compared  to the 
untreated  control,  with  the  chlorambucil  treated  sample  demonstrating  92%  PARP 
cleavage  and  the  anti-CD 19-D(KLAKLAK)2  treated  sample  having  an  intermediate 
value of 44%.  This  intermediate value may be partly explained  by the observation that 
anti-CD 19-conjugate does  not  have  its  maximal  effects  until  48  hours, and also  by the 
fact  that  this  particular  sample  had  a  relatively  high  CD2  count  of  13%  and  these  T- 
cells would have been resistant to the cytotoxic effects of the conjugate.
157pi 16 PARP  ~
p85 PARP 
Actin
P85/total PARP  10.78  92.3  44.03
Fig 5.8 Western blot analysis of lysates of CLL cells
CLL cells were incubated in the presence or absence of of anti-CD 19 D(KLAKLAK)2 or chlorambucil. 
Lysates were analysed by Western blottingElectron  microscopic  analysis  of glutaraldehyde-fixed  osmium  tetroxide-stained  cells 
also established that anti-CD 19 D(KLAKLAK )2  induced apoptotic death of CLL cells. 
Mononuclear cells  isolated  from  the  peripheral  blood  of a  patient  with  CLL  (CLL 14) 
were treated with either nothing (negative control), 5nM anti-CD 19-D(KLAKLAK)2 or 
20fig/ml chlorambucil (positive control). After 24 hours incubation,  lOOpl of cells were 
taken  for  MTT  cell  viability  assay  (in  duplicate),  and  the  rest  were  fixed  in  0.5ml  of 
gluteraldehyde.  Electron  microscopy  of the  samples  was  kindly  performed  by  Jackie 
Lewin of the  Electron Microscopy  department of the  Royal  Free  Hospital.  The  results 
of the  MTT  assay  (not  shown)  confirmed  that  both  the  treated  CLL  samples  showed 
decreases in cell viability of between 68-72% (mean 70%) at 24 hours compared to the 
untreated control.
The  electron  microscopic  images  of  the  CLL  cells  treated  with  both  anti-CD 19 
D(KLAKLAK )2  and  chlorambucil  (  not  shown)  illustrated  morphological  features 
typical  of  apoptotic  cell  death.  In  the  low  magnification  images  (xl400)  (fig  5.9) 
nuclear condensation was noted in 50% of the treated cells  in this field, whereas in the 
untreated  control  cells  the  majority  of  the  nuclei  appeared  normal.  At  higher 
magnification (x  6300)(Fig  5.10) changes in mitochondrial  morphology  were  noted  in 
addition to the nuclear chromatin condensation. Many of the mitochondria in the treated 
cells  showed  abnormal  morphological  features  such as  prominent cristae  and  swelling 
(green  arrow),  with  a  lesser  proportion  showing  more  advanced  changes  with 
vacuolisation of two mitochondria seen in the cell (pink arrow).
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Fig 5.9 Electron microscopic analysis of CLL cells  (lower magnification  x2000)
Orange arrow -  apoptotic cells with nuclear condensationCONTROL D(KLAKLAK)2
Fig 5.10 Electron microscopic analysis of CLL cells  (higher magnification x 6300) 
Changes in mitochondrial morphology in treated cells
Green arrow -  swollen mitochondria with prominent cristea 
Pink arrow -  vacuolated mitochondria5.2.1.7  The  cytotoxic  activity  of  anti-CD19  D(KLAKLAK>2  on  CLL  cells  is 
independent of the cell's expression of anti- apoptotic proteins
Increased  expression  of  various  proteins  has  been  implicated  in  resistance  to 
chemotherapeutic  agents245’247256.  Members  of  the  pro-survival  Bcl-2  subfamily  of 
proteins  such  as  Bcl-2  and  Mcl-1  are  thought  to  exert  their effects  by  modulating the 
apoptotic pathway by  forming  inactive heterodimers with pro-apoptotic proteins of the 
BH-only  family170  (section  1.4.4.2)  .Similarly  members  of the  inhibitors  of apoptotic 
protease family (IAPs) inhibit apoptosis by binding to downstream effector caspases 
To  assess  the  effect  of the  expression  of anti-apoptotic  proteins  by  CLL  cells  on  the 
cytotoxic action of anti-CD 19 D(KLAKLAK)2 , protein lysates were prepared  from the 
untreated  mononuclear  cells  isolated  from  the  peripheral  blood  of nine  CLL  patients. 
The  lysates  were  fractionated  by  SDS-PAGE  and  the  blots  were  then  probed  with 
antibodies against actin (to ensure equal loading) and the anti-apoptotic proteins XIAP, 
Mcl-1 and  Bcl-2.  The  level  of expression  of these  proteins  was  assessed  after probing 
with  the  appropriate  secondary  antibodies.  A  representative  western  blot  is  shown  in 
Figure  5.11 A.  Intensities  of individual  bands  were  determined  by  laser  densitometric 
scanning and normalised with respect to the intensity of actin bands determined for the 
same samples.  These  expression ratios were plotted against the  IC50 values determined 
by  incubation  of  the  CLL  isolates  with  anti-CD 19  D(KLAKLAK )2  (Fig  5.1).  We 
observed  no correlation between the expression of Bcl-2,  Mcl-1  or XIAP  and the  IC50 
(Figure  5.11  B,  C,  D),  suggesting  that  killing  of CLL  cells  by  the  conjugate  was  not 
modulated by expression of these anti-apoptotic proteins.
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Fig 5.11  Relationship between IC^ for anti-CD19 D(KLAKLAK)2and the expression of anti-apoptotic proteins.
Expression of anti-apoptotic proteins was determined by western blot analysis (A). The band intensity for each protein 
was normalized with respect to actin (B-D). The resulting ratios were plotted against IC5 0  values determined as in Fig 5.1 
Statistical analysis was by Spearman rank correlation.5.2.1.8  The  cytotoxic  activity  of  anti-CD 19  D(KLAKLAK>2  on  CLL  cells  is 
independent of the cell's ZAP-70 status
Zeta-Associated  Protein  70  (ZAP-70)  is  a  70kD  cytoplasmic  protein  tyrosine  kinase 
that is normally only expressed fn natural killer cells and T-cells, where it is associated 
with the T-cell receptor complex and plays critical role in signal transduction pathways. 
Microarray  technology  has  identified  ZAP-70  as  one  of a  relatively  small  number  of 
genes  that  is  expressed  at  higher  levels  in  B-CLL  cells  that  have  unmutated 
immunoglobulin VH  genes  compared to those  that  have  mutated  immunoglobulin  VH 
genes"  .  ZAP-70  is  not  normally  functional  in  B-cells,  however  it’s  anomalous 
expression  in CLL cells with unmutated IgVH  enhance the signaling process when the 
B-cell  receptor  is  engaged  and  may  contribute  to  the  pathogenesis  of the  disease259. 
Detection of ZAP-70 protein expression in CLL cells has been used a surrogate marker 
for  immunoglobulin  VH  gene  status  and  hence  as  a  prognostic  indicator235’236.  In  one 
large study ZAP-70 expression was even found to be a better indicator for the need for 
treatment in CLL than immunoglobulin VH gene status260.
In order to determine whether the expression of ZAP-70 had any effect on the cytotoxic 
action of anti-CD 19-D(KLAKLAK)2 on CLL cells, the mononuclear cells isolated from 
the  peripheral  blood  of  13  patients  with  CLL  were  analysed  for  ZAP-70  protein 
expression by  flow cytometry. Of the  13  samples analysed 9 were found to be ZAP-70 
negative  and  4  ZAP-70  positive.  Immunoglobulin  VH  gene  mutational  status  was 
available nine out of the thirteen samples analysed and in each case showed concordant 
results  i.e  ZAP  positive/unmutated  IgVH  ,  ZAP  negative  /mutated  IgVH.  Fig  5.12 
illustrates the IC>o derived from dose response curves (see Fig 5.1) of the action of anti- 
CD 19-D(KLAKLAK)2 on the  13  CLL  samples  in  which  ZAP  status  was  assessed.  No
164significant  difference  was  noted  between  the  median  IC 50 in  the  ZAP  positive  group 
compared to the ZAP negative group.
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Fig 5.12 Relationship between IC50 for anti-CD19 D(KLAKLAK)2 and ZAP-70 
expression
ZAP-70 expression of thirteen CLL samples was determined by flow cytometry 
(section 2.3.9)
IC 50 values were determined as in Fig 5.1
Statistical analysis was by unpaired t-test with Welch’s correction
1665.2.1.9  Anti-CD19  D(KLAKLAK) 2  and  chlorambucil  have  synergistic  cytotoxic 
effects on CLL cells
In order to assess whether D(KLAKLAK )2 and chlorambucil  had  synergistic, additive 
or  antagonistic  cytotoxic  effects  on  CLL  cells,  mononuclear  cells  isolated  from  the 
peripheral  blood of 6 patients with CLL  (CLLs  18-23  Table  5.2) were  incubated with 
increasing concentrations of chlorambucil , anti-CD 19 D(KLAKLAK )2 and  with serial 
dilutions of the two drugs in a fixed molar ratio of 20 000 :  1   (chlorambucil: conjugate). 
lOOpl of cells were taken for MTT assay (in duplicate) after 48 hours  incubation.  Data 
were analysed using Calcusyn software (Biosoft, Fergusson Missouri261)
Median  effect  plots  were  created  for all  6  samples.  Two  representative  examples  are 
shown  in  Fig  5.13.  In  these  plots  the  movement  of  the  combination  line  (in  red) 
slanting upwards from the chlorambucil alone line (in blue) gives a graphical indication 
of synergy.  In Fig 5.13 the plot for CLL 18 demonstrates drug synergy, whereas the plot 
for CLL22  does not.  Overall  strong synergy was demonstrated  in 4 out of the  6 of the 
samples tested.
The  IC$o  values  towards  chlorambucil  alone  were  decreased  approximately  two-fold 
when  combined  with  anti-CD 19  D(KLAKLAK )2  (Table  5.3).  Synergistic  interactions 
were  rigorously  assessed by computing the combination index  (Cl)  for each of the  six 
CLL  samples.  .  These figures were derived using an equation of Chou and Talalay that 
determines  the  additive  effect of multiple drugs262,  with  synergism  being defined  as  a 
more  than  expected  additive  effect,  and  antagonism  as  less  than  expected  additive 
effect.
167CI= (D),/(Dx)i + (D)2/(Dx)2+ ((D), (D)2/(D x) j (Dx)2
Where  (D)i  =  the  concentration  of drug  1   that  results  in  a  fixed  percentage  of cell 
killing when used  in  combination and  (Dx)i  = the concentration of drug  1   that gives 
the same percentage of killing when used alone.
Cl  =  1   indicates an additive effect.
Cl >  1   indicates an antagonistic effect.
Cl  <  1   indicates  a  synergistic effect,  with  lower values  indicating  stronger synergistic 
effect.
Table  5.3  shows  the  Cl  values  for each  of the  six  CLL  samples  calculated  at various 
levels  of killing.  Five  of the  six  isolates  showed  evidence  of synergistic  interaction 
between  chlorambucil  and  anti-CD 19  D(KLAKLAK)2.  In  general,  the  Cl  values 
decreased  under  conditions  of  increasing  cell  killing,  indicative  of  progressively 
increasing  synergy.  However,  for the  CLL22  isolate,  the  Cl  values  remained  close  to 
unity at all levels of cell killing, indicative of an essentially additive interaction.
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Fig 5.13 Analysis of interaction between anti-CD19 D(KLAKLAK>2 and 
chlorambucil
Dose effect curves (upper panel) and median effect plots (lower panel) of the 
synergistic action of chlorambucil and anti-CD 19 D(KLAKLAK)2 on CLL samples 
CLL18 and 22
Median effect: [log (fa/fii) vs. log D] 
fa  fraction affected, fu: fraction unaffected, D dose 
IC5 0CHL: chlorambucil  KLAK: anti-CD 19 D(KLAKLAK)2 
CHL/KLAK: chlorambucil in the presence of anti-CD 19 D(KLAKLAK>2
169Patient
number
IC50 (uM) Combination Index at:
Chi alone Chi + anti- 
CD19:K
IC 50 IC 75 IC 90
18 46.2 19.1 0.53 0.41 0.34
19 1 1 .8 5.4 0.47 0.33 0.23
2 0 3.6 2 .8 0.84 0.69 0.58
2 1 35.3 13.9 0.56 0.51 0.47
2 2 16.3 14.0 0.98 0.94 0.91
23 14.9 6.7 0.51 0.58 0.64
Table 5.3 Interactions between chlorambucil and anti-CD 19D(KLAKLAK)2.
Chi chlorambucil
anti-CD19K  anti-CD 19 D(KLAKLAK )2 
Chi: conjugate was at a 20,000:  1   molar ratio
1705.2.2 Assessment of cytotoxicty of anti-CD33-D(KLAKLAK)2 against AML cells
Mononuclear  cells  were  isolated  from  the  bone  marrow  or  peripheral  blood  of  5 
patients  with  AML  by  Ficoll  density  gradient.  The  characteristics  of the  patients  are 
summarised in table 5.5
Age  Sex Tissue  FAB type CD33 expression
AML 1 59  M BM  M1 3%
AML 2 54  M BM  M2 76%
AML 3 63  M BM  M4 76%
AML 4 39  M PB*  M4 90%
AML 5 44  M BM  M1 94%
* Indicates leuopheresis sample
Table 5.4 Characteristics of patients and AML samples used in Chapter 5.
5.2.2.1  Anti-CD 3 3 -D(KLAKLAK)2  has  cytotoxic  activity  against  CD33  positive 
AML cells as assessed by MTT assay
Cytotoxicity  of anti-CD33-D(KLAKLAK)2 (antibody:  peptide  ratio  1:6)  was assessed 
by  incubation  of  increasing  concentrations  of the  conjugate  with  mononuclear  cells 
isolated  from  the  bone marrow or peripheral blood of patients with AML.  Samples  for 
MTT  assay  were  taken  at  24  and  48  hours.  All  MTT  assays  were  performed  in 
duplicate.  In  each  experiment  a  positive  control  of CD33  positive  THP1  cells  and  a 
negative control of CD33 negative Jurkat cells were used.  .
The  cumulative  results  of the  MTT assays  at  24  are  shown  in  Fig5.14.  In  contrast  to 
the  anti-CD 19  conjugate,  the  anti-CD33  conjugate  had  maximal  effects  at  24  hours,
171with  mean  decreases  in  cell  viability  at  24  hours  of 45.84%  (range  5.3%-65.1%).  As 
with the cell  line experiments the IC50 values at 24 hours were in the nanomolar range, 
with a mean value of 26.69nM (range 6.8nM-45.5nM).
In  section  5.2.1.2,  the  specificity  of  the  anti-CD19  conjugate  was  demonstrated 
indirectly by  showing  a strong correlation between the  percentage  of CD2  positive  T- 
cell  in  the  samples  and  the  proportion  of cells  that  were  resistant  to  the  anti-CD 19 
conjugate. In the case of the AML samples, CD33 expression was estimated directly by 
flow cytometry  before  exposing the cell  samples to anti-CD33  conjugate.  There  was a 
wide variation in CD33 expression (Table  5.4), with one sample AML1  demonstrating 
only 3% of positive cells. Although negative CD33 expression in AML is a rare finding 
it has been reported in literature to occur in approximately 3% of AML cases263. As this 
was  an  unexpected  result,  the phenotype  was  kindly  confirmed  by  APAP  staining  by 
Faith Wright in the Royal Free immunophenotyping laboratory.
Unsurprisingly this AML sample was resistant to the cytotoxic effects of the anti-CD33 
conjugate.
172MTT assay
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CD33%  IC50nM  % resistant cells
-o- AML 1 3% - 94.7
AML 2 76% 6.80 34.1
AML 3 76% 14.29 47.2
-A-AML 4 90% 40.17 49.3
-♦-AML 5 94% 45.50 49.8
Fig 5.14 Cytotoxicity of anti-CD33 D(KLAKLAK)2  towards AML cells
Dose response curve for the action of anti-CD33 D(KLAKLAK)2 on cells isolated from 
the bone marrow or peripheral blood of  five patients with AML.
MTT assays were at 24 hours.
Error bars represent SEM of duplicate determinations.
1735.3 Discussion
We have demonstrated that anti-CD 19 D(KLAKLAK >2 and anti-CD33 D(KLAKLAK )2 
conjugates have potent and specific activity against CD 19 positive CLL cells and CD33 
positive  AML cells  respectively.  In the case  of the  anti-CD 19 conjugate,  an  apoptotic 
mechanism of cell killing was inferred on the basis of morphological nuclear features of 
affected cells demonstrated by electron microscopy, by PARP cleavage analysis and by 
annexin V /propidium  iodide staining of treated cells.  In addition the data suggests that 
the  cytotoxic  effect  of the  drug  on  CLL  cells  is  independent  of baseline  expression 
levels  of the  anti-apoptotic  proteins  implicated  in  chemoresistance  (Bch,  Mcl,  XIAP) 
and of ZAP-70 expression.
We  have  also  demonstrated  that  the  anti-CD19  D(KLAKLAK )2  conjugate  acts 
synergistically with chlorambucil against CLL cells.
CLL  has  certain  features  that  make  it  an  ideal  candidate  for  this  type  of 
immunoconjugate  therapy.  The  relative  resistance  to  cytotoxic  drug  induced 
programmed cell death that occurs secondary to abnormalities of anti-apoptotic protein 
expression  and  the  characteristically  quiescent  nature  of CLL  cells  arrested  in  Go/Gi 
phase  of the  cell  cycle264  leads  to  resistance  to  many  conventional  chemotherapeutic 
agents  which  are  targeted  towards  rapidly  dividing  cells.  CLL  cells  also  have  a 
characteristic phenotype providing many potential antigens for targeted therapy.
Therapy  with  unconjugated  antibodies  targeted  to  non-internalising  antigens  such  as 
CD52 (Campath  1-H .Alemtuzumab) and  CD20 (Rituximab) have shown some benefit 
in CLL.  Alemtuzumab has an overall response rate of 33% in patients with relapsed or 
refractory disease63  and  is clinically effective  in patients with abnormalities of the p53 
pathway265.  Response  rates  with  Rituximab  used  in  previously  treated  patients  vary 
from  0-45%,  with  better  response  rates  when  used  in  combination  with  other
174chemotherapeutic  agents59,67.  In  addition  Rituximab  in  combination  with  CHOP 
chemotherapy  may  bypass  Bcl-2  associated  chemorsistance266.  Other  unconjugated 
antibodies  currently  in  development  for  CLL  therapy  include  antibodies  directed 
against CD22, CD23, HLA class II, TRAIL and CD8067.
The  ideal  surface  antigen  for  the  targeted  delivery  of toxins  to  CLL  cells  would  be 
expressed  reliably  and  selectively  on  CLL  cells  and  would  internalise  efficiently  on 
bonding  to  the  ligand.  Although  CD 19  is  the  most  reliably  expressed  target  antigen 
expressed  in  CLL  cells,  internalisation  may  not  be  as  efficient  as  that  of some  other 
targets113,267.  Anti-CD19  antibodies  have  however  been  used  effectively  to  target 
various toxins77104,268 and immunoliposomes269  to other B-cell  malignancies.  CD22  is 
only  very  weakly  expressed  in  CLL112,  however  it  has  been  shown  to  internalise 
particularly  well  in  CLL  cells  and  has  also  proved  to  be  a  suitable  target  for  the 
delivery  of  immunotoxins  in  this  disease143.  The  IL-2  receptor  complex  (including 
CD25,CD122 and CD 132) which  is expressed in approximately 50% of CLL  patients 
270  is the target for an IL-2 /diphtheria toxin fusion protein  (Ontak), which has shown
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some  responses  in  Phase  II  trials  .  As  well  as  levels  of cell  surface  expression  and 
degree of internalisation the therapeutic  efficacy of these  immunoconjugates may  also 
be affected  by  other  factors  such as  signalling events  triggered  by  ligand  binding and 
differences in intracellular trafficking of the toxins once internalised.
Our results  indicate that the anti-CD 19 antibody used internalises to a sufficient extent 
to effectively deliver toxic doses of (KLAKLAK )2 peptide to the  CD 19  positive CLL 
cells  while  sparing  CD2  positive  T-cells.  The  presumed  mechanism  of  action  of 
(KLAKLAK >2  is  disruption  of  the  mitochondrial  membrane  and  triggering  of  the 
apoptotic cascade. We have demonstrated apoptotic morphology in treated cells as well 
as evidence of PARP cleavage and characteristic patterns of Annexin V and Propidium
175iodide staining.  Other groups who have targeted this peptide, mainly to target vascular 
endothelial  cells  in  various  malignancies,  have  similarly  demonstrated  apoptotic
1  77  701
morphology  and  shown  evidence  of  caspase  3  processing  in  treated  cells  ’  .  In
addition  the  Ellerby  group  have  demonstrated  that  the  peptide  alone  causes 
mitochondrial swelling and caspase 3 processing in a mitochondria- dependent cell free
r*  •  ">03 272 system of apoptosis~  ’
The  observation  that  the  cytotoxic  action  of the  anti-CD 19  conjugate  appears  to  be 
independent  of  the  baseline  expression  levels  of anti-apoptotic  proteins  involved  in 
chemoresistance or of ZAP-70 status and that it acts  synergistically  with chlorambucil 
would further suggest that this immunoconjugate may be a useful addition to currently 
available therapeutic agents for CLL.
Summary'
We have demonstrated  that the antibody- D(KLAKLAK)2 conjugates synthesised 
in  chapter 3  have  selective  cytotoxic  activity  against  cells  isolated  from  patients 
with CLL and AML. An anti-CD19 conjugate had cytotoxic activity towards cells 
isolated from ptients with CLL, with IC50S  in the low nanomolar range. Cell killing 
was  by  an  apoptotic  mechanism  as demonstrated  by  flow  cytometrric  analysis  of 
annexin  V  and  propidium  iodide stained  cells,  Western  blot of analysis  of PARP 
cleavage  and  characteristic  morphology  on  electron  microscopy.  The  cytotoxic 
activity  the  anti-CD19  conjugate  was  independent  of  the  level  of  expression  of 
anti-apoptotic  proteins  and  ZAP-70.  In  the  majority  of cases  studied,  combined 
treatment  with  the  antibody  conjugate  and  chlorambucil  resulted  in  highly 
synergistic cell killing. In addition, an anti-CD33 conjugate was cytotoxic towards 
cells isolated from patients with AML
176Chapter 6   Selection of CD33 binding peptides from a phage display library
6.1  Introduction
In the previous  results chapters,  we described a reliable  method  for the conjugation of 
the  amphipathic  peptide  D(KLAKLAK )2  to  monoclonal  antibodies  and  demonstrated 
that  the  resulting  immunoconjugates  have  a  potent  and  selective  cytotoxic  action 
against  targeted  cells.  These  results  provide  a  proof of principle  that  D(KLAKLAK )2 
can be used effectively as targeted therapy for haematological malignancies.
The  results  in  this  section  describe  our  attempts  to  isolate  a  peptide  that  binds  to 
antigens expressed on the surface of malignant haematological cells and thereby create 
a multifunctional peptide reagent which combines the cytotoxic and targeting functions 
and  would  therefore  have  selective  cytotoxic  actions  against  leukaemia/lymphoma 
cells.
There  are  potential  advantages  of using  peptides  rather  than  antibodies  for  targeting: 
They can be easily and economically synthesized. Purification is also easier as they are 
less  likely  to  be  contaminated  by  DNA  and  viruses.  They  are  less  immunogenic  than 
antibodies  and  due  to  their small  size  may have  better tumour penetration  than  larger 
antibody conjugates.
Short peptides  that  bind  to tumour vasculature  have  been  selected  from  phage  display 
libraries  and  been  used  to  successfully  target  cytotoxic  peptides  which  inhibit 
angiogenesis  in  various  solid  tumours127,203,273.  Although  ScFv  that  bind  to  target 
antigen  expressed  on  haematological  malignancies  have  been  isolated129,  peptide 
sequences, which bind to CD 19 or CD33, have not as yet been described.
1776.2 Results
Despite  the  fact  that  our  results  in  the  previous  chapters  indicate  that  the  anti-CD 19 
D(KLAKLAK )2 conjugate was more  effective at killing CLL cells than the anti-CD33 
conjugate  was  at  killing  AML  cells,  we  chose  to  attempt  to  isolate  a  CD33  binding 
peptide.This  decision  was  made  on  the  basis  of  the  availability  of  a  CD33-Fc 
secreting  Chinese  hamster  ovary  (CHO)  cell  line  which  was  kindly  supplied  Paul 
Crocker at Dundee University .
6.2.1  Isolation and purification  of a CD33-Fc construct from the supernatant of a 
CD33-Fc secreting CHO cell line
The construct secreted by the CHO cell line consisted of four Ig domains (two domains 
from  CD33  and two from  the  Fc portion of IgG l120.  The cell  line was cultured for six 
weeks  in medium  supplemented with immunoglobulin-depleted FCS, with supernatant 
being removed weekly and frozen in aliquots.
To  ensure  that  the  CHO  cell  lines  were  secreting  CD33-Fc,  an  ELISA  assay  of the 
supernatant was  performed  fortnightly, using murine anti-human CD33  as the primary 
antibody  and  horseradish  peroxidase  linked  goat  anti-mouse  immunoglobulin  as  the 
secondary antibody.  In each ELISA negative controls of the  immunoglobulin depleted 
culture medium and PBS were used, with a positive control of mouse immunoglobulin. 
Fig  6.1a  illustrates  the  results  of one  such  assay,  confirming  that  the  cell  line  was 
secreting  the  CD33-Fc  construct.  Fig  6.1b  shows  the  results  of the  three  fortnightly 
ELISAs and demonstrates that the secretion of the construct remained essentially stable 
over the culture period.
After six weeks the aliquots were pooled and the CD33-Fc construct was isolated by 
high performance liquid chromatography using a protein A column.
1780.4-|
o
S
O o
<
0.2-
0. 1-
0.0
✓   ✓   A
Fig 6.1a
0.4n
0.1-
Fig 6.1b
Fig 6.1  ELISA of CHO supernatant
ELISA assays were performed at fortnightly intervals on the supernatant of the CD33- 
Fc secreting CHO cell line using murine anti-human CD33 as the primary antibody and 
HRP-goat anti-mouse as the secondary antibody. Fig 6. la, positive controls of mouse 
immunoglobulin and negative controls of Ig-depleted culture medium and PBS were 
used in each experiment.
Fig 6. lb shows the the results of three fortnightly ELIS As
1796.2.2  Screening  of bacteriophage  library  to  select  phage  that  bind  to  CD33-Fc 
construct and sequencing of the selected phage
A  phage  library  consisting  of random  peptide  7-mers  fused  to  a  minor  coat  protein 
(pill) of the M13  phage was used  Biopanning was carried out as illustrated in Fig 6.2 
according to manufacturer’s instructions136.
r
A library of M13 coliphage, 
each displaying a different
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and the process is repeated for a
total of 3-4 rounds
Fig 6.2 Schematic representation of biopanning a phage display library136
180Briefly  150(4.1 of CD33  supernatant was added to a single well of a 96 well  flat bottom 
plate and incubated overnight at 4°C. After removing the supernatant,  lOpl of the phage 
library  containing  approximately  2xlOn  phage  were  added  to  the  well.  Human 
immunoglobulin  was  added to  the  phage  media  in  order to  decrease  the  likelihood  of 
selecting phage that bound the immunoglobulin portion of the construct rather than the 
CD33 portion. Unbound phage were removed by extensive washing. Bound phage were 
eluted with 0.2M glycine HCL pH2.2  and then neutralized with  1M Tris HCL pH9.1. 
The  eluted  phage  were  propagated  in  E.coli  and  carried  onto  the  next  panning  round. 
Ten phage clones were selected  for sequencing from the  fourth round of panning.  The 
sequence of the  random  peptide  inserts  was  deduced  from  positive  clones  by  BigDye 
terminator cycle sequencing.
Results  of the  phage  sequencing  are  shown  in  Fig  6.3.  Two  amino  acid  sequences 
appeared  multiple  times.  One  sequence  was  identical  in  five  out of the ten  sequenced 
clones:  FHENWPS  (in  green)  with  one  additional  clone  M5  sharing  only  the  WPS 
sequence. Another sequence LPPQTLI (in red) was seen in three out of the ten clones.
181Ml.  TTG -  CCT - CCG -  TAG -  ACT -  TTG - ATT 
L  P  P  Q  T  L  I
M2  TTG-CCT-CCG-TAG-ACT-TTG-ATT 
L  P  P  Q  T  L  I
M3.  TTT - CAT - GAG - AAT - TGG - CCT - TCG
F  H  E  N  W P S
M4  TTT - CAT - GAG - AAT - TGG - CCT - TCG
F  H  E  N  W P S
M5.  TAN - GGC - ATN - AAA - TGG - CCT - TCG
Y/Q  ?  I/M  ?  W  P  S
M6.  TTG - CCT - CCG - TAG - ACT - TTG - ATT
L  P  P  Q  T  L  I
M7.  TTT-CAT-GAG-AAT-TGG-CCT-TC-
F  H  E  N  W P S
M8.  TTT-CAT-GAG-AAT-TGG-CCT-TC-
F  H  E  N  W P S
M9  AGT -  CTG - CCG - ACT - TAT - ACT - CAT
S  L  P  T  Y  T  H
M10.  TTT - CAT - GAG - AAT - TGG - CCT - TC- 
F  H  E  N  W P S
Fig 6.3 Results of biopanning experiments
Genetic code and amino acid sequence of 10 phage clones selected after 4 rounds of 
biopanning on the CD33-Fc construct.
1826.2.3 Binding of peptide sequences to CD33
The two amino acid sequences derived from the biopanning of the phage display library 
on  the  CD33-Fc  construct  were  custom  synthesised  (Alta  Biosciences)  with  a  biotin 
residue  at  the  N-terminus,  separated  from  the  peptide  by  two  glycine  residues,  as 
follows:
Peptide  1   JGGLPPQTLI
Peptide 2  JGGFHENWPS
Where J=biotin
Binding  of  the  peptides  to  CD33  was  assessed  by  an  ELISA  assay  and  by  flow 
cytometry.
Fig  6.4  illustrates  the  results  of an ELISA  assay  in  which  binding  of the  biotinylated 
peptides  to  immobilised  CD33-Fc  and  human  immunoglobulin  was  compared  using 
streptavidin-HRP  as  the  second  layer.  Both peptides  demonstrated a slight  increase  in 
binding to CD33 as compared to the immunoglobulin control.
For the  flow  cytometry  experiment,  THP1  and  Raji  cells  were  incubated  at  4°C  with 
each biotinylated peptide for 30 minutes, followed by incubation with streptavidin-APC 
for a further 30 minutes at 4°C.  Neither peptide bound more streptavidin-APC than the 
control CD33  negative Raji cell line. Peptide 2, however, showed a slight shift possibly 
indicating increase in binding to CD33 positive THP1  cells as compared to both peptide 
1   and the control (Fig.6.5).
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Fig.6.4 ELISA of binding of peptides  1   and 2 to CD33-Fc containing supernatant
Binding of the two biotinylated peptides 1   and 2 to immobilised CD33-Fc and human 
immunoglobulin was assessed by ELISA assay using streptavidin-HRP as the second 
layer.
184THP1
101  102  103 
CD33ARC
Ke^
Cells + 0
Cells + streptavidin APC 5ul
Cells +  peptide  1   + streptavidin APC 5ul
Cells + peptide 2  +   streptavidin APC 5ul
10 '   10  10'
CD33APC
Fig  6.5  Flow cytometric analysis of binding of peptides 1  and 2 to cell lines
FACScan analysis of binding of biotinylated peptides  1   and 2 to THP1  and Raji cells, 
with 2nd layer of streptavidin APC.
1856.2.4 Cyotoxicity of peptide constructs based on the sequence of peptide 2
Two  peptide  constructs  based  on  the  sequence  of peptide  2  were  custom  synthesised 
(Alta  Biosciences).  The  first  construct (A)  consisted  of the  D(KLAKLAK )2  sequence 
linked to the  sequence of peptide 2  by two glycine residues.  The  second construct (B) 
consisted  of  the  D(KLAKLAK )2  sequence  flanked  on  either  side  by  the  peptide  2  
sequence linked by two glycine residues.
Construct A  FHENWPS GG D(KLAKLAK )2
Construct B  FHENWPS GG D(KLAKLAK ) 2  GG FHENWPS
Both constructs were  incubated at increasing concentrations with a CD33 positive cell 
line  (THP1)  and  a  CD33  negative  cell  line  (Jurkat).  After 48  hours  incubation,  MTT 
assays  were  performed on duplicate  lOOpl  aliquots.  Both constructs  showed cytotoxic 
action  towards  both  CD33  positive  and  negative  cell  lines  with  IC50  of 25-35pM  as 
illustrated  in  Fig  6 .6 .  These  results  are  similar  to  the  IC50S  seen  when  unconjugated 
D(KLAKLAK )2  was  incubated  with  the  same  cell  lines  (section  4.2.1.4).  This 
observation and the lack of specificity of the toxic effects of the constructs suggest that 
neither  construct  enabled  the  selective  internalisation  of  the  cytotoxic  peptide  into 
CD33 positive cells.
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Fig 6 . 6  Cytotoxicity of peptide constructs towards haemopoeitic cell lines
Dose response curve of the action of 2 peptide constructs consisting of a CD33 binding 
motif and D(KLAKLAK)2  on THPl  and Jurkat cell lines. Cell viability was assessed 
by MTT assay at 48 hours.
Results are representative of three independent experiments.
Error bars represent SEM of duplicate determinations.
1876.3 Discussion
By  using  a  phage  display  library  to  pan  a  CD33-Fc  construct  we  identified  two 
consensus  peptide  sequences.  Only  one  of these  (peptide  2)  appeared  to  bind  to  the 
CD33  positive cell  line THP1.  In  addition neither of the two peptide  constructs based 
on the sequence of peptide 2 and the D(KLAKLAK )2 peptide had any cytotoxic action 
over and above the cytotoxicity of the D(KLAKLAK )2 peptide alone ( demonstrated in 
previous  chapters).  These  results  indicate  that the  peptide  sequences  derived  from  the 
phage  display  biopanning  experiments  failed  to  selectively  internalise  the  cytotoxic 
peptide into CD33 positive cells.
There  are  numerous  possible  reasons  why  we  were  unable  to  identify  selective 
internalising  phage  in  these  experiments.  Firstly  the  construct  on  which  the  phage 
library was panned was a CD33-Fc construct rather than pure CD33. Although care was 
taken  to  avoid  selecting  phage  that  bound  to  the  immunoglobulin  moiety  of  the 
construct  by  adding  human  immunoglobulin  to  the  phage  containing  media,  it  is 
possible  that  the  phage  selected bound  to  some  other part  of the  construct rather than 
the  CD33  portion.  Equally  phage  may  have  been  selected  that  did  not  bind  to  the 
construct at all but to some material in the experimental system such as the plastic wells 
or eppendorphs.  It is also possible that the phage bound to an epitope of CD33 that did 
not  facilitate  endocytosis  of the  CD33  antigen.  Secondly,  the  experiments  were  not 
specifically  designed  to  select  internalising  phage.  This  can  be  achieved  in  protocols 
where  biopanning  is  done  on  whole  cells,  and  internalised  phage  are  recovered  from 
lysed cells before the amplification stage274'276.  Thirdly the addition of the two glycine 
linker peptides to the  sequences derived  from  the  selected  phage  may have  altered the 
peptides’ binding characteristics and decreased their affinity for the CD33 target.
188Unfortunately  due  to  time  constraints  we  were  unable  to  investigate  any  of  these 
possibilities or to repeat the biopanning experiments under different conditions.
Summary
We used a phage display library to pan a CD33-Fc construct in an attempt to find 
peptide sequences that bind to and internalise into CD33 expressing myeloid cells. 
Two consensus sequences were identified but neither bound convincingly to CD33 
as demonstrated by ELISA or flow cytometric experiments. Peptide constructs 
base on the consensus sequences and D(KLAKLAK)2  did not show any specific 
cytotoxic activity towards CD33 expressing cells. The possible reasons why this 
strategy was not sucessful are discussed.
189Chapter 7  Discussion
We  have  described  a  simple,  reproducible  procedure  for  coupling  an  amphipathic 
cytotoxic  peptide  to antibodies directed against  lineage-restricted cell  surface  antigens 
expressed by B  -lymphoid and myeloid cells.  Conjugation of the peptide to anti-CD 19 
generated a reagent which efficiently killed 3/3  malignant B lymphoid cell lines tested. 
The  killing  of one  of these  lines  (Raji)  was  shown  to  be  by  an  apoptotic  mechanism. 
However,  a  peptide-anti-CD33  conjugate  killed  only  1/4  myeloid  cell  lines.  The 
resistance of one of these lines (K562) could be accounted for by the lack of expression 
of cell-surface  CD33.  However,  the  remaining  two  resistant  lines  (HL60  and  U937) 
expressed abundant CD33, suggesting that resistance to killing resulted from a cell-type 
dependent  inability  of  internalised  peptide  to  access  and/or  activate  the  cell  death 
machinery. This interpretation was corroborated by our demonstration that the resistant 
HL60  cell  line  nevertheless  internalised  a conjugate  containing  a  biotinylated  peptide 
and was also susceptible to anti-CD33 conjugated to a different toxin, calicheamycin. 
While micromolar levels of the peptide itself was uniformly toxic to all of the cell lines 
tested here, linkage to antibodies resulted in at least a  100-fold increase in efficiency of 
killing of the targeted cells. The reagents generated by our protocol showed IC50 values 
in  the  low  nanomolar  range.  The  increased  efficiency  was  accompanied  by  highly 
selective  killing,  since  neither conjugate  tested here  killed cells  which did  not express 
the appropriate cell-surface target molecule.
We also  show that conjugation of the  amphipathic  cytotoxic  peptide  D-(KLAKLAK )2 
to  an  anti-CD 19  monoclonal  antibody  results  in  a  reagent  showing  potent  and  highly 
targeted toxicity towards malignant cells  isolated  from  patients  with CLL  .  Cells  from 
untreated  or  previously  treated  patients  showed  very  similar  susceptibility  to  the
190conjugate,  suggesting  that  it  may  be  of value  in  treating  patients  who  have  become 
resistant  to  conventional  therapeutic  agents.  Cell  killing  was  by  an  apoptotic 
mechanism  and  was  independent of level  of expression of anti-apoptotic  proteins  and 
ZAP-70.  In  the  majority  of  cases  studied,  combined  treatment  with  the  antibody 
conjugate and chlorambucil resulted in highly synergistic cell killing.
The  mechanism  by which  internalised D(KLAKLAK )2  is thought to engage the  cell’s 
apoptotic  machinery  is  by  disruption  of  mitochondrial  membrane.  We  have 
demonstrated  an  apoptotic  mode  of  cell  death  by  PARP  cleavage  analysis  and  by 
annexin  V  /propidium  iodide  staining  of  treated  cells  as  well  as  demonstating 
characteristic  morphological  features  on  light  and  electron  microscopy.  Ellerby  et  al 
demonstrated  that  D(KLAKLAK )2  induced  mitochondrial  swelling  and  caspase  3 
processing  in  a  mitochondria-  dependent  cell  free  system  of apoptosis203,272.  Another 
group has demonstrated rapid release of cytochrome c from mitochondria in Jurkat cells 
which were temporarily transfected with (KLAKLAK )2 linked to a protein transduction 
domain277.
Mitochondrial  membranes  differ  from  eukarytic  cell  membranes  in  their  lipid 
composition.  Eukaryotic cell membranes are rich  in cholesterol  whereas mitochondrial 
membranes  contain  very  little.  The  main  phospholipids  present  in  eukarytoic  cell 
membranes  are  the  amino-glycerophospholipids  (phosphatidylcholine  and 
phosphatidylethanolamine).  The  outer  mitochondrial  membrane  also  contains  high 
levels  of phosphatidylcholine;  the  inner  mitochondrial  membrane  however  is  rich  in 
phosphatidylglycerol and its derivative cardiolipin278 (lesser amounts of cardiolipin are 
also  found  in  the  outer  mitochondrial  membrane279).  Cardiolipin  is  a  unique 
phospholipid having a dimeric structure with four acyl groups and the potential to carry 
two negative charges.  Cardiolipin is also unique  in that its biosynthesis  is restricted to
191mitochondria  presumably  reflecting  a  common  ancestry  with  bacteria,  given  that 
cardiolipin is also present in aerobic bacteria.
The  majority  of mitochondrial  proteins  are  encoded  by  nuclear  DNA  and  targeted  to 
mitochondria  by  temporary  amino  terminal  extentions  called  pre-sequences.  These 
sequences  have  an  amphipathic  character  containing  both  positively  charged  and 
neutral  amino  acids  and  have  been  predicted  to  adopt  an  a   helical  conformation  in 
which the cationic residues  lie on one  side of the helix and the non-polar amino acids 
on the other.  It is suggested that the non-polar face of the helix may penetrate into the 
hydrophobic region of the outer membrane of mitochondria, while the basic residues on 
the polar side of the helix would interact with the headgroup of the negatively charged 
phospholipids. Nicolay et al synthesised three such amphipathic peptides based on the 
pre-sequence  of cytochrome c oxidase  subunit IV to  study the effect of these peptides 
on the structural and functional integrity of rat liver mitochondrial membranes280. They 
demonstrated  that  at  low  peptide  to  mitochondrial  ratios  peptide  binding  to  the  outer 
mitochondrial  membranes  occurred,  outer  membrane  permeabilisation  was 
demonstrated  at  higher  ratios  and  at  still  higher  concentrations  the  inner  membrane 
permeability was increased.
Another  group  of  amphipathic  a   helix  forming  peptides  are  the  host  defence 
antimicrobial  peptides  such  as  magainins.  These  peptides  have  the  ability  to  kill 
bacteria by  permeabilising their cell  membranes but do not  lyse erytherocytes281.  The 
absence of acidic  phospholipids on  the  outer monolayer and the  abundant presence  of
sterols cells were thought to account  for the reduced suseptibilty of the red blood cells
281 to these agents
These  models  of the  mechanism  of action of amphipathic  peptides  have been cited by
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Ellerby  et  a t  as  the  likely  explanation  for  apoptosis  induction  following
192internalisation of the  amphipathic  peptide  D(KLAKLAK)2.  However,  this  hypothesis 
has  not been  directly  proven  and  it  is  possible  that  in  haemopoeitic  cells  apoptosis  is 
induced  by  an  entirely  different  pathway.  We  have  demonstrated  antibody  conjugate 
internalisation  into  haemopoeitic  cells  by  confocal  microscopy.  However  further 
tracking of the  intracellular pathway  of the  conjugate  proved  problematic.  The  initial 
strategy of tracking a biotinylated version of the peptide was hampered by high levels 
of a constitutively expressed biotin containing protein  in the  Raji  cells  leading to high 
levels  of background  staining.  Using  FITC  labelled  anti-mouse  immunoglobulin  we 
were able to demonstrate internalisation into vesicular like structures within Raji cells, 
however it is  likely that the peptide would be cleaved from the antibody portion of the 
conjugate  within  the  acidic  environment  of the  endosome  so  further  tracking  of the 
active peptide portion would not be possible by this  method.  One way of overcoming 
this problem would be to use an alternative tag for the amphipathic peptide alternatively 
an  antibody  could  be  generated  towards  the  peptide  itself.  Unfortunately  due  to  time 
constraints we were unable to investigate any of these possibilities.
Rituximab  and  alemtuzumab,  which  target  CD20  and  CD52  respectively,  are  the 
principal  antibodies  currently  used in the  treatment  of CLL.  However,  treatment  with 
these agents alone rarely results in complete remissions in patients who are refractory to 
conventional cytotoxic drugs59,63,67,265.  Rituximab in combination CHOP chemotherapy 
appears  to  bypass  Bcl-2  associated  chemoresistance266  but  its  cytotoxcity  has  been 
demonstrated  to  be  compromised  by  elevated  expression  of  Mcl-1  and  other  anti-
^40
apoptotic proteins  . The targeted killing of T lymphocytes by alemtuzumab can result 
in  immunosuppression  and  fatal  infections67.  The  ability  of CD 19  D(KLAKLAK )2  to 
kill CLL cells irrespective of treatment history and of anti-apoptotic protein expression
193together with the  lack  of killing of T lymphoid cells  may  offer significant advantages 
compared with currently available therapeutic antibodies.
Various  natural  toxins,  including  ricin  and  pseudomonas  exotoxin,  have  been  used  in 
targeting  strategies141.  However,  amphipathic  peptides  may  offer  some  potential 
advantages  over  these  natural  agents.  First,  construction  using  D-amino  acids  would 
render these species resistant to proteolytic degradation, in both extra- and intracellular 
compartments.  Second,  they  can  be  synthesized  economically  by  purely  chemical 
procedures,  circumventing  the  risk  of  contamination  by  potentially  hazardous 
biomolecules. Third, induction of vascular leak syndrome  is a key dose-limiting factor 
in the therapeutic  use  of many natural toxins.  A conserved three  amino acid  sequence 
has been identified as a cause of this syndrome147,282.
The absence of this motif from the amphipathic peptide suggests that its use in targeted 
strategies may circumvent limitations resulting from vascular leakage.
Our attempts to identify peptides which bound to CD33 by biopanning a phage display 
library  were  unsuccessful.  (The  possible  reasons  for  this  have  been  discussed  in  the 
relevant  chapter.)  However  peptides  which  bind  selectively  to  specific 
immunoglobulins132  or  other  unidentified  cell-surface  structures134  of  malignant  B 
lymphoid  cells  have  been  identified  by  other  groups.  Our demonstration  that targeted 
D-(KLAKLAK )2  is  toxic  towards  CLL  cells  offers  the  prospect  of  constructing 
completely  synthetic  reagents  consisting  of  the  amphipathic  peptide  linked  to  a 
targeting  sequence.  This  type  of multifunctional  peptide  reagent  has  previously  been 
designed  for  targeting  the  neovasculature  of  solid  tumors.127,203  Adaptation  of  this 
concept  to  leukemias/lymphomas  may  therefore  result  in  the  generation  of  highly 
elective targeted agents for the treatment of hematopoietic malignancies.
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